Molecular drivers in age-related macular degeneration by Paun, C.C.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/197550
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
MOLECULAR DRIVERS
——— in ———
Age-related Macular 
Degeneration
codruţ constantin păun
Molecular Drivers
— in — 
Age-related Macular 
Degeneration
codruţ constantin păun
ISBN/EAN: 978-94-6380-085-3 
This research was supported by the Foundation Fighting Blindness Center 
Grant to the Radboud University Medical Center (Grant C-GE-0811-0548-
RAD04; Columbia, MD, USA) and the Netherlands Organization for 
Scientific Research (Vidi Innovational Research Award 016.096.309 to 
AIdH; Den Haag, Zuid-Holland, The Netherlands). 
Publication of this thesis was financially supported by Radboud University 
Nijmegen.
Cover and photography: “Complexity of AMD“ by Constantin C. Păun
Design: Denise Janssen
Printed by: Proefschriftmaken || www.proefschriftmaken.nl
© Constantin C. Păun
 
Molecular drivers in 
age-related macular degeneration
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken, 
volgens besluit van het college van decanen
in het openbaar te verdedigen op donderdag 6 december 2018
om 10:30 uur precies
door
Codruţ Constantin Păun
geboren op 14 februari 1986
in Reşiţa, Roemenië
PROMOTOREN:   prof. dr. A.I. den Hollander
    prof. dr. C.B. Hoyng
COPROMOTOR:   dr. E.K. de Jong
MANUSCRIPT-   prof. dr. N.P. Riksen (voorzitter) 
COMMISSIE:  
    dr. M.I. de Jonge
    prof. dr. L. Paraoan (University of Liverpool,  
    Verenigd Koninkrijk)
 
Molecular drivers in 
age-related macular degeneration
Doctoral Thesis
to obtain the degree of doctor
from Radboud University Nijmegen
on the authority of the Rector Magnificus prof. dr. J.H.J.M. van Krieken, 
according to the decision of the Council of Deans
to be defended in public on Thursday, December 6, 2018
at 10.30 hours
by
Codruţ Constantin Păun
born on February 14, 1986
in Reşiţa, Romania
SUPERVISORS:   prof. dr. A.I. den Hollander
    prof. dr. C.B. Hoyng
CO-SUPERVISOR:   dr. E.K. de Jong
DOCTORAL THESIS   prof. dr. N.P. Riksen (chair) 
COMMITTEE:  
    dr. M.I. de Jonge
    prof. dr. L. Paraoan (University of Liverpool,  
    Verenigd Koninkrijk)
TABLE OF CONTENTS
Chapter 1. General Introduction
1.1 The retina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.2 Age-related macular degeneration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.3 AMD is a multifactorial disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.4 Complement system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.5 Other pathways involved in AMD pathogenesis: lipid metabolism, oxidative stress, ECM 
remodeling, and angiogenesis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.6 Treatment for AMD  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.7 Aims and outline of the thesis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.8 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Chapter 2. Systemic and ocular fluid compounds as potential biomarkers in 
age-related macular degeneration
Abstract  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.2 Neovascularization and hemostasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.3 Oxidative stress  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.4 Immunity  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.5 Lipid metabolism/homeostasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
2.6 Extracellular matrix  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
2.7 Dietary factors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
2.8 Hormones  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
2.9 Factors related to comorbidities  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
2.10 Hypothesis-free techniques  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
2.11 Conclusion and future directions  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
2.12 Methods of literature search . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
2.13 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
2.14 References supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
2.15 References main text . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Chapter 3. Analysis of rare variants in the C3 gene in patients with age-related 
macular degeneration
Abstract  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
3.4 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
3.5 supplementary data  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169
3.6 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
Chapter 4. Impact of the common genetic associations of age-related macular 
degeneration upon systemic complement component C3d levels
Abstract  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180
4.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
4.5 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
Chapter 5. A novel complotype combination associates with age-related macular 
degeneration and high complement activation levels in vivo 
Abstract  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
5.4 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213
5.5 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
5.6 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220
Chapter 6. Genetic variants and systemic complement activation levels are 
associated with serum lipoprotein levels in age-related macular degeneration
Abstract  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
6.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235
6.5 Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239
6.6 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 243
Chapter 7. Genome-wide association study reveals variants in CFH and CFHR4 
associated with systemic complement activation: implications in age-related 
macular degeneration
Abstract  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249
7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250
7.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251
7.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255
7.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 265
7.5 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268
7.6 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 273
Chapter 8. General Discussion
General discussion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278
8.1 Why investigate factors involved in complement activation? . . . . . . . . . . . . . . . . . . . . . . . . . 278
8.2 Which genetic factors influence complement activation?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 280
8.3 Is AMD driven by local or systemic complement activation? . . . . . . . . . . . . . . . . . . . . . . . . . . 281
8.4  Why is the top SNP in the complement GWAS not associated with AMD? . . . . . . . . . . . 282
8.5 What are the interactions of complement with other pathways? . . . . . . . . . . . . . . . . . . . . . 283
8.6 What do these findings mean for the prediction and treatment of AMD?  . . . . . . . . . . . . 286
8.7 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288
Summary    
Summary  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 294
Samenvatting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 296
acknowledgements 
Acknowledgements  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300
About the author 
About the author . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 308


Chapter 1. 
General IntroduCtIon
12
Chapter 1 
1.1 THE RETINA
The retina is the light-sensitive inner lining of the eye, which is responsible for vision 
(Figure 1A). A radial section of the retina reveals its highly organized multilayered 
structure (Figure 1B). 
Figure 1. The retina. A. Schematic representation of the eye. B. Schematic representation of a cross-section 
of the retina. The light that enters the eye passes through all the layers, starting with the inner limiting 
membrane, before reaching the rod and cone photoreceptors where signal transduction is initiated. Retinal 
cells layers are annotated in the figure. C. fundus photograph of a healthy human retina with the black arrow 
indicating the macula.
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Upon light stimulation, the phototransduction cascade in the photoreceptor cells is 
initiated, resulting in a signal to the brain. Underneath the neurosensory retina lies a 
single layer of highly specialized cells: the retinal pigment epithelium (RPE). RPE cells 
serve multiple crucial functions, such as maintaining photoreceptor homeostasis by 
facilitating the removal of cellular and metabolic waste from the neurosensory retina 
to the underlying vasculature, the choroid, and the diffusion of nutrients from the 
choroid to the retina. 
The RPE is separated from the underlying choroid by Bruch’s membrane, an 
extracellular matrix structure comprised of the RPE basement membrane, an inner 
collagenous zone, central elastin, an outer collagenous zone and the choriocapillaris 
basement membrane. 
A color photograph of the inner lining of the eye shows an area in the center of the 
retina called macula lutea (Latin for yellow spot; Figure 1C). The macula is responsible 
for central, high-resolution vision as well as color vision under daylight conditions 
due to the high density of cone photoreceptors located in this area. In contrast, in 
the peripheral retina the rod photoreceptors that specialize in contrast detection 
predominate, enabling vision in low light conditions.
1.2 AGE-RELATED MACULAR DEGENERATION
Age-related macular degeneration (AMD) is the leading cause of irreversible vision 
loss in elderly of European decent. It is projected that 196 million people will be 
affected worldwide with any form of AMD in the year 2020, and due to aging of the 
population this number will increase to 288 million by 2040.1 AMD is a progressive 
disease that causes gradual loss of central vision as a result of degenerative processes 
that occur in the macula. 
An important hallmark of the disease is the formation of extracellular deposits called 
drusen, found between the RPE and the inner collagenous zone of Bruch’s membrane, 
which can be readily observed upon ophthalmological examination. The number, size 
and location of drusen, together with the presence or absence of pigmentary changes 
are phenotypic characteristics that are used to categorize the early phases of the 
disease into different stages. Progression to late stage disease can lead to two forms: 
14
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dry AMD or geographic atrophy (GA), where widespread cell death underlies vision 
loss, and wet AMD, characterized by choroidal neovascularization (CNV). 
1.3 AMD IS A MULTIFACTORIAL DISEASE
AMD is a multifactorial disorder caused by a combination of genetic and environmental 
factors. The two strongest environmental factors that increase risk for AMD are 
age and smoking. Pooled data from three continents showed that AMD prevalence 
increases dramatically with age, from 0.2% in individuals 55-64 years old to 13% in 
individuals above 85 years. 
Independent of the risk given by older age, smoking adds a 2-4 fold higher risk towards 
AMD 2. 
Nutritional factors have also been linked to AMD. Increased dietary fat intake and 
obesity were positively associated with increased risk for AMD while a protective 
effect for antioxidants, nuts, fish, and omega-3 polysaccharide unsaturated fatty 
acids has been described 3-5. The association with smoking and the protective effect of 
antioxidants suggests that oxidative stress contributes to the pathogenesis of AMD. 
Evidence that AMD has a strong genetic component comes from early familial and twin 
studies 6-10, and the heritability of AMD has been assessed to be as high as 45% 11. Since 
then, a series of genome-wide association studies (GWAS) have attempted to unravel 
the genetic components contributing to the disease. In a GWAS, commonly occurring 
single nucleotide polymorphisms (SNPs) that are spread across the genome are tested 
for association with a (disease) trait. In AMD, several GWASes had been performed 
12-25, but it became clear that only part of the genetic contribution to disease could 
be explained through this approach. It was hypothesized that rare or low frequency 
genetic variation could fill that gap, and several reports have linked rare variants in a 
number of genes to AMD 26.
Using an exome chip, a microarray that contains 264,655 common variants and 
174,695 low frequency or rare variants, a very large GWAS was recently conducted27. 
In this study, using 16,144 cases and 17,832 control individuals, 34 genomic loci were 
identified to be associated with AMD, explaining between 18 to 34% of the disease 
15
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liability. At the 34 loci, 52 variants were identified that are independently associated 
with AMD, of which 45 were common genetic variants and 7 were low frequency 
variants 27. 
Because of the inherent low occurrence of rare genetic variants (<1% allele frequency), 
it is challenging to obtain statistical significance in association studies for individual 
variants, unless very large sample sizes are available. Alternatively, burden tests have 
been developed to test for an accumulation of (rare) genetic variation in one gene, or 
a group of genes that constitute a pathway in cases compared to controls. In AMD, 
so far, only the CFH, CFI, SLC16A8 and TIMP3 genes have shown a burden of rare 
variants compared to controls 27,28
Although 34 independent genomic loci have been identified in the largest genetic 
study in AMD to date, from a biological perspective, these loci are far from being 
independent. The genes in these AMD-associated loci can be clustered into four major 
biological pathways: the complement system, lipid metabolism, extracellular matrix 
(ECM) remodeling and angiogenesis signaling.  
1.4 COMPLEMENT SYSTEM
The first association identified in a GWAS study in AMD was with a SNP in the CFH) 
gene12. This association remained strongly associated with AMD as subsequent GWA 
studies increased in size 15,25,27, and additional genes encoding components of the 
complement cascade emerged (Table 1).
The complement system is a complex integral part of our innate immunity, with 
a multitude of functions that extend beyond simple danger elimination. The 
complement system acts as the first line of defense against foreign intruders and it 
also complements the rest of the immune system by orchestrating immunological and 
inflammatory processes 29. Besides its well-known role of host defense against foreign 
intruders 30 the complement system is recognized to participate in diverse processes 
such as clearance of immune complexes, angiogenesis, tissue regeneration and lipid 
metabolism 31. With such a wide range of functions, the complement system is tightly 
regulated to discriminate between healthy host tissue, cellular debris, apoptotic cells 
and foreign intruders. This is achieved by maintaining a balance between activation 
16
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and inhibition 29. The complement system is composed of three pathways: the classical 
pathway (CP), the lectin pathway (LP) and the alternative pathway (AP), which 
converge at the level of complement component 3 (C3) 32. The process continues 
through a series of enzymatic reactions that finally lead to the formation of the 
membrane-attack-complex (MAC) 33. A schematic representation of the complement 
system is presented in Figure 2.
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Table 1. Variants in or near genes encoding component of the complement system, 
found to be associated with AMD at genome wide level (p<5x10–8).  
No. Locus name Index variant Major /  minor allele 
Minor allele 
frequency 
   Association results 
   
Cases Controls 
   
OR P 
1 CFH rs10922109 C/A .223 .426 
   
0.51 1.0 x 10–131 
2 CFH rs570618 G/T .580 .364 
   
1.74 9.2 x 10–76 
3 CFH rs121913059 C/T .003 .00014 
   
47.63 2.2 x 10–35 
4 CFH rs148553336 T/C .003 .009 
   
0.31 8.8 x 10–17 
5 CFH rs187328863 C/T .054 .028 
   
1.47 2.8 x 10–12 
6 CFH (CFHR3/CFHR1)b rs61818925 G/T .284 .385 
   
1.18 6.3 x 10–9 
7 CFH rs35292876 C/T .021 .009 
   
1.54 9.5 x 10–8 
8 CFH rs191281603 C/G .007 .006 
   
0.41 7.7 x 10–7 
9 CFI rs10033900 C/T .511 .477 
   
1.15 1.2 x 10–13 
10 CFI rs141853578 C/T .003 .0008 
   
5.12 7.4 x 10–12 
11 C9 rs62358361 G/T .016 .009 
   
1.67 7.2 x 10–9 
12 C2/CFB/SKIV2L rs116503776 G/A .090 .148 
   
0.51 5.0 x 10–96 
13 C2/CFB/SKIV2L rs144629244 G/A .016 .012 
   
2.79 1.0 x 10–32 
14 C2/CFB/SKIV2L (PBX2) b rs114254831 A/G .284 .260 
   
1.13 8.8 x 10–9 
15 C2/CFB/SKIV2L rs181705462 G/T .018 .012 
   
1.56 2.8 x 10–8 
16 TMEM97/VTN rs11080055 C/A .463 .486 
   
0.92 1.5 x 10–5 
17 C3 rs2230199 C/G .266 .208 
   
1.47 1.6 x 10–60 
18 C3 rs147859257 T/G .012 .004 
   
3.22 4.1 x 10–26 
19 C3 (NRTN/FUT6) b rs12019136 G/A .036 .048 
   
0.74 4.0 x 10–9 
Table was adapted from 27 
 
The complement system is a complex integral part of our innate immunity, with a 
multitude of functions that extend beyond simple danger elimination. The complement 
system acts as the first line of defense against foreign intruders and it also 
Table 1. Variants in or near genes encoding component of the complement system, found to be associated 
with AMD at genome wide level (p<5x10–8). 
Table was adapted from 27
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Figure 2. Schematic overview of the complement system. Each pathway of the complement system has a 
different way of activation. Only the AP self-activates in a process known as tick-over, where the spontaneous 
hydrolysis of C3 to a bioactive form, C3(H
2
O), which binds complement factor B (FB), and subsequently 
is cleaved by complement factor D (CFD) into C3(H
2
O)Bb, thus forming the initial C3 convertase of the 
alternative complement pathway. This maintains a low level of continuous activation, which is essential 
for pathogen monitoring 34. The CP is activated by IgM/IgG clusters, but also by endogenous pattern 
recognition molecules and by recognizing distinct structures directly on microbial and apoptotic cells 29. The 
LP is activated by mannose-binding lectin and ficolins that recognize carbohydrate patterns 35. The three 
complement pathways converge after the cleavage of C3 into C3a and C3b and the subsequent formation 
of the C5 convertase complexes, which in turn cleave C5 into C5a and C5b, initiating the final steps of the 
complement cascade. C5b together with  C6, C7, C8, and C9 form the MAC, which creates pores in the 
membrane lipid bilayer, thus resulting in pathogen or cell destruction 36.
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Deregulations and deficiencies within the complement system have been reported 
to be associated with numerous inflammatory diseases and autoimmune disorders 
37. In AMD, the association of the complement system is not limited to genes only 38-
41. Starting with the work of Van der Schaft 42 in the early ‘90s, multiple studies have 
identified complement activators, components and regulatory proteins in drusen 
of AMD patients 43. In addition to this, complement activation has been observed in 
AMD patients, both systemically and in the eye 40,44,45, but these activation patterns 
are highly variable and large groups of patients and controls are needed to obtain 
statistical significance. Thus, genetic, histopathological and physiological evidence 
firmly supports the notion that aberrant complement regulation is involved in AMD.
1.5 OTHER PATHWAYS INVOLVED IN AMD PATHOGENESIS: LIPID 
METABOLISM, OXIDATIVE STRESS, ECM REMODELING, AND 
ANGIOGENESIS 
1.5.1 Lipid metabolism
A second major pathway associated with AMD is the lipoprotein/lipid metabolism 
pathway. Variants in four genes encoding components of the lipid metabolism have 
been associated with AMD (Table 2.) 27. Besides the genetic associations, involvement 
of lipoproteins in AMD comes from evidence that lipids and apolipoproteins make 
up more than 40% of drusen volume 46. Systemic levels of components belonging to 
this pathway, such as HDL and LDL, have been extensively studied in AMD with no 
clear consensus on the exact contribution of these particles in the disease process 
47,48. Many conflicting results have been published, but when taken together, larger 
and thus a more statistically powered study implicated the HDL particle as a risk 
conferring entity in AMD 49. 
1.5.2 Oxidative stress
During aging, accumulated effects of environmental stresses put a strain on multiple 
systems, including the cells and tissues of the eye. One of the major outcomes of these 
accumulated effects is thought to be an increased vulnerability to oxidative stress, 
to which the retina is particularly sensitive because of its high oxygen demand. With 
aging mitochondrial oxidation is impaired and oxidative damage is widely observed 
50-52. Oxidative damage has been reported in AMD 53, and patients’ RPE cells display 
higher reactive oxygen species (ROS) production and lower mitochondrial activity 54 
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Table 2. Variants in or near genes encoding components of the lipid metabolism, reported to be associated 
with AMD at genome wide level (p<5x10–8) 
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more statistically powered study implicated the HDL particle as a risk conferring entity in 
AMD 49.  
Table 2. Variants in or near genes encoding components of the lipid metabolism, 
reported to be associated with AMD at genome wide level (p<5x10–8)  
No. Locus name Index variant Major /  minor allele 
Minor allele 
frequency 
 Association results 
 
Cases Controls 
 
OR P 
1 ABCA1 rs2740488 A/C .255 .275 
 
0.89 6.0 x 10–7 
2 LIPC rs2043085 T/C .350 .381 
 
1.15 7.7 x 10–13 
3 LIPC rs2070895 G/A .195 .217 
 
0.86 1.8 x 10–10 
4 CETP rs5817082 C/CA .232 .264 
 
0.87 2.7 x 10–8 
5 CETP rs17231506 C/T .348 .315 
 
1.11 1.2 x 10–6 
6 APOE rs429358 T/C .099 .135 
 
0.67 3.9 x 10–39 
7 APOE(EXOC3L2/MARK4)b rs73036519 G/C .284 .302 
 
0.91 2.4 x 10–5 
Table was adapted from 27 
 
1.5.2 Oxidative stress 
During aging, accumulated effects of environmental stresses put a strain on multiple 
systems, including the cells and tissues of the eye. One of the major outcomes of these 
accumulated effects is thought to be an increased vulnerability to oxidative stress, to 
which the retina is particularly sensitive because of its high oxygen demand. With aging 
mitochondrial oxidation is impaired and oxidative damage is widely observed 50-52. 
Oxidative damage has been reported in AMD 53, and patients’ RPE cells display higher 
reactive oxygen species (ROS) production and lower mitochondrial activity 54 compared 
to controls. Because the eye, and especially the macula, is susceptible to pathological 
Table was adapted from 27
14 
 
oxidative processes affecting proteins and lipids, multiple factors related to oxidative 
stress have been the subject of research and found to be associated with AMD 55-58.  
1.5.3 Extracellular matrix (ECM) remodeling 
Genetic evidence also suggests that ECM remodeling is involved in the disease 
process. Drusen form within Bruch’s membrane, which is layered sheet of ECM 59. 
Moreover, genetic variation in genes encoding proteins involved in ECM remodeling, 
such as matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases, 
are associated with AMD 27 (Table 3). These findings suggest that tissue remodeling, 
potentially in the context of an immunological response with infiltrating immune cells, 
contributes to the etiology of the disease.  
Table 3. Variants in or near genes encoding proteins involved in ECM remodeling, 
found to be associated with AMD at genome wide level (p<5x10–8)  
No. Locus name Index variant 
Major / Minor allele 
Association results minor allele frequency 
  Cases Controls OR P 
2 COL4A3 rs11884770 C/T .258 .278 0.92 2.6 x 10–4 
3 ADAMTS9-AS2 rs62247658 T/C .466 .433 1.14 7.8 x 10–11 
4.1 COL8A1 rs140647181 T/C .023 .016 1.85 1.6 x 10–14 
4.2 COL8A1 rs55975637 G/A .132 .117 1.16 3.8 x 10–7 
17 ARHGAP21 rs12357257 G/A .243 .223 1.12 1.8 x 10–6 
18 ARMS2/HTRA1 rs3750846 T/C .436 .208 2.93 6.0 x 10–645 
19 RDH5/CD63 rs3138141 C/A .222 .207 1.18 4.7 x 10–8 
21 B3GALTL rs9564692 C/T .277 .299 0.90 1.0 x 10–6 
25 CTRB2/CTRB1 rs72802342 C/A .067 .080 0.79 8.0 x 10–9 
29 CNN2 rs67538026 C/T .460 .498 0.90 1.4 x 10–6 
31 MMP9 rs142450006 TTTTC/T .124 .141 0.84 5.3 x 10–9 
33 SYN3/TIMP3 rs5754227 T/C .109 .137 0.79 5.7 x 10–16 
34 SLC16A8 rs8135665 C/T .217 .195 1.14 1.4 x 10–8 
Table was adapted from 27 
Table 3. Variants in or near genes encoding proteins involved in ECM remodeling, found to be associated 
with AMD at genome wide level (p<5x10–8) 
Table was adapted from 27
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compared to controls. Because the eye, and especially the  macula, is susceptible to 
pathological oxidative processes affecting proteins and lipids, multiple factors related 
to oxidative stress have been the subject of research and found to be associated with 
AMD 55-58. 
1.5.3 Extracellular matrix (ECM) remodeling
Genetic evidence also suggests that ECM remodeling is involved in the disease 
process. Drusen form within Bruch’s membrane, which is layered sheet of ECM 59. 
Moreover, genetic variation in genes encoding proteins involved in ECM remodeling, 
such as matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases, 
are associated with AMD 27 (Table 3). These findings suggest that tissue remodeling, 
potentially in the context of an immunological response with infiltrating immune cells, 
contributes to the etiology of the disease. 
1.5.4 Angiogenesis
The formation of new blood vessels from the choroid and growth into the retina is 
central to AMD pathology in the late (wet) stage. Upon a hypoxic cue, the choroid 
begins to develop fragile new blood vessels to oxygenize the retina. The main driver 
of this effect is vascular endothelial growth factor (VEGF). The gene coding for this 
molecule is also genetically associated with the disease 27, but more importantly, 
when VEGF is targeted using antibodies, the neovascular disease process is arrested, 
resulting in an improved visual outcome in many patients with the wet form of AMD 
60-62. 
1.6 TREATMENT FOR AMD
To date, only people that suffer from wet AMD have an approved therapy available to 
them, targeting VEGF with monthly intravitreal injections. These patients represent 
the minority, as only between 10%-15% of patients progress to this form of AMD 63. 
Patients with early, intermediate or the GA forms of AMD do not have a treatment 
available to them. Although AREDS2 supplementation can slow down the progression 
of AMD 64, no definitive therapy exists to arrest disease progression definitively. 
Based on all the available evidence, targeting of the complement system is becoming 
an emerging alternative strategy for the treatment of AMD. Several clinical trials 
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targeting components of the complement system (C3, C5, and FD), have been 
performed or are currently ongoing 36,65,66. The outcomes of these trials showed limited 
67 or no meaningful effects [NCT01603043] 68. It is not well understood why targeting 
the complement system was not very effective so far, but it may be a result of the high 
variability in complement activation in both patients and controls. 
1.7 AIMS AND OUTLINE OF THE THESIS
The aim of this thesis is to understand the molecular drivers of AMD, and to study the 
functional consequences of genetic variation associated with AMD. 
Chapter 2 summarizes all reported findings of compounds measured in systemic and 
eye fluids, in relation to AMD. This literature review represents the first systematic 
categorization of potential biomarkers for AMD and their use in research, diagnostics 
and clinical trials. 
Chapter 3 explores rare variants in the C3 gene of the complement system. This 
strategy was developed in an attempt to solve part of the missing heritability in AMD. 
Chapter 4  describes the association of AMD-associated variants with systemic 
complement activation to identify how these variants influence complement activation 
levels.
Chapter 5 advances the work in Chapter 4 by combining the effects of several 
variants in genes encoding components in the complement system into a complotype. 
Here, we examined the combined effect of multiple genetic variants and identified 
a novel complotype combination, which is associated with both AMD and systemic 
complement activation. 
Chapter 6 describes a statistical analysis of AMD-associated variants and complement 
activation levels with multiple factors belonging to the lipid metabolism pathway. As 
multiple pathways are involved in the pathogenesis of AMD, this chapter explores 
where these pathways intersect and what the relevance of this intersection is.
Chapter 7 takes a non-biased approach using GWAS to identify genetic variants 
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that influence complement activation levels. In the future, such genetic markers can 
potentially help stratify patients into subgroups that could benefit the most from 
novel treatments targeting the complement system in AMD. 
Chapter 8 discusses the results of the previous chapters, and places them in the 
context of current literature and advancements in the field.
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ABSTRACT
Biomarkers can help unravel mechanisms of disease and identify new targets for 
therapy. They can also be useful in clinical practice for monitoring disease progression, 
evaluation of treatment efficacy, and risk assessment in multifactorial diseases, such 
as age-related macular degeneration (AMD). AMD is a highly prevalent progressive 
retinal disorder for which multiple genetic and environmental risk factors have been 
described, but the exact etiology is not yet fully understood. Many compounds have 
been evaluated for their association with AMD. We performed an extensive literature 
review of all compounds measured in serum, plasma, vitreous, aqueous humor, and 
urine of AMD patients. Over 3600 articles were screened, resulting in more than 
100 different compounds analyzed in AMD studies, involved in neovascularization, 
immunity, lipid metabolism, extracellular matrix, oxidative stress, diet, hormones, 
and comorbidities (such as kidney disease). For each compound, we provide a short 
description of its function and discuss the results of the studies in relation to its 
usefulness as AMD biomarker. In addition, biomarkers identified by hypothesis-free 
techniques, including metabolomics, proteomics, and epigenomics, are covered. In 
summary, compounds belonging to the oxidative stress pathway, the complement 
system, and lipid metabolism are the most promising biomarker candidates for AMD. 
We hope that this comprehensive survey of the literature on systemic and ocular fluid 
compounds as potential biomarkers in AMD will provide a stepping stone for future 
research and possible implementation in clinical practice.  
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2.1 INTRODUCTION
The term biomarker refers to an objective, measurable characteristic that is indicative 
of a biological process (normal, pathogenic, or in response to treatment).30 Biomarkers 
can help unravel mechanisms of disease and identify (new) targets for treatment. The 
potential benefit of biomarkers in drug development is to allow earlier, more robust 
drug safety and efficacy measurements.385  In addition, biomarkers can be useful in 
clinical practice for detecting disease, monitoring disease progression, evaluation 
of treatment efficacy, and risk assessment. Biomarker testing is an important step 
toward personalized medicine in many diseases, such as cancer,198  but also in age-
related macular degeneration (AMD).
AMD is the leading cause of irreversible loss of vision among the elderly in the Western 
world, and the prevalence of AMD is expected to increase with population ageing.364
The early stage of AMD is characterized by subretinal yellowish deposits, known 
as drusen, and changes in macular pigmentation.43,  151  At this stage, patients 
usually express little or no complaints. As AMD progresses, central vision becomes 
increasingly blurred, resulting in irreversible vision loss in the advanced stages of the 
disease. Two subtypes of advanced AMD can be distinguished: geographic atrophy 
(GA) and neovascular AMD (nAMD).43, 151 The atrophic form of AMD is characterized 
by cell death of the retinal pigment epithelium (RPE) and photoreceptors causing 
gradual vision loss.136 Neovascular AMD, also referred to as “wet” or “exudative” AMD, 
is characterized by abnormal vessel growth into the retina from the choroid (choroidal 
neovascularization [CNV]). Leakage from these fragile neovascularizations can cause 
rapid loss of vision.363 In this review, we will use the following terms for the different 
AMD subgroups described in literature: any AMD, early AMD, advanced AMD (GA/
neovascular/any advanced), and dry AMD (for definitions of these terms, see Table 1).
AMD is a multifactorial disease, and many risk factors for the development of AMD 
have been described. The most commonly reported environmental risk factors include 
aging, smoking, family history, low dietary intake of antioxidants and omega-3 fatty 
acids, and reduced physical activity.44, 192, 204 In addition, multiple genetic risk factors 
have been identified, consisting of genetic variants that are either common or rare in 
the population. A large risk effect has been reported for genetic variants located at 
the CFH and ARMS2/HTRA1 loci.101 Most genes associated with AMD can be clustered 
into 5 main pathways: the complement pathway, lipid transport, extracellular matrix 
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(ECM) remodeling, angiogenesis, and cell survival.100 Despite considerable progress in 
understanding the genetic architecture of AMD, the exact disease etiology is not yet 
fully understood.
In attempts to unravel the etiology of AMD, to improve patient stratification, to 
monitor disease progression, and to discover new drug targets, many biomarker 
studies have been performed. In general, new analytical strategies have emerged, 
moving from single markers toward complex biomarker signatures, increasing the 
chance for greater specificity and a higher diagnostic or predictive value.
There has been no comprehensive overview of all potential biomarkers and their 
applicability in AMD. Here, we present a detailed summary of the current literature on 
molecular compounds reported as analyzed in serum, plasma, aqueous humor, vitreous, 
and urine of AMD patients. The scope of this review is limited to nongenetic chemical 
compounds. For all compounds, a short description of their function is provided, and 
the results of the studies are summarized and discussed in relation to AMD. Currently, 
most of these markers are not yet established as routine clinical diagnostic tools and 
are discussed here to direct future research and eventually clinical implementation.
Table 1. Explanation of terms used in this review to describe different types of AMD
26 
 
AMD subgroups described in literature: any AMD, early AMD, advanced AMD 
(GA/neovascular/any advanced), and dry AMD (for definitions of these terms, 
see Table 1). 
Table 1.   Explanation of t rms u ed in this r view to d scribe different types of 
AMD 
Type of AMD Criteria 
Any AMD No specific definition of AMD reported or analyses were 
performed on all AMD stages together Early AMD Analyses 
were performed on AMD cases in the absence of advanced 
stage disease (GA or CNV) and 
can include early and/or intermediate AMD 
Advanced: GA Geographic atrophy of the RPE secondary to AMD 
Advanced: neovascular Choroidal neovascular lesion (active or occult) secondary to 
AMD, including serous and/or hemorrhagic RPE detachment, 
subretinal fibrovascular tissue and scarring 
Any advanced AMD No specific definition of advanced AMD reported or analyses 
were performed on both advanced AMD stages (GA and 
CNV) together 
Dry AMD No specific definition of dry AMD reported or analyses were 
performed on AMD cases in the absence of advanced 
neovascular AMD (can therefore include early AMD and/or 
advanced: GA) 
AMD, age-related macular degeneration; CNV, choroidal neovascularization; GA, 
geographic atrophy; RPE, retinal pigment epithelium. 
 
AMD is a multifactorial disease, and many risk factors for the development of AMD have 
been described. The most commonly reported environmental risk factors include aging, 
smoking, family history, low dietary intake of antioxidants and omega-3 fatty acids, and 
reduced physical activity.44, 192, 204 In addition, multiple genetic risk factors have been 
identified, consisting of genetic variants that are either common or rare in the 
population. A large risk effect has been reported for genetic variants located at 
the CFH and ARMS2/HTRA1 loci.101 Most genes associated with AMD can be clustered 
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2.2 NEOVASCULARIZATION AND HEMOSTASIS
Because choroidal neovascularization is one of the subtypes of advanced AMD, it is 
not surprising that the factors involved in neovascularization and hemostasis have 
been extensively studied. The results of the studies describing these factors are 
described in Sections 2.2.1, 2.2.2, respectively. A complete overview of the studies and 
references is provided in Supplementary Table 1.
2.2.1 Neovascularization
2.2.1.1 Vascular endothelial growth factor and soluble VEGF receptor 1
Vascular endothelial growth factor (VEGF) is currently the most important target 
in the treatment of nAMD, and the expression profile of VEGF has been extensively 
investigated in AMD patients. VEGF acts as a hypoxia-driven local signal to induce the 
formation of new blood vessels. Treatments inhibiting its function can partially restore 
and/or maintain vision in nAMD patients.
Contrary to expectation, VEGF is not consistently upregulated in AMD patients 
across studies. One study showed that VEGF levels in the aqueous humor of 12 nAMD 
patients were highly elevated (668.9 pg/mL) compared with 10 controls (cataract 
patients; 108.3 pg/mL).334  In a second study involving aqueous humor, however, 
significant higher VEGF levels could only be demonstrated in the most aggressive 
form of nAMD (type 3 neovascularization) compared with controls.74 A third study did 
not report a difference in VEGF levels in aqueous humor between nAMD and controls 
at all.290 Of note, a considerable range in VEGF levels in aqueous humor exists among 
these studies. In the study by Tong and colleagues,334  the levels of VEGF in control 
individuals were around 100 pg/mL, whereas the VEGF levels in the 2 other studies 
were much lower in controls (39.5 pg/mL and 63.9 pg/mL, respectively).74,  290  These 
differences may be explained by the use of 3 different analytical systems, emphasizing 
the need for standardized assay systems for key marker compounds in eye fluids. In 
addition, studies analyzing VEGF levels in vitreous samples did not detect differences 
between VEGF levels of nAMD cases and controls.135, 142
Although the measurement of VEGF levels in vitreous or aqueous humor is expected 
to best reflect VEGF levels in the macula, the procedure is invasive and therefore 
not desirable in individuals with early or intermediate AMD. Thus, for purposes of 
a clinical tool for diagnosis and progression, measurement of VEGF levels in more 
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accessible body fluids such as serum or plasma is preferable. Several studies did 
investigate VEGF levels in AMD patients and controls in serum or plasma, with mixed 
results. Four studies detected significantly upregulated levels of VEGF in serum or 
plasma,6, 115, 205, 338 but these findings are contrasted with 10 other studies that reported 
no association.41, 80, 112, 122, 125, 211, 231, 299, 353, 380
VEGF signaling is mediated through a complex of receptors and coreceptors, of which 
the soluble form of VEGF receptor 1 has been investigated in a number of studies. As 
in the case of VEGF, these studies do not offer a clear direction of effect. One study 
investigated the levels of soluble form of VEGF receptor in vitreous and found that 
levels were higher in nAMD patients.142 In contrast, 2 studies performed on serum could 
not corroborate these findings. One of the studies did not find any association,256 the 
other even reported lower levels of soluble form of VEGF receptor in nAMD.340
2.2.1.2 Pigment epithelium–derived factor
Pigment epithelium–derived factor (PEDF) is produced by RPE cells and has 
antiangiogenic properties, opposing the effects of VEGF. It has been proposed as a 
target to inhibit choroidal neovascularization and its expression signature in model 
systems suggests that it is downregulated under hypoxic conditions.139  Two studies 
on vitreous support this by demonstrating a marked reduction in PEDF levels in 
AMD patients versus controls.135,142  One study analyzing aqueous humor showed 
the opposite result, an increase of PEDF levels in AMD patients.334 These conflicting 
results are not readily explained. It is possible that in different fluids or in different 
parts of the eye (anterior/posterior), PEDF is regulated differently, but additional 
experiments are needed to determine the direction of the effect with certainty.
2.2.1.3 Transforming growth factor beta
Transforming growth factor beta (TGF-β) has been described to increase the expression 
of VEGF and is therefore also implicated in neovascularization.20 In vitreous samples 
of nAMD patients, TGF-β was significantly elevated when compared with controls 
(patients with idiopathic macular holes).20 An earlier study had already demonstrated 
that urinary TGF-β levels were increased in cases compared with controls, but only in 
early AMD was the difference significant.121
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2.2.2. Hemostatic system
2.2.2.1 Fibrinogen
Fibrinogen is a hemorheological factor involved in endothelial functioning.34   
Abnormalities in this factor are linked to thrombogenesis and vascular disorders166; 
hence, fibrinogen has been examined for its potential involvement in AMD. Studies 
have yielded mixed results. A number showed that increased fibrinogen level is a 
significant risk factor,65,  205,  223,  271,  321  whereas others did not find evidence for an 
association.58, 149, 185, 188, 288, 295, 331, 352,367
2.2.2.2 Plasminogen activator inhibitor 1
Plasminogen activator inhibitor 1 is another main component of the fibrinolytic 
system.29  Four studies have investigated whether a relation between plasminogen 
activator inhibitor 1 and AMD exists, with some support for a positive 
association,367 whereas other studies did not find any association.26, 288, 352
2.2.2.3 Platelet count
Several studies have measured platelet count. Most did not find any association 
between platelet counts and AMD.149, 180, 181, 186, 205 Two larger studies did find lower 
platelet counts in AMD, but this minimally protective effect for platelets on the 
development of AMD was only significant in univariate analyses.50, 285
2.2.2.4 Von Willebrand factor
Von Willebrand factor is a blood glycoprotein that is essential for normal 
hemostasis.289  Because vascular pathology is hypothesized to be involved in the 
pathogenesis of AMD, Von Willebrand factor was investigated as a possible risk factor. 
One study showed higher levels compared with controls (but in multivariate analysis 
no significant correlation was found),205  and 3 more studies found no association at 
all.288, 352, 367
In summary, many inconsistent results for factors involved in neovascularization have 
been reported, and further work is required to determine whether these could be used 
as AMD biomarkers. Factors involved in hemostasis described in Section  2.2.2  are 
unlikely to serve as biomarkers for AMD.
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2.3 OXIDATIVE STRESS
The human body is dependent on an aerobic environment for survival. This constant 
exposure to oxygen can lead to detrimental oxidative modifications of cell components 
and tissues. Usually, cells are equipped with sufficient antioxidative mechanisms 
to maintain oxidant homeostasis, but if this balance is disrupted, oxidative stress 
occurs.38 Oxidative stress in cells and tissues is characterized by an excess in molecules 
containing free radicals such as reactive oxygen species (ROS) and reactive nitrogen 
species.
Polyunsaturated fatty acid (PUFA) molecules are present in lipids on the membranes 
of cells and are prone to oxidation due to the presence of susceptible double carbon 
bonds.38,  245  During the process of lipid peroxidation by ROS, the double carbon 
bond is oxidized, leading to the formation of unstable reactive carbonyl compounds 
(e.g., malondialdehyde [MDA]).18, 22, 263, 357 ROS can also oxidize proteins, resulting in 
2-(ω-carboxyethyl) pyrrole (CEP) protein adducts117 and induce formation of advanced 
glycosylation end products (e.g., Nε-carboxymethyllysine).146, 304
Increased oxidative stress is thought to be one of the underlying factors in 
the occurrence of AMD.18,  24,  38,  245,333,  374  The eye, and especially the macula, is 
susceptible to oxidative stress because of its high metabolic activity and high PUFA 
content in the membranes of the photoreceptors.38  High oxygen pressure from 
the blood in the choroid and exposure to bright light also causes increased ROS 
levels in the retina.22,  263,  333  In addition, photoreceptors are subjected to constant 
shedding, and subsequent phagocytosis of the shed fragments leads to ROS 
generation.38, 374 Environmental factors such as smoking and alcohol consumption can 
also increase ROS production.346 Therefore, factors related to oxidative stress could 
potentially be valuable biomarkers for the incidence and/or progression of AMD and 
are discussed in more detail in Sections 2.3.1, 2.3.2, 2.3.3, 2.3.4. A schematic overview 
of these oxidative stress related factors is provided in  Figure  1  and a complete 
overview of the studies and references is provided in Supplementary Table 2.
2.3.1 Oxidation products
2.3.1.1 Malondialdehyde
MDA is one of the reactive carbonyl compounds originating from PUFA oxidation, 
and its presence is often used to measure lipid peroxidation levels in blood or serum 
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samples.18,  22,  335  Increased systemic levels of MDA have been consistently observed 
in both wet and dry AMD.18,  22,  86,  155,  263,  311,  335,  336,  346,  374,  375  In addition, an allele-
dependent increase of MDA levels was measured in subjects carrying the A69S variant 
(rs10490924) in the ARMS2 gene that is associated with AMD. Patients heterozygous 
or homozygous for the risk allele showed higher MDA levels.263
MDA is a highly reactive molecule that forms covalent bonds with the amino acids 
of endogenous proteins. This MDA modification can be recognized by factors of 
Figure  1. Networks of oxidative stress in age related macular degeneration (AMD). Spheres are 
colored to indicate levels in AMD patients compared to controls based on literature: upregulated 
(green), downregulated (blue), or inconsistent levels (gray). In this figure, studies reporting no association 
were not taken into account for the sake of readability. Apo, apolipoprotein; CEP, 2-(ω-carboxyethyl) 
carboxyethylpyrrole; DHA, docosahexaenoic acid; GSH, glutathione; GSHP, glutathione peroxidase; GSHR, 
glutathione reductase; HCTL, homocysteine thiolactone; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; MDA, malondialdehyde; MS, methionine synthase; Ox, oxidized; PON1, paraoxonase 1; PUFA, 
polyunsaturated fatty acid; RNS, reactive nitrogen species; ROS, reactive oxygen species; SOD, superoxide 
dismutase; Vit, vitamin.
37
Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration 
2
the innate immune system such as complement factor H (FH), immunoglobulin M 
(IgM), and macrophages.53, 357, 358 Binding of MDA by IgM or macrophages leads to a 
proinflammatory response by increasing the expression of the inflammation factor 
interleukin (IL)-8,274, 358 whereas binding to FH attenuates inflammation.358
2.3.1.2 CEP adducts and N(6)-carboxymethyllysine (CML)
Docosahexaenoic acid (DHA) accounts for about 80% of all PUFAs in the photoreceptor 
outer segments and is most prone to oxidation in human tissues.96  Upon oxidative 
stress, DHA is oxidized forming specific CEP adducts.117  Plasma CEP levels in AMD 
patients are elevated compared with controls.118, 242, 351 Moreover, elevated CEP levels 
combined with AMD risk alleles in ARMS2, HTRA1, CFH, or C3 increased the risk of 
AMD twofold to threefold compared with genotype alone.118
Furthermore, plasma of AMD patients contained more and a higher diversity of CEP 
autoantibodies compared with controls in 2 studies from the same group.117, 118 Another 
independent study found no association between CEP autoantibodies and AMD.242
CML is an advanced glycation end product that originates from a protein lysine 
modification and is a major immunological epitope recognized by the immune 
system.146  Plasma CML levels were upregulated in AMD in one study,242  but no 
significant difference was found in another.304
Both CEP adducts and CML are present on proteins. They are recognized by the immune 
system146, 359 and can stimulate angiogenesis in vivo.78, 248 Receptor-mediated binding 
of CEP adducts results in an angiogenic response of endothelial cells independent of 
VEGF signaling.359 Upregulation of CML and CEP levels in AMD might be implicated 
in the progression toward nAMD by promoting angiogenesis, but further studies are 
necessary to support this hypothesis.
2.3.1.3 Protein carbonyl groups and total oxidation status
Levels of protein carbonyl groups are often used to assess the total protein oxidation 
status in subjects as they are easy to measure.64 Protein carbonyl groups consist of an 
oxygen molecule bound to a carbon atom with a double bond (-RC=O) resulting from 
protein oxidation and are therefore indicative of oxidative stress. Elevated levels of 
both protein carbonyl group336, 379 and total oxidation status336, 341 were found in nAMD 
patients.
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2.3.1.4 Oxidized low density lipoprotein
Low-density lipoprotein (LDL) is abundantly present in and around cells and is an easy 
target for oxidation by ROS. LDL cholesterol (LDL-C) has been studied extensively in 
the context of AMD, described in Section 2.5.2; however, studies on its oxidized form 
(oxidized low density lipoprotein [Ox-LDL]) are more limited. Higher Ox-LDL levels 
were found systemically in AMD patients compared with controls,147, 152, 153 but a lack 
of association has also been reported.184
Increased Ox-LDL levels are known to activate various factors of the complement 
system such as C3b, C5b-9, and complement factor B (FB).79  These factors are 
described in more detail in Section  2.4.1. High Ox-LDL levels as observed in AMD 
might initiate apoptosis of RPE cells through disruption of the mitochondrial pro- 
(Bax) and antiapoptotic (Bcl2) balance,373 leading to GA. In addition, uptake of Ox-LDL 
molecules by macrophages contributes to the formation of foam cells, implicated in 
the development of atherosclerotic plaques.270
2.3.2 Nitric oxide
Nitric oxide is one of the most abundant free radicals in the human body and is able 
to react with other ROS resulting in cell dysfunction and apoptosis.86 It is synthesized 
by endothelial cells and is an important vasoactive agent affecting blood flow and 
other vascular functions.28 Involvement of nitric oxide in AMD is less clear. One study 
observed increased levels of nitric oxide in AMD patients,86 another study described 
downregulation of nitric oxide in nAMD,335 and a third study reported no association.338
2.3.3 Homocysteine
Homocysteine is an intermediate molecule in the conversion of the amino acid 
methionine to cysteine and glutathione (GSH), a process mediated by multiple 
enzymes.104, 294 Homocysteine can autooxidize in plasma, leading to the formation of 
various reactive products such as homocysteine thiolactone, which is also accompanied 
by ROS generation (Figure 1).60
Dysregulation of the homocysteine balance has been associated with 
various diseases such as vascular dysfunction, autoimmune diseases, and 
neurodegenerative disorders.294  Increased systemic levels of homocysteine 
were observed in both neovascular and dry forms of AMD compared with 
controls,18,  19,  60,  110,  113,152,  153,  168,  213,  284,  300,  347 and there were also higher levels in the 
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vitreous of nAMD patients.213  Moreover, some studies found higher homocysteine 
levels in nAMD compared with dry AMD19, 110; however, other studies did not find an 
association between homocysteine levels and AMD.54, 132, 188, 247, 352, 367
2.3.4 Antioxidants
Antioxidants enhance ROS clearance and prevent ROS formation thereby averting 
damage in the aging eye and other tissues.333  Enzymes such as catalase, superoxide 
dismutase, and paraoxonase prevent the accumulation of oxidized lipids by converting 
ROS before they can react or by removing the oxidized products from the endogenous 
proteins.333 Several vitamins and trace elements act as cofactors for these enzymes, or 
react with ROS to prevent accumulation.357, 374
Multiple studies hypothesized that the antioxidant capacity in AMD patients might 
be impaired, and some showed a decreased overall antioxidant capacity in serum 
of patients.58,  87,  269,  311,  336,  379  In the following sections, we discuss levels of thiols 
(Section 2.3.4.1), carotenoids (Section 2.3.4.2), and enzymes with antioxidant activity 
(Section 2.3.4.3) in AMD patients.
2.3.4.1 Thiols and GSH
Thiols mediate an important part of the balance between proper oxidation versus 
antioxidants in tissues. Their main characteristic is a carbon-bonded sulfhydryl group 
(C-SH), which can form a disulfide bridge with other thiols via redox reactions (C-S-
S-C). Thiols can neutralize ROS by providing an electron during the formation of the 
disulfide bridge.218 Although their normal function is to prevent oxidative stress, thiols 
can also promote oxidative stress in the presence of metal ions such as iron.152
Thiol content is either measured by focusing on the individual thiols or by evaluating 
total thiol (tSH) content of the blood. GSH is one of the most important thiols in the 
body. GSH can be transformed into glutathione disulfide (GS-SG) by the enzyme 
glutathione peroxidase (GSHP), thereby breaking down hydrogen peroxide (2 GSH 
+ H2O2 → GS-SG + 2 H2O).
218 Glutathione reductase (GSHR) is able to transform the 
formed glutathione disulfide to its monomeric form (GS-SG + NADPH + H+ → 2 GSH 
+ NADP+), making it available for conversion by GSHP again.218 This circular process 
(Figure 1) is of vital importance for proper ROS maintenance.
Lower levels of GSH and tSH are thought to result in more ROS formation owing 
to the absence of hydrogen peroxide clearance, resulting in subsequent oxidative 
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damage.60,  333  Lower levels of total thiol content60,  152,  341and plasma GSH60,  152  were 
found in patients with AMD compared with control subjects, and both were negatively 
correlated with homocysteine levels60; however, multiple studies have found no 
association between systemic GSH levels and AMD.35, 72, 273, 291, 375
Plasma and serum GSHR levels were lowered in patients with AMD,55, 58, 379 although 
1 study did not find this association in erythrocytes.68  Systemic GSHP levels were 
lowered in some studies85,  269,  272,  346  and higher in 1 study,71  but in most studies, no 
association was found.55, 58, 68, 375, 379
2.3.4.2 Carotenoids
Carotenoids are a group of natural red and yellow hued pigments (carotenes and 
xanthophylls) synthesized in most plants. The antioxidant capacity of carotenoids is 
based on their ability to absorb and process free electrons from ROS such as singlet 
oxygen (1O2) and peroxyl radicals (ROO
•). After the uptake of an electron, the carotenoid 
releases its energy in the form of heat and can be used again. Humans are unable to 
synthesize carotenoids and rely on dietary intake of vegetables.95,  325  In AMD, total 
serum carotenoid levels were decreased in 2 studies by the same group,87, 88 whereas 
2 other studies described a lack of association.40, 313
Two main xanthophylls are located in the macula: lutein is concentrated in the 
peripheral macula and zeaxanthin in the fovea. Here, they are able to attenuate 
blue light wavelengths, preventing the light from reaching and damaging the 
underlying photoreceptors.195  In blood, lutein and zeaxanthin are transported by 
lipoproteins such as high-density lipopotein (HDL) and LDL. Zeaxanthin and lutein 
exert their antioxidant abilities by reacting with free radicals both in the macula 
and in blood.195 Levels of lutein and zeaxanthin were found to be decreased in AMD 
patients in several studies.70, 87, 384 One study described decreased levels of zeaxanthin 
but not lutein in AMD patients.103  Others found no association for either lutein or 
zeaxanthin.40, 214, 224, 292, 313
β-cryptoxanthin is a carotenoid most commonly found in citrus fruits. Besides its 
role as an antioxidant, in  vitro experiments have shown that β-cryptoxanthin also 
stimulates DNA repair mechanisms.206  Levels of β-cryptoxanthin were decreased in 
patients with advanced AMD in some studies,87, 224, 313, 384 whereas others did not find a 
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significant association with AMD.40, 70, 214, 292
A decrease of α-carotene was found in patients with nAMD,87,  384  whereas higher 
levels of α-carotene were present in early AMD.384  Also β-carotene levels were 
decreased in advanced AMD in some studies87,  224,  384; however, most studies did 
not find a significant association between AMD and α-carotene or β-carotene 
levels.40,70,  214,  224,  292,  313,  322,  360  Importantly, supplementation of β-carotene has been 
associated with an increased risk of lung cancer in smokers and former smokers, and 
therefore, long-term use to inhibit AMD progression is not recommended.5, 251
Finally, one of the most potent antioxidants present in blood is lycopene. The main 
dietary sources of this red pigment carotenoid are red fruits or vegetables, such as 
tomatoes.102 Levels of lycopene were either decreased in AMD patients40, 313, 384 or not 
associated with AMD.70, 87, 214, 224, 292
In summary, when studies reported a significant association between carotenoids 
and AMD, the vast majority described decreased carotenoid levels in patients. This 
probably reflects a difference in dietary intake of these carotenoids between AMD 
patients and controls. Several studies reported that a higher intake of carotenoids is 
associated with a reduced risk of AMD.332,  344,  365  In addition, a beneficial effect was 
shown for supplementation with lutein and zeaxanthin on progression to advanced 
AMD.3, 4, 5
2.3.4.3 Enzymes
2.3.4.3.1 Superoxide dismutase
Superoxide dismutase (SOD) is an important antioxidant that catalyzes the conversion 
of superoxide (O2
•−) into oxygen and hydrogen peroxide (H2O2).
333 Two families of SOD 
exist based on their metal ion cofactor: SOD1 (CuZnSOD), which is localized to the 
cytoplasm and SOD2 (MnSOD), found in mitochondria.333  The absence of SOD1 or 
SOD2 has been associated with early retinal cell degeneration in mice,129, 164 suggesting 
an important role for SOD in the eye.
With regard to AMD, several reports show elevated systemic SOD activity in AMD 
patients compared with controls,10,  155,  310,  311  others found lowered SOD activity 
levels,86, 272, 346, 375, 379 and still others measured no significant association.55, 58, 68, 71, 269 One 
study showed a significant difference in SOD activity between late and early AMD, 
with a lower SOD activity in late AMD patients.86
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The association of both low and high SOD serum activity levels with AMD might be 
explained by the damaging effects of both high and low levels of SOD. High levels 
of SOD lead to higher H2O2  production, whereas low SOD activity leads to the 
continuing presence of O2
•− molecules. The detrimental effects of both low SOD and 
high SOD activity on ROS production suggest that imbalance of the enzyme activity 
leads to pathological conditions and that proper SOD balance is important to maintain 
homeostasis.
2.3.4.3.2 Paraoxonase 1
Paraoxonase 1 (PON1) is bound to HDL. PON1 hydrolyzes organophosphates and 
lipid peroxides and inhibits the oxidation of LDL.18,  153  In addition, PON1 is able 
to detoxify homocysteine thiolactone, one of the highly reactive metabolites of 
homocysteine.151  Active PON1 interacts with oxidized proteins or lipids, leading 
to its own inactivation.17  The low serum PON1 activity levels observed in AMD 
patients18,  22,  341  could be due to inactivation of PON1 after reacting with oxidized 
proteins.
2.3.4.3.3 Catalase
Catalases are important in ROS clearance by converting hydrogen peroxide (H2O2) 
to oxygen and water.47 In AMD, 3 studies reported downregulated systemic catalase 
activity levels,272,  346,  374 whereas 3 others reported no difference in catalase activity 
levels between AMD patients and controls.68, 86, 269
Taken together, dysregulation of the oxidative stress pathway and the manner in 
which oxidative stress is managed by the body seems to play an important role in 
AMD. A large number of investigators have reported decreased levels of antioxidants 
and elevated oxidized protein or lipid levels (Figure 1). The most promising biomarker 
candidates in the oxidative stress pathway are MDA and homocysteine, which were 
consistently reported to be increased in AMD patients. For other factors, however, the 
reported associations were less clear and with mixed results. This could indicate that 
an imbalance of the entire oxidative stress system may play a role, rather than levels of 
individual factors of this system specifically.
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2.4 IMMUNITY
The involvement of the immune system in the pathology of AMD is widely accepted, 
and some suggest reframing AMD as an autoimmune disease.39  The activity of the 
immune system in AMD, both innate and adaptive, has been implicated at several 
levels. Immune cell infiltrates have been shown in the retinas of AMD patients 
examined postmortem,198  with evidence of cytokine/chemokine expression at the 
affected site, as described in more detail in Section 2.4.2.
Strong evidence for the involvement of the immune system in AMD also comes from 
several GWAS studies (described in Section  2.1).99,  101  In particular, the role of the 
complement system is apparent. In the following sections, we discuss immunity-related 
compounds, including systemic markers of the complement system (Section 2.4.1) and 
elements of adaptive and innate immunity (Sections 2.2, 2.3, 2.4). A complete overview 
of the studies and references is provided in Supplementary Table 3.
2.4.1 The complement system
The complement system is an integral part of innate immunity with essential roles in 
protection against foreign intruders via tissue inflammation, cell opsonization, and 
cytolysis. It is also involved in monitoring and maintaining host tissues by clearing 
cellular debris, maintaining cellular integrity, tissue homeostasis, and modifying the 
adaptive immune responses.105
Ever since histopathological studies demonstrated the presence of complement 
components in drusen,11,  127  the involvement of the complement system in AMD 
has been studied extensively and genetic evidence showing strong links between 
components of the alternative pathway of the complement system and AMD 
followed.101,193 Although the complement system acts locally, its components can also 
be detected systemically in serum or plasma. A number of studies have investigated the 
expression levels of complement regulators, complement components, and activation 
products in AMD patients versus controls. An overview of the alternative pathway of 
the complement system is provided in Figure 2.
The central molecule of the complement system is complement component 3 (C3). 
Enzymatic cleavage of C3 results in the generation of its active fragments C3a (a potent 
proinflammatory molecule) and C3b that, via several digestion steps, leads to C3d.220  
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Figure 2. Overview of the alternative pathway of the complement system. Spheres are colored to indicate 
levels in AMD patients compared with controls based on literature: upregulated (green), upregulated/no 
difference (dark green), upregulated/downregulated (gray), and no difference (yellow). (1) Complement 
component 3 (C3) splits into C3a and C3b by spontaneous hydrolyzation or by the C3-convertase (C4bC2) 
resulting from activation of the classical or lection pathway. (2) Factor B (FB) can bind C3b to form C3bB. 
(3) The bound factor B is then cleaved by factor D (FD) which results in the formation of the C3-convertase: 
C3bBb (4). This C3-convertase can cleave C3 which leads to more C3b and in turn increased formation of 
the C3-convertase (known as the C3 amplification loop). The C3-convertase can also bind another C3b 
molecule to form C3bBb3b, which is a C5-convertase (5). This C5-convertase can convert C5 into C5a and 
C5b. (6) C5b then sequentially binds C6, C7, C8, and multiple C9 molecules to form the terminal complement 
complex (SC5b-9), also known as membrane attack complex. * The C3-convertase is inhibited by several 
complement regulators, among which decay accelerating factor (DAF) and factor H (FH). ** Factor I (FI) can 
breakdown C3b via several digestion steps to C3c and finally C3d, this protease activity, however, requires 
a cofactor, such as FH.
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A number of studies measured systemic C3 levels but did not find an association with 
AMD,278, 298, 312, 319 whereas higher systemic levels of its active fragments, C3a and C3d, 
were detected in AMD patients.130, 278, 298, 319 These findings suggest that the processing 
of C3, that is its activation, may be associated with AMD and a number of studies have 
investigated this. Complement activation was measured as the ratio of C3 and its 
degradation product C3d (C3d/C3)280, 281, 319 or as a cleaved form of C3a (C3a-desArg) 
in blood317 and urine.121 Of the 5 studies that investigated complement activation in 
AMD, 4 found higher complement activation levels in AMD patients.280, 281, 317, 319 An 
association of C3a-desArg in urine with AMD was not established.121 A recent study 
suggests that complement activation levels may decrease at more advanced stages 
of the disease, but this finding needs to be confirmed in prospective AMD cohorts.320
Besides C3, complement component 5 (C5) is also essential in the activation cascade 
because it serves as the entry point for the formation of the terminal complement 
complex (SC5b-9).220  The activation product of C5, C5a, is a potent anaphylatoxin. 
Increased levels of C5a were detected in most, but not all130 studies examining the role 
of C5a in AMD.278, 298, 319 These same studies also tested whether SC5b-9 is associated 
with AMD. Higher SC5b-9 levels were detected in AMD in 1 study,298 but the other 2 
studies found no evidence for an association.278, 319
The activity of the complement system is tightly controlled by regulatory factors 
that ensure appropriate, but not excessive, generation of terminal complexes. Among 
others, they include complement FH (encoded by the CFH gene), factor I (FI, encoded 
by CFI), FB (encoded by CFB), factor D (FD, encoded by CFD), and decay accelerating 
factor (DAF/CD55, encoded by CD55).220
Genetic association studies showed strong evidence of an association between 
the  CFH  gene and AMD.101 Systemic levels of FH have been investigated with 
mixed results, however. Four studies report lower FH levels in AMD,14,  278,  308,  310  1 
study detected higher levels of FH in AMD,128 and another 4 studies did not find an 
association with AMD.120, 298, 312, 319
Similar to FH, FI also inhibits the activity of the complement system through inactivation 
of C3b. Genetic evidence for FI involvement in AMD has been shown previously, but 
no conclusive evidence links FI levels to AMD in general. One study reports increased 
FI levels in AMD,312 another reports decreased levels but only in patients carrying a 
rare genetic variant in CFI,343 and 2 did not find any association.278, 319
46
Chapter 2 
The findings for FB and FD levels in AMD are also inconsistent. Three studies 
reported higher FB levels in AMD patients,130, 298, 319 whereas 2 others did not detect 
an association with AMD.278, 312 Similar results were described for FD, where 3 studies 
reported higher FD levels,130,  298,  326  1 study reported lower levels in AMD,312 and 
another found no association with AMD.278 Finally, 2 studies that examined the role of 
CD55 did not find evidence for an association with AMD.123, 314
In summary, not only genetic studies but also studies measuring complement 
components provide evidence that link complement activation to AMD (Table  2). 
Some factors, however, should be taken into account when considering the use of 
systemic complement activation levels as a biomarker for AMD in individual patients. 
Often antibody-based tests do not discriminate between the total amount of a specific 
complement factor and its processed activated part, as cleavage of the preform to the 
active mature form cannot be distinguished by the reagent. Moreover, complement 
activation levels are subject to high variability, and other causes of increased 
complement activity should be excluded because increased complement activation 
may reflect immune system activity that is not necessarily connected to disease 
progression. Linking exacerbated complement activation in an individual patient to 
his or her genetic blueprint is potentially more useful. For example, haplotypes and 
combinations of genotypes in several complement genes have been associated with 
increased complement activation levels.130, 266 In addition, several investigations have 
now demonstrated that FI levels are lower in AMD patients carrying rare genetic 
variants in the CFI gene.107, 172, 343 For FH levels, there were similar associations with 
genotype. Some but not all rare variants in the CFH gene were associated with reduced 
FH levels.337,  349,  378  Thus, patients carrying rare variants in complement genes tend 
to have higher complement activation levels than AMD patients in general.106 These 
insights may benefit ongoing clinical trials on the effectiveness of complement 
inhibitors and could prioritize patients who carry rare variants in these genes.
2.4.2 Cytokines
2.4.2.1 Interleukins
Cytokines are a large family of small proteins that play a pivotal role in cell signaling. 
An important group of cytokines are interleukins. Interleukins play a key signaling role 
in the inflammatory response. Interleukin-6 (IL-6) is a cytokine with many described 
functions,215, 225 and its relationship to AMD has been investigated. A number of studies 
reported increased levels of IL-6 in AMD patients,7, 124, 191 but the majority found no 
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Table 2. Overview of studies measuring complement components in AMD patients compared with controls
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Table 2.  Overview of studies measuring complement components in AMD patients 
compared with controls 
Component Upregulation No difference Downregulation 
C3   Scholl et al, 2008298   
  
 
Reynolds et al, 2009278   
  
 
Silva et al, 2012312   
    
Smailhodzic et al, 
2012319   
C3a Scholl et al, 2008298     
  Reynolds et al, 2009278     
C3d Scholl et al, 2008298     
  Hecker et al, 2010128 
 
  
  
Smailhodzic et al, 
2012319     
C3a des Arg 
C3d/C3 
Sivaprasad et al, 
2007317  Guymer et al, 2011121   
C3d/C3 
Smailhodzic et al, 
2012319     
  Ristau et al, 2014280 
 
  
  Ristau et al, 2014281     
C5a Scholl et al, 2008298 Hecker et al, 2010130   
  Reynolds et al, 2009278 
 
  
  
Smailhodzic et al, 
2012319     
SC5b-9 Scholl et al, 2008298 Reynolds et al, 2009278   
    
Smailhodzic et al, 
2012319   
FH Hakobyan et al, 2008128 Scholl et al, 2008298 Reynolds et al, 2009278 
  
 
Silva et al, 2012312 Ansari et al, 201314 
  
 
Smailhodzic et al, 
2012319 Sharma et al, 2013308 
    Guymer et al, 2015120 Sharma et al, 2013310 
FI Silva et al, 2012312 Reynolds et al, 2009278   
  
 
Smailhodzic et al, 
2012319   
    
Van de Ven et al, 
2013a,343   
FB Scholl et al, 2008298 Reynolds et al, 2009278   
  Hecker et al, 2010130 Silva et al, 2012312   
  
Smailhodzic et al, 
2012319     
FD Scholl et al, 2008298 Reynolds et al, 2009278 
Silva and colleagues 
2012312 
  Hecker et al, 2010130 
 
  
  Stanton et al, 2011326     
DAF/CD55 
 
Haas et al, 2011123   
    Singh et al, 2012314   
a Significant downregulation of FI was described in a subgroup of patients with a rare variant in the CFI 
gene. 
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association with AMD in general.15, 58, 183, 188, 231, 240, 290, 352, 367 Notably, a number of these 
studies did find an association in subgroup analyses. For instance, an association with 
AMD was reported only in patients with high IL-6 levels58 or the association with IL-6 
was established only for GA patients.188  In addition, only the highest tertile of IL-6 
levels was associated with progression of AMD in a prospective cohort study.303
Other interleukins have also been studied in relation to AMD, although to a lesser 
extent. In most studies, these interleukins were measured in a multiplex analysis of 
inflammatory markers. Two studies measured multiple interleukins in serum.231, 240 In 1 
study, there were higher serum levels of IL-1β, IL-4, IL-5, IL-10, and IL-13 in patients with 
nAMD,240 but these factors were not associated with early, atrophic, or neovascular 
AMD in another study.231 Higher serum levels of IL-1α and IL-17 in nAMD patients were 
only reported in the first study. In addition, no association was found for IL-2, IL-12, 
and IL-15.240 Other studies also detected no association between IL-2,188  IL-15,89 and 
AMD. For IL-8, although no association was present in 2 studies,229, 235 a third larger 
study described higher IL-8 levels in AMD patients, in particular in dry AMD.7 Higher 
IL-18 levels were reported in dry, but not nAMD, in 1 study.143 A second study did not 
find different levels between different types of AMD and controls.89
Although most studies focused on systemic levels of interleukins, a small number 
performed measurements in aqueous humor290  and vitreous.383  Higher IL-1β levels 
were found in the vitreous of nAMD patients.383  In aqueous humor, IL-1α and IL-15 
were upregulated and IL-13 was downregulated, whereas for IL-2, IL-4, IL-8, IL-10, IL-
12, and IL-17, no differences were detected.290
2.4.2.2 Chemokines and chemokine receptors
Chemokines (chemotactic cytokines) have the ability to direct movement of cells 
through receptor-mediated chemotaxis. Evidence from postmortem material and 
animal models have implicated infiltrating immune cells in pathological eye tissues, 
suggestive of the involvement of chemokines in these environments.200, 287, 305, 329
Chemokine ligand 2 (CCL2; or monocyte chemoattractant protein 1) attracts C-C 
chemokine receptor type 2 (CCR2)-expressing monocytes into tissues and is one of 
the most studied chemokines in AMD. Five relatively small, case-control studies did 
not find an association between levels of CCL2 and AMD,92, 116, 120, 231, 290 but several 
larger studies did see an association with increased levels of CCL2.9, 310, 382 This effect 
was also reported in a cross-sectional study linking higher levels of urinary CCL2 
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to early AMD.121 Overall, these findings support the notion that CCL2 is involved in 
AMD. Interestingly, CCR2-expressing cells can also be detected systemically, and both 
decreased and increased levels have been associated with AMD.9, 115 Two other studies 
did not find any association.94, 376
Another receptor involved in the recruitment of monocytes, CX3C receptor 1, was 
measured in two AMD studies.92,  116  Only the more recent study reported CX3C 
receptor 1 to be upregulated in both early and neovascular AMD.92
Eotaxin (eosinophil chemotactic protein/CCL11) and closely related eotaxin-2 
(CCL24) attract eosinophils. These are interesting molecules for AMD pathogenesis 
because CCL11 and CCL24 and their receptor CCR3 are implicated in choroidal 
neovascularization.91, 309 CCR3 is expressed on choroidal neovascular endothelial cells 
and signaling through this receptor leads to endothelial proliferation, even without 
the involvement of eosinophils or other immune cells. Blocking CCR3 signaling in 
animals led to a potent inhibition of neovascularization, even stronger than blocking 
VEGFA signaling.329  Levels of CCL11 were investigated in 2 studies, one reporting 
increased levels in AMD,231  and the other finding no differences.91  Supportive of 
the aforementioned findings, 2 studies of the same group reported CCL24 to be 
upregulated in AMD.309, 310 Despite these overall promising results, systemic elevations 
of CCR3 on immune cells have not yet been reported. The only study investigating 
CCR3 on granulocytes reported no association, although there was a trend toward 
higher expression of CCR3 in nAMD.91 Taken together, the CCL11/CCL24-CCR3 axis 
is potentially involved in human AMD pathology, but it is not yet clear whether this is 
mostly a local signaling, mediated through CCR3 expression on endothelial cells, or 
whether systemic CCR3-expressing cells could also be involved.
The chemokine ligand CXCL10, also known as interferon gamma-induced protein 10, 
attracts a range of cell types and is an inhibitor of angiogenesis.13 Two studies showed 
no association with CXCL10 in serum or plasma and AMD,93, 116 and only 1 study showed 
elevated serum CXCL10 levels in AMD patients.231 Of interest is a recent publication, 
showing upregulation of CXCL10 in aqueous humor of AMD patients compared with 
controls undergoing cataract surgery,290 suggesting that the effect of this chemokine 
might be local.
The receptor for CXCL10 is CXCR3 which is expressed on a variety of cell types. Only 
one study investigated numbers of CXCR3-expressing cells peripherally and detected 
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reduced presence of CD8+ T-cells expressing CXCR3 in AMD,93 but additional research 
is warranted before concluding whether the CXCL10-CXCR3 axis can be reliably used 
as a biomarker for AMD.
It has been suggested that stem cell progenitor cells are involved in the disease 
etiology of AMD. Chemokine ligand CXCL12, also known as stromal cell-derived factor 
1, plays a role in the movement of these stem cell progenitor cells throughout the 
body. Four small case-control studies have investigated the plasma levels of stromal 
cell-derived factor 1 in AMD patients with mixed results. Two studies, by the same 
group, report significantly lower levels of stromal cell-derived factor 1 in patients with 
nAMD,210, 211 whereas another study showed the inverse effect,299 and the fourth did 
not report any differences between nAMD and control individuals.115
2.4.2.3 Other cytokines
2.4.2.3.1 Tumor necrosis factor alpha
Tumor necrosis factor alpha, an important marker for systemic inflammation, has been 
investigated as such in several studies; however, no significant associations between AMD 
cases and controls were reported in serum or plasma.120, 124, 183, 188, 231, 240, 380 Increased 
levels of soluble tumor necrosis factor alpha receptor 2 were reported in a case-control 
study in early and neovascular AMD,89 which in a large population-based study did not 
reach statistical significance, but there was a trend toward upregulation in early AMD 
patients.191
2.4.2.3.2 Interferon gamma
Interferon gamma is an important cytokine in both innate and adaptive immunity as it 
induces cellular response to infections.297 Three studies measured interferon gamma 
in AMD cases and controls, but none found an association with AMD.89, 231, 240
2.4.3 Other immune factors
2.4.3.1 C-reactive protein
C-reactive protein (CRP) is a marker of inflammation and a so-called acute phase 
protein because its levels change quickly upon disturbances of homeostasis. 
Evidence regarding the possible relation of this protein with AMD is inconclusive, 
with a roughly equal number of studies reporting higher CRP levels in AMD 
patients7,  56,  57,138,  174,  228,  282,  290,  301,  302,  304,  342,  347,  356,  376  or no clear evidence for an 
association.33,  58,  65,  120,  134,  141,  161,185,  217,  285,  312,  315,  327  Those that used a more precise 
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measurement of CRP (high-sensitivity CRP) were also not able to provide 
conclusive results: 5 studies detected higher levels of high-sensitivity CRP in AMD 
patients,32,124,  191,  230,  295  compared with 5 that did not show an association with 
AMD.15, 183, 188, 352, 367
2.4.3.2 (Soluble) Intercellular adhesion molecule and vascular cell 
adhesion molecule
Intercellular adhesion molecule and vascular cell adhesion molecule are 
immunoglobulins that are usually upregulated on cell surfaces after immune 
signaling has taken place.48  They form a sticky surface to which immune cells that 
express integrins can adhere. These molecules and their soluble counterparts are 
rarely investigated alone but usually as part of a panel that measures inflammatory 
activity. For intercellular adhesion molecule, 1 study reported higher levels to be 
associated with the incidence of AMD in women,295  whereas 6 others did not find 
any association.120,  134,  183,  191,  352,  367  In the case of vascular cell adhesion molecule, 1 
study measured higher levels in AMD patients,191  whereas 2 studies did not find 
any association with AMD.120,  134  In addition, no association with AMD progression 
and either Intercellular adhesion molecule or vascular cell adhesion molecule was 
reported.303
2.4.3.3 White blood cell count
As mentioned previously in Section 2.4, a clear link with inflammation and inflammatory 
processes and AMD has been established, and several immune competent cells have 
been implicated in the disease etiology. As a result of local stress  or  inflammation, 
the body may respond by cellular proliferation  of immune cells and recruitment of 
these cells to the affected site. From this perspective, white blood cell count is an 
interesting parameter to measure in AMD. A relatively large number of studies have 
investigated white  blood cell count in AMD, and some did detect increased white 
blood cell numbers.31, 181, 182, 191, 307, 356 This contrasts with most studies that did not find 
any association.50, 113, 149, 157, 180, 181, 183, 185, 187, 205, 285, 315, 352, 367 Nevertheless, white blood 
cell count may still be considered as a potential biomarker for AMD if the analysis is 
performed in the context of a different theoretical framework. It is conceivable that 
it is not the total number of cells that change but rather the ratio between different 
cell types. Supporting this notion, a higher neutrophil/lymphocyte ratio has been 
associated to AMD and AMD subtypes.148 A more in-depth analysis of the different 
cellular subtypes, such as the relative expression of cytokine/chemokine receptors, 
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would offer more insights.
2.4.3.4 Pentraxin-3
Pentraxin-3 (PTX3), like CRP, belongs to the pentraxin superfamily. Upon inflammation, 
PTX3 is produced locally by the RPE162 and can interact with complement component 
C1q and enhances activation of the classical and lectin pathways of the complement 
system. In addition, PTX3 attracts complement FH, thereby inhibiting the amplification 
loop and preventing excessive activation of the alternative pathway.76, 162 Although 1 
case-control study reported higher plasma PTX3 levels in nAMD,228 a more recent study 
(including also early AMD and GA patients) could not replicate these findings.162 The 
latter study did however describe an increased expression of the PTX3 gene with age- 
and inflammation-induced apical PTX3 secretion of the RPE.162  Taken together, this 
suggests a more local expression of PTX3 in AMD; however, measurements of PTX3 
locally in vitreous samples have not yet been performed and would therefore be a 
target of further research.
2.4.4 Antibodies
2.4.4.1 Antiretinal autoantibodies
The formation of antibodies against foreign epitopes is a key element of immunity. 
When endogenous epitopes become the trigger for mounting an immune response, 
autoimmunity ensues.271 Antibodies against epitopes found in retinal material of AMD 
patients have been investigated in various studies. Several studies demonstrated 
upregulation of circulating antiretinal autoantibodies (ARAs) in the serum of AMD 
patients.49,  119,264,  268  Although one study showed similar levels of ARAs in cases and 
controls, it did show a difference in types of antibodies specific for each disease stage.2 In 
addition, higher concentrations of circulating ARAs were detected in treatment-
naive nAMD patients compared with controls.196,  197  These levels also correlated to 
lesion size.197  After the loading phase of anti-VEGF treatment, autoantibody levels 
decreased.196,  197  Moreover, correlations were reported between ARA levels and 
improvement of visual acuity, fluid reduction on optical coherence tomography, and 
decreased leakage on fluorescein angiography after 3 months.197
Furthermore, other studies attempted to identify specific circulating ARAs associated 
with AMD.145, 156, 232 Surprisingly, one study showed not only upregulation of antibodies 
but also downregulation of a specific ARA in AMD. Lower antibody concentrations 
were reported for α-crystallin, whereas α-enolase and glial fibrillary acidic protein 
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antibodies were both significantly higher in serum of AMD patients.156  The latter 
finding is supported by results from a previous study which showed different staining 
patterns in serum of AMD patients, with the most frequent pattern observed being 
almost identical to that using antiglial fibrillary acidic protein antibodies.268 In addition, 
using an untargeted approach, 1 study identified 4 novel retinal antigens in serum of 
AMD patients: retinol binding protein 3 (Rbp3), aldolase C, pyruvate kinase isoform 
M2, and retinaldehyde binding protein 1.232 Because Rbp3 and retinaldehyde binding 
protein 1 were previously reported in other ocular diseases, this study focused on 
aldolase C and pyruvate kinase isoform M2. A significant higher reactivity to aldolase 
C in nAMD, but not in early AMD, was reported. Because reactivity to pyruvate 
kinase isoform M2 was higher in both AMD groups compared with controls, this could 
potentially be a biomarker for the development of AMD.232 A more recent study with 
a similar approach also identified ARAs with higher reactivity in AMD; heat shock 
70 kDa protein 8 and 9, α-crystallin A chain, annexin A5, and protein S100-A9.145
2.4.4.2 Other autoantibodies
Serum autoantibodies have been extensively investigated by Morohoshi and 
colleagues using an antigen microarray analysis containing 85 autoantigens. Serum of 
AMD patients and controls showed a different IgG and IgM autoantibody profile, and 
multiple autoantibodies were significantly higher in AMD. In addition, they calculated 
IgG/IgM ratios for the antibodies and evaluated whether this ratio correlated to 
disease severity. Antiphosphatidylserine IgG/IgM was significantly elevated in AMD 
and correlated best with AMD stage. Moreover, reactivity to phosphatidylserine was 
highly increased in retina of AMD patients compared with controls.232
Other investigators focused specifically on antiphospholipid antibodies, which are 
reported to be found in aging people and diseases associated with aging.257  In this 
study, anticardiolipin IgG levels were associated with AMD, supported by the findings 
of Morohoshi and colleagues which showed higher expression of anticardiolipin 
antibodies in nAMD compared with controls.233, 257
As described in Section  2.3.1, anti-CEP antibodies have also been investigated in 
association with AMD.118, 117, 242
2.4.4.3 Antibodies against pathogens
Infection by pathogens leads to increased antibody titers of the foreign pathogen. 
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Several infectious agents have been implicated in AMD, and we detail the antibodies 
against these pathogens in this section.
Chlamydia pneumoniae  is an intracellular bacterial species that has been linked 
to atherosclerosis.137  Since AMD involves inflammatory processes similar to 
atherosclerosis, the association of  Chlamydia pneumoniae  with AMD was explored. 
One small case-control study found support for this with increased antibody levels in 
AMD patients,167 whereas 4 larger studies did not find evidence for a relation between 
anti-Chlamydia pneumonia antibodies and AMD.183, 188, 227, 283
The cytomegalovirus is another infectious agent that has been hypothesized to be 
associated with the pathogenesis of AMD, based on the relation between inflammatory 
processes induced by infection and the resulting vasculopathy.227  Only 2 studies 
investigated this association. One found no evidence for an association,90  whereas 
the other described higher levels of antibodies against cytomegalovirus in nAMD 
compared with controls and dry AMD.227
Another infectious agent possibly involved in the pathogenesis of AMD is Helicobacter 
pylori. Two studies have tested an association between antibodies against Helicobacter 
pylori and AMD but found no evidence for this, even when distinguishing between dry 
and neovascular AMD.188, 227
To summarize the most important findings regarding immune-related factors, 
involvement of the complement system in AMD is evident and complement activation 
products seem to be good biomarker candidates. Increased levels of inflammatory 
factors, such as CCL2 or CRP, have been frequently reported and support the notion 
that inflammatory processes underlie AMD. Yet, these are not specifically related 
to AMD and may therefore not be the best biomarker for clinical implementation. 
The use of multiplex assays for the simultaneous detection of multiple inflammatory 
markers (cytokines and chemokines) holds great promise, but additional data are 
required to determine their usefulness as AMD biomarkers. In addition, ARAs are also 
associated with AMD, but at present, it is unclear whether these autoantibodies play 
a direct role in the etiology of the disease or rather are the result of retinal damage. 
Further research is therefore necessary to determine if (specific) ARAs could be used 
as a biomarker for AMD.
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2.5 LIPID METABOLISM/HOMEOSTASIS
Lipid metabolism is one of the major pathways involved in the pathogenesis of AMD 
as evidenced by genetic associations of lipid-linked genes  CETP,  LIPC,  ABCA1, 
and APOE.99,  101  Moreover, drusen, the major hallmark of AMD, consists of at least 
40% lipids.126, 350 In addition, as mentioned in Section 2.4.4, there are similarities in the 
pathogenesis of atherosclerosis and AMD.368 Because lipids are important risk factors 
for atherosclerosis and CVD,207 these might also be associated with AMD. Numerous 
studies have measured lipid levels in serum or plasma, and the results of these studies 
are summarized in Sections 2.5.1, 2.5.2, 2.5.3, 2.5.4. We focus on studies that reported 
associations with AMD and results from large population-based studies. A complete 
overview of all studies and references is provided in Supplementary Table 4.
2.5.1 Lipids
Cholesterol has multiple functions. It is required for building and maintaining cell 
membranes, is involved in cell signaling processes, and is a precursor molecule for 
synthesis of steroid hormones, bile acids, and vitamin D.131
The population-based Cardiovascular Health Study reported lower levels of total 
cholesterol in AMD patients, of which the majority had early AMD.185, 217 Also in the 
Beaver Dam Eye Study, lower cholesterol levels were associated with development 
of early AMD in women,182  and there was a trend for lower levels of cholesterol in 
nAMD186; a more recent analysis of the Beaver Dam Eye Study data, however, did 
not show an association between AMD and cholesterol levels.183 In addition, 2 case-
control studies described lower levels of cholesterol in AMD patients.36, 267 In contrast, 
higher cholesterol was associated with AMD in 10 studies, although these were all 
case-control studies, and only half studied nAMD.8,  57,  67,  88,  97,  109,  134,  152,  246,  342  The 
vast majority of studies (Supplementary Table  4), however, did not demonstrate a 
difference in cholesterol levels between AMD patients and controls, including a meta-
analysis of 3 large population-based studies,190  and several large population-based 
studies.33, 37, 42, 50, 61, 73, 141, 143, 157, 160, 161, 176, 177, 184, 199, 261, 304, 306, 321, 331, 345, 354, 367,371
Triglycerides are molecules that have a glycerol backbone connected to 3 fatty acids 
of variable length. Most studies did not report differences in triglyceride levels 
between AMD cases and controls (Supplementary Table 4). Lower triglyceride levels 
were reported in early AMD,185, 371 nAMD,219 and any AMD.33, 177, 265, 285, 304 In contrast, 3 
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studies reported a higher level of triglycerides to be associated with AMD,67, 235, 246 of 
these, 1 study included only women,245 and 1 study found the association in women 
only.235
Phospholipids are another class of lipids and are an important component of cell 
membranes. In 3 studies, no association was found between phospholipids and 
AMD.1, 40, 292
2.5.2 Lipoproteins
Because of the insoluble nature of lipid molecules, lipoproteins are needed for 
transportation of lipids through the circulation. Five different lipoproteins exist, 
differing in their density and size: chylomicrons, very low–density lipoprotein, 
intermediate-density lipoprotein, LDL, and HDL.255  Both HDL and LDL carry 
cholesterol between the liver and periphery.131, 208, 265 The association between these 2 
lipoproteins and AMD has been extensively studied.
For AMD, higher levels of LDL-C were found in several studies. Half of these studies 
found this association when comparing controls to nAMD,109,  152,  154,  279,  342  others 
found an association in early AMD,273  any AMD,57,  67  and in women with dry 
AMD.246  Almost all other studies, including multiple large population-based 
studies,33, 37, 50,61, 184, 304, 331, 354, 371, 377 did not report an association between AMD and 
LDL-C (Supplementary Table  4). Only the Cardiovascular Health Study associated 
lower LDL-C levels with early AMD patients185  and reported a trend toward lower 
levels in patients with any AMD.217 Differences in results regarding LDL-C levels can 
be partly due to different measurement methods across studies, as it can either be 
measured directly, but more often is estimated using the Friedewald equation.98
Since HDL cholesterol (HDL-C) is inversely associated with CVD, one may have 
expected to also find this inverse association with AMD. Surprisingly, lower HDL-C 
levels were only described in a few studies in varying AMD stages; in late AMD,279, 331 in 
women with dry AMD,246 and in early AMD.180 Increased HDL-C levels in AMD patients 
were present in multiple studies.15, 36, 50, 61, 73, 141, 144, 161, 182, 184, 186, 265, 304, 345, 356, 376 It must 
be noted that most of these studies only found a weak association in a subgroup of 
AMD patients. Most of the studies did not describe significant differences in HDL-C 
levels (Supplementary Table 4).
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Three studies evaluated non-HDL-C, which is calculated by subtracting HDL-C from 
total cholesterol. Two studies, including a large meta-analysis of 3 population-based 
studies, reported no association with AMD,190, 265 whereas the third study found higher 
non-HDL-C to be associated with any AMD.57
Lipoprotein (a), Lp(a), is an LDL-like particle, which consists of apolipoprotein-B100 
and apoliprotein-A. Its precise function is unclear, but higher levels of Lp(a) have been 
repeatedly associated with CVD.82,  171 Contrarily, no association of Lp(a) levels with 
AMD or progression of AMD has been described so far.1, 57, 83, 94,185, 246, 303
2.5.3 Apolipoproteins
Apolipoproteins bind lipids to form lipoproteins that are responsible for lipid 
transport. They also function as enzyme cofactors and receptor ligands.1  There are 
several classes of apolipoproteins. The overview presented in this section is restricted 
to apolipoprotein A1 (ApoA1), the major component of HDL-C, apolipoprotein B 
(ApoB), mostly found in LDL-C, and apolipoprotein E (ApoE), found in IDL-C and 
chylomicrons. Several investigations found an association between apolipoproteins 
and AMD or features of AMD.1,  73,  94,  246,  265  The Pathologies Oculaires Liées à l’Age 
(POLA) study described ApoA1 to be associated with an increased risk of soft 
drusen73 and also in the European Genetic Database (EUGENDA) cohort, higher levels 
of ApoA1 were associated with AMD, even after adjustment for genetic variants that 
influence lipid levels.265 In contrast, one study reported a lower ApoA1 concentration 
in women with dry AMD.246 This study also described a higher concentration of ApoB 
in dry AMD cases, which is in concordance with another study.94 Higher ApoE levels 
were reported in advanced AMD compared with early AMD and control individuals; 
this difference could be due to a higher allelic burden of the  APOE  gene in these 
patients.1  Other studies did not describe an association between ApoA1, ApoB, or 
ApoE and AMD.57, 66, 83, 185
2.5.4 Fatty acids
There are different types of fatty acids. PUFAs usually derive from phospholipids or 
triglycerides.245, 254 The most commonly studied PUFAs in AMD are the omega-3 fatty 
acids DHA and eicosapentaenoic acid (EPA). Fish and other seafood are the main source 
of these omega-3 PUFAs.219, 221 Animal and epidemiological studies have shown a lower 
risk for AMD in subjects with high dietary intake of omega-3 fatty acids.21, 324 Also 2 
interventional studies with omega-3 fatty acid supplementation have been performed; 
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the Age-related Eye Disease Study 2 showed no beneficial effect for omega-3 fatty 
acid supplementation,3  whereas the Nutritional AMD Treatment 2 study showed a 
protective effect for DHA supplementation only in patient homozygous for the major 
allele (T) of the Y402H variant in the CFH gene.222
Considering omega-3 fatty acids as potential biomarkers, a number of studies 
investigated plasma or serum levels of these factors. In the Antioxydants, Lipides 
Essentiels, Nutrition et maladies Oculaires (ALIENOR), a population-based study, 
advanced AMD cases had lower plasma levels of α-linoleic acid and DHA compared 
with no or early AMD. In addition, lower plasma levels of EPA were associated with 
GA.221 This is in line with baseline measurements performed in the Nutritional AMD 
Treatment 2 study that showed that nAMD cases had lower EPA and DHA levels in 
red blood cell membranes and lower serum EPA.219  On the contrary, smaller case-
controls studies reported no effect or opposite effects for DHA, EPA, and α-linoleic 
acid.165,  252,  254,  292  For plasma or serum levels of docosapentaenoic acid, another 
omega-3 fatty acid, no significant associations were described.165, 221, 292
Omega-6 fatty acids, arachidonic acid and linoleic acid, and omega-9 fatty acid, oleic 
acid, have also been measured. A small case-control study found lower levels of 
linoleic acid and oleic acid, and higher levels of arachidonic acid in the membranes of 
erythrocytes of AMD patients.254 In line with these findings, a recent study reported 
higher serum arachidonic acid in nAMD.252 Two larger case-control studies, however, 
did not show different levels of these omega-6 and omega-9 fatty acids.165, 292
Regarding saturated fatty acids (which are single bonded), lower levels of palmitic acid in 
erythrocytes of AMD patients were reported in a small, case-control study,254 although 
systemic levels were not different between cases and controls.165, 254 Also for stearic 
acid, no association with AMD was detected.165, 254
Evidence for the involvement of lipids in AMD comes from epidemiologic, molecular, 
and genetic studies, but the exact role of systemic lipid levels is not yet clear. These 
studies are complicated by high variability of lipid and fatty acid levels in general and 
are potentially further confounded by the use of medication and/or dietary intake, 
including supplements. Although a combination of factors could constitute a risk 
profile that may be linked to the development and progression of AMD, it is unlikely 
that these factors individually could act as proper biomarkers for the disease.
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2.6 EXTRACELLULAR MATRIX
Remodeling of the ECM plays a role in the pathogenesis of AMD.158,  241  Drusen 
development, as well as alterations of Bruch membrane52,  59  and infiltration of 
immune cells, relate to a balance between structural tightness or looseness 
of the extracellular environment. The constant remodeling of the ECM is 
carefully regulated by matrix metalloproteinases (MMPs) and tissue inhibitors 
of metalloproteinases.236  Dysregulation of MMPs and/or tissue inhibitors of 
metalloproteinases could lead to ECM changes seen in AMD, and therefore, these are 
potentially useful biomarkers for AMD.
Genetic variations in several ECM-related genes are associated with AMD99,  101,  275; 
however, only few studies have measured plasma or serum levels of MMPs and 
tissue inhibitors of metalloproteinases.45, 46, 120, 188, 381 An overview of the studies and 
references is provided in  Supplementary Table 5. Upregulation of MMP9 in plasma 
was associated with AMD in 1 study45; however, 2 other studies could not replicate 
these findings.120, 381 No association was found for serum MMP1 levels120, 381 or MMP2 
in serum or plasma.45, 120, 381
All 3 studies were limited because of small samples sizes and the measurement 
techniques used. Moreover, in these studies, both the proenzyme and active forms 
were measured together. Increased immunoactivity of MMPs does not necessarily 
mean an increase in enzymatic activity. Other measurement techniques are required 
to measure MMP activity more reliably, and larger future studies are needed to 
elucidate the potency of MMPs as biomarkers for AMD.
One of the main constituents of the ECM in Bruch membrane is elastin.241  Elastin, 
in combination with other proteins of the ECM,348  provides strong and long-lasting 
elasticity to the Bruch’s membrane. The elastin layer degrades with age, however, 
and elastin metabolism may contribute to AMD where there is frequently thinning 
and fragmentation of the elastic layer,52  especially in relationship to choroidal 
neovascularization.31,  133  There is also evidence for abnormal systemic elastin 
metabolism in AMD. Patients with nAMD had significantly increased susceptibility to 
elastolysis in the skin.31 Patients with nAMD had significantly higher levels of serum 
elastin-derived peptide levels,318 probably due to the aforementioned elevated levels 
of MMPs in serum.45 Apart from elevated elastin peptide fragment levels, sera from 
patients with AMD contain specific autoantibodies against elastin and it has been 
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suggested that the IgG/IgM ratio for elastin, and other, autoantibodies might allow 
monitoring the progression of AMD.233  Therefore, analyzing elastin degradation 
products or autoantibody levels or ratios might be useful tools as biomarkers, at least 
for nAMD.
2.7 DIETARY FACTORS
Known risk factors for AMD include dietary factors, such as low intake of antioxidants. 
Some vitamins are antioxidants, whereas others act as cofactors for enzymes 
involved in ROS clearance,333  as detailed in Section  2.7.1. Trace elements have also 
been hypothesized to be involved in the pathogenesis of AMD and are described in 
Section 2.7.2. Another marker influenced by diet is serum albumin; this is considered to 
be an indicator of nutritional status and inflammation and is discussed in Section 2.7.3. 
In addition, diet is also an important source for fatty acids and carotenoids both related 
to AMD. These are described in Sections  2.3.4.2,  2.5.4, respectively. A complete 
overview of the studies and references is provided in Supplementary Table 6.
2.7.1 Vitamins
Vitamin C can act as an ROS scavenger, and it mediates reactivation of vitamin 
E.333  When vitamin C hydrolyzes and reactivates vitamin E, the molecule itself is 
inactivated, and hydrolysis by GSH can reactivate vitamin C (Figure 1).258  Lowered 
levels of vitamin C result in less vitamin E conversion to its active form. In addition, 
vitamin C itself cannot fulfill its antioxidant function, and as a consequence ROS 
production will rise.258 Vitamin C levels were found to be lower in AMD patients than 
those in controls311 and lower in advanced versus early AMD313; however, most studies 
do not report an association between vitamin C and AMD.31, 72, 87, 88, 360, 375
Vitamin E is anchored in the plasma membrane and prevents lipid peroxidation.333 Lower 
levels of serum vitamin E in AMD patients were reported.25,  214,  313,  360  However, 
associations with vitamin E were not conclusive because no difference in vitamin E 
levels has been found in several studies.31, 40, 72, 87, 88, 224, 292, 311, 322, 339
One study reported lower levels of vitamin A in patients with nAMD.384  However, 
most studies did not find a significant association between vitamin A levels and 
AMD.31, 72, 88, 224, 292, 313, 360
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B vitamins are essential molecules in homocysteine metabolism and synthesis of 
methionine. Both vitamin B9 (folate) and B12 (cobalamin) act as cofactors to convert 
homocysteine into methionine.294 In AMD patients, lower serum levels of vitamin B12 
were detected compared with controls.113, 168, 284 These results were not consistently 
replicated, as equal levels of serum vitamin B12 in patients and controls have also 
been described.132, 247 Folate levels were similar between controls and AMD patients 
in all studies.113, 132, 168, 183, 247,284
Vitamin D can be produced in the dermis upon sunlight exposure or can be obtained 
through diet. For its activity, the molecule has to be converted into its active form in 
the liver and kidney before it can regulate uptake of nutrients such as iron, calcium, 
magnesium, and zinc.244  There are inconsistent results for vitamin D levels in AMD 
patients. They have been described to be higher,177 lower,150, 259 or not associated with 
the disease.50, 62,111, 226, 234, 261, 316
2.7.2 Trace elements
Trace elements are required by the human body in very low concentrations for proper 
physiological functioning; however, deficiency or excess amounts may be harmful.27
Iron is essential for retinal functioning, as phototransduction is dependent on iron-
containing enzymes. Accumulation of iron, however, can be harmful. Iron can convert 
hydrogen peroxide (H2O2) into highly reactive ROS and thereby enhance oxidative 
stress.323  Cadmium can also increase ROS formation361  and mercury can decrease 
oxidant defense mechanisms,140 both leading to increased oxidative stress. In contrast, 
manganese, copper, and zinc contribute to antioxidant activity as they are cofactors 
for the antioxidant enzyme SOD.333,  362 GSHP is dependent on the presence of the 
essential heavy metal selenium.17  In addition, copper and zinc are able to stabilize 
proteins, reducing their vulnerability to oxidation362 but can also lead to pathological 
aggregation or even precipitation of proteins.237, 238, 239 Both zinc and manganese can 
reduce uptake or accumulation of toxic cadmium.293
Several studies reported elevated cadmium levels in blood,50,  176,  262,  366  aqueous 
humor,163  and urine of AMD patients.366  Measurement of cadmium levels in blood 
might represent only recent cadmium exposure, whereas urinary cadmium reflects 
long-term exposure to cadmium and might therefore be a more accurate biomarker. A 
study comparing both blood and urinary cadmium levels did not show an association 
with AMD in the total study group; however, when stratified for smoking status, 
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increased urinary cadmium levels were associated with AMD in smoking individuals, 
suggesting a smoke-related association of cadmium with AMD.81  Lead levels were 
elevated in serum and urine of both early and advanced AMD,50,  262,  366  and 1 study 
reported an association between lead and AMD only for women.143 Levels of mercury 
were only elevated in patients with advanced AMD.50, 262
Selenium was in general not associated with AMD.87, 88, 163 One study found a borderline 
significant association with AMD,339  and another measured significantly lower 
levels of selenium in nAMD patients.216 Conflicting results are reported for levels of 
iron,31, 163, 369 copper,40, 163 manganese,163, 262 and zinc.25, 88, 163, 262, 313
2.7.3 Albumin
Albumin is essential for maintenance of plasma colloid oncotic pressure, acts as a 
plasma binding protein, and also has antioxidant activity.202  In addition, albumin is 
one of the most common proteins found in drusen.63 A few studies measured serum 
albumin in AMD patients and controls. Two case-control studies did not show a 
significant association between serum albumin and AMD.31, 88 The population-based 
Cardiovascular Health Study and Beaver Dam Eye Study did report significantly lower 
serum albumin levels in early and neovascular AMD, respectively.185, 187 A more recent 
nested case-control study within the Beaver Dam population further analyzing these 
data could not confirm decreased albumin levels in AMD.183
Taken together, because of the highly variable diet between subjects, and varying 
levels of dietary factors within subjects based on fasting state, assessment of the 
role of these dietary factors as biomarkers in AMD remains difficult. Dietary intake 
and/or supplementation of antioxidants and vitamins, however, have therapeutic 
benefit. The Age-related Eye Disease Study trial, one of the largest investigations into 
vitamin supplementation in AMD, focused on daily supplementation with vitamin E, 
vitamin C, β-carotene, and zinc and demonstrated a lower chance of advanced AMD 
development in subjects taking these supplements.4  In the Age-related Eye Disease 
Study 2, an improved formula was evaluated and β-carotene was replaced by lutein/
zeaxanthin because of the increased risk of lung cancer in smokers.3, 5
Regarding trace elements, toxic heavy metals (such as lead, mercury, and cadmium) are 
mainly associated with an increased risk of AMD, whereas essential heavy metals (e.g., 
zinc and manganese) seem to protect against the development of AMD. For most trace 
elements, there are only a limited number of studies available in the public domain to 
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date, and further research is required to assess their potential role as a biomarker or 
as protective supplement.
2.8 HORMONES
In this section, we discuss the few hormones that have been investigated in relation 
to AMD: leptin, melatonin, and dehydroepiandrosterone sulfate (DHEAS). A complete 
overview of the studies and references is provided in Supplementary Table 7.
2.8.1 Leptin
Because AMD is a multifactorial disease in which dietary factors and body mass index 
also play a role in the disease mechanism, it has been suggested that the principal 
hormone involved in food intake behavior, leptin, may be associated with AMD. Two 
studies support this theory; both showed a reduction in serum leptin levels in AMD 
patients compared with controls.85,  306  After controlling for potential confounders, 
including smoking, body mass index, blood pressure, and HDL-C, the association 
remained significant, which suggests that mechanisms other than body fat underlie 
the relationship between leptin levels and AMD.306 The third study did not observe a 
difference in leptin levels in patients versus control individuals.124
2.8.2 Melatonin
Melatonin has strong antioxidative capacities, is expressed in the retina, and expression 
levels decrease during aging.173, 276, 277 Two studies investigated the levels of melatonin 
in AMD. One showed elevated blood levels of daytime melatonin in pseudophakic 
AMD patients.296  The second study analyzed the major metabolite of melatonin in 
urine, 6-sulfatoxymelatonin, and described lower levels in AMD.286 Comparing the 2 
studies is difficult because of the differences in methodology and fluid matrix analyzed, 
so additional experiments linking melatonin and AMD are necessary.
2.8.3 Dehydroepiandrosterone sulfate
DHEAS is a sulfate ester of DHEA, which is an endogenous steroid hormone synthesized 
from cholesterol in the adrenal glands and serves as precursor molecule for sex 
steroids, androgen and estrogen.212 It has been suggested that DHEAS has antioxidant 
effects.212, 330, 342 In addition, the DHEAS level in blood decreases with age.23, 212, 330 Since 
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both oxidative stress and aging are important risk factors for AMD,59  the question 
arises whether DHEAS and AMD could be correlated. Three studies investigated 
the association between AMD and DHEAS, all with different outcomes; higher levels 
of DHEAS were reported in women with early AMD,69 another study described low 
DHEAS in both dry and neovascular AMD cases,330 and a third study did not find an 
association between nAMD and controls.342
In summary, only a limited amount of studies assessing hormones in AMD have been 
performed with inconclusive results and do not seem to be reliable biomarkers for 
AMD at this point in time.
2.9 FACTORS RELATED TO COMORBIDITIES
AMD has been suggested to share risk factors or coexist with other diseases, such as 
kidney disease, diabetes mellitus, and Alzheimer’s disease. Factors related to these 
comorbidities are discussed in Sections 2.9.1, 2.9.2, 2.9.3, respectively. Although AMD 
has not been associated with liver disease before, some studies investigated factors 
related to liver function and these are described in Section 2.9.4. A complete overview 
of the studies and references is provided in Supplementary Table 8.
2.9.1 Kidney disease
Several studies have suggested overlapping risk factors between AMD and kidney 
diseases.77,  189,  203,  356  A number of large, often population-based, studies have not 
only investigated kidney function, such as glomerular filtration rate, but also markers 
that can be measured in serum/plasma like creatinine and cystatin-C. In the Beaver 
Dam Eye Study, serum cystatin-C was associated to the incidence of early AMD and 
nAMD.189  In the Multi-Ethnic Study of Atherosclerosis, this association was only 
found when the highest deciles of cystatin-C were compared with other deciles with 
prevalence of early AMD.51 In the Hatoyama study, no association between cystatin-C 
and AMD was found.15
Several large studies investigated creatinine in patients, but no clear association 
between serum creatinine and AMD was found. Two reports from the Korean 
National Health and Nutrition Examination Survey describe a significant difference 
between AMD patients and controls, but after adjustment for other variables, no 
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significant association was found.50,  261 The remainder of the studies, including large 
population-based studies such as the Multi-Ethnic Study of Atherosclerosis and the 
Singapore Malay Eye Study, did not find any association between serum creatinine and 
AMD.31, 33, 37, 150, 152, 153, 247
Another indicator of renal health is blood urea nitrogen, but also for this factor, no link 
was established with AMD.31, 50, 189, 261
2.9.2 Diabetes mellitus
Although some cardiovascular risk factors, such as smoking, have been consistently 
related to AMD, there are conflicting results for an association between diabetes mellitus 
and AMD.43 Several studies, mostly population-based, measured glycated hemoglobin 
and glucose as indicators for the presence of diabetes mellitus. Only one study found 
lower levels of glucose in advanced AMD,199 but none of the other studies described an 
association of either markers with AMD.31, 33, 37, 73, 88, 143, 152, 153, 160, 176, 321, 371, 377 Several 
studies, all reports from the Korean National Health and Nutrition Examination 
Survey, reported lower glycated hemoglobin levels in AMD50,143,  176,  177,  199; however, 
studies from other cohorts detected no difference.33, 37, 160, 342, 380
2.9.3 Alzheimer’s disease
Similar to AMD, the prevalence of Alzheimer’s disease increases with age. This 
neurological disorder is characterized by amyloid plaques in the brain, with the main 
component being amyloid beta (Aβ).16 In AMD, 2 studies identified Aβ as a component 
of drusen.12, 75 In addition, Aβ might trigger activation of the complement cascade in 
AMD.159 Several isoforms of Aβ with different amino acid lengths exist; in this section, 
we discuss the most common isoforms: Aβ1-40 and Aβ1-42.
A small, case-control study did not show different levels of Aβ1-42 between controls 
and either dry or neovascular AMD247; however, 2 more recent case-control studies 
showed significantly higher Aβ1-42 peptide levels in AMD patients.120,  124 Also after 
correction for age, Aβ1-42 was significantly associated with AMD, and there was a 
trend toward increasing levels of Aβ with increasing disease severity.120 An association 
of AMD with Aβ1-40 in these studies was less clear. A significant upregulation was 
described in one study in nAMD only,120 whereas the other study did not report a 
difference between nAMD patients and controls.124
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2.9.4 Liver function
So far, to our knowledge, no study has focused specifically on liver function and AMD. 
In a few studies, indicators of liver function have been reported as part of a routine 
blood examination with no associations between lactate dehydrogenase, aspartate 
transaminase, or alanine transaminase and AMD.31, 50, 285
For hepatitis B surface antigen on the other hand, an association was described in 
several Korean studies, a country where hepatitis B is still endemic.50, 261, 285 In these 
studies, hepatitis B surface antigen carrier status was positively associated with AMD. 
Hepatitis B surface antigen has been detected in subretinal fluid, and it is hypothesized 
these individuals are therefore at increased risk for uveoretinal pathology, such as 
AMD.261, 285
In conclusion, despite coexistence and overlapping risk factors with AMD, biomarkers 
for kidney disease, diabetes mellitus, and liver disease discussed here do not seem good 
biomarker candidates for AMD. As an exception, Aβ could potentially be a marker of 
disease progression; however, larger prospective studies are required to confirm these 
findings. In addition, also in terms of a potential new drug target, further evaluation of 
this biomarker in AMD seems worthwhile, as promising anti-Aβ therapies are being 
developed for Alzheimer’s disease.16
2.10 HYPOTHESIS-FREE TECHNIQUES
In the past decade, many advanced high-throughput omic technologies have been 
developed. These technologies enable us to analyze large numbers of markers at 
the same time in an untargeted and unbiased manner. Here, we discuss several 
omic technologies in association with AMD (Figure  3): proteomics (Section  2.10.1), 
metabolomics (Section  2.10.2), and epigenomics (Section  2.10.3). Expression of 
circulating microRNAs can also be measured using high-throughput techniques; these 
are described in Section 2.10.4.
2.10.1 Proteomics
The field of proteomic research uses mass spectrometry, or variations to this technique, 
to determine the nature of peptides or proteins in various tissues or other biological 
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samples. The advantage of proteomic research is that it delivers results that are 
unbiased by preconceived notions or hypotheses. Within the field of AMD, proteomics 
has been used in a number of investigations, and several have been successful in 
showing particular proteomic signatures in plasma, vitreous, and aqueous humor from 
AMD patients when compared with controls.
A small study by Kim and colleagues identified 154 proteins in aqueous humor of 
9 nAMD patients and 8 cataract controls.178  In this study, 7 potential biomarker 
candidates were selected for further analysis: ceruloplasmin, PEDF, plasma protease 
C1 inhibitor, TGF-β1, clusterin, cathepsin D, and cystatin D. The relative abundances 
of TGF-β1, plasma protease C1 inhibitor, ceruloplasmin, and PEDF were shown to be 
significantly higher in AMD samples compared with controls. Another small study, 
collecting and profiling aqueous humor of 6 nAMD patients and 6 cataract controls, 
found 68 proteins to be differentially expressed.372 Only 9 proteins were identified in 
both studies, among which were some that were related to AMD previously (CCL24 
and complement FI), lipocalin-1 and several members of the crystallin family. These 
crystallins, known for their chaperone function, may also be involved in protein-protein 
interaction, prevention of apoptosis, and inhibition of inflammation among others.170 
Lipocalin-1 concentrations were quantified using enzyme-linked immunosorbent 
assay, and levels were significantly elevated in the aqueous humor of nAMD patients.
Figure 3. Omics in age-related macular degeneration.
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A third small study performed a focused proteomic analysis on protein members of 
the ubiquitin pathway.201 Difference in expression of 6 proteins in aqueous humor 
of 2 AMD patients compared with 2 controls was reported. This included the 26S 
proteasome non-ATPase regulatory subunit 1 (Rpn2), a protein that is also present 
in plasma. Rpn2 was therefore selected as potential AMD biomarker and liquid 
chromatography-multiple reaction monitoring mass spectrometry of another 15 
aqueous humor samples showed a relative increase of Rpn2 in nAMD patients.
Kang and colleagues analyzed aqueous humor samples of 26 treatment naive patients 
with nAMD and 18 controls.169  By comparing expression profiles in exosomes of 
aqueous humor and cultured RPE cells, 6 candidate proteins were selected for 
verification in an independent sample set by liquid chromatography-multiple 
reaction monitoring mass spectrometry: actin, myosin-9, heat shock protein 70, 
cathepsin D, cytokeratin 8, and cytokeratin 14. Of these, cytokeratin 8 showed the 
highest area under the curve value (0.929), suggesting that it is a strong predictor 
for AMD. Although cytokeratins were not previously reported in other proteomic 
analyses in AMD and might be valuable markers to further investigate, it is disputable 
whether they could qualify as manageable biomarkers. Cytokeratins are abundant 
contaminants in laboratories,209  so careful replication of these findings in other 
laboratories is warranted.
One other study investigated in a targeted manner the involvement of Wnt modulators 
in aqueous humor and found that WNT inhibitory factor 1 (WIF-1) and Dickkopf-
related protein 3 (DKK-3) were upregulated in nAMD.260
In a study of 73 nAMD patients and 15 controls, a large set of proteins were detected 
in vitreous humor, of which 19 were upregulated in nAMD patients.194 Bioinformatic 
analyses suggested enrichment of the complement and coagulation cascades, as 
well as markers involved in arachidonic acid metabolism. Of the 19 proteins, 5 were 
randomly selected for Western blot validation; alpha-1-antitrypsin reached statistical 
significance, whereas ApoA1 and transthyretin showed a nonsignificant increase in 
AMD. These findings need validation in a larger sample set.
Nobl and colleagues investigated vitreous samples of 108 nAMD patients and 
24 controls, distributed over a discovery and validation set, and discovered 101 
different proteins.243 Using a closed testing procedure, they focused on 4 differentially 
expressed proteins as candidate AMD biomarkers: clusterin, opticin, PEDF, and 
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PH2D, which were increased in nAMD compared with controls, except for opticin, 
which was reduced. Upregulation of PEDF and PH2D in nAMD was described 
previously.178, 194 Clusterin and PEDF remained significantly increased in nAMD after 
validation and correction for multiple testing in an independent sample set using 
enzyme-linked immunosorbent assay.
There have been limited plasma proteomic studies. Xu and colleagues found 28 
clinically relevant proteins to be altered in  AMD patients (N = 24) compared with 
healthy volunteers (N  = 6),370  but further investigation of these plasma proteins is 
necessary to validate these findings. In addition, 2 studies using proteomic profiling 
of the same data set identified 3 potential AMD biomarkers: vinculin, phospolipid 
transfer protein, and mannan-binding lectin protease-1.175, 179 In general, proteomics 
of plasma or serum is a great analytical challenge due to the dominant fraction of 
highly abundant proteins, which have effectively prevented the discovery of novel 
proteomic biomarkers in these fluids in the past. Therefore, improved technologies 
are needed. Fortunately, some progress has been made using quantitative shot-gun 
proteomics, recently.108
2.10.2 Metabolomics
Metabolomic studies use mass spectrometric technologies or nuclear magnetic 
resonance spectroscopy to measure derivatives of metabolism. The technique offers 
a snapshot of the physiological state of an organism at the level of body fluids (urine, 
tears, serum, and plasma), cells or even tissues. Metabolomic analysis of AMD has 
great potential to uncover novel pathways in the disease that are reflective of the 
interaction between the genetic blueprint of individual and environmental factors that 
influence the metabolites (e.g., diet and smoking). To date, only one metabolome-wide 
study was conducted in plasma samples of 26 nAMD patients and 19 controls. Pathway 
analysis pointed toward involvement of tyrosine metabolism, urea metabolism, and 
vitamin-D–related metabolism.253
2.10.3 Epigenomics
Although it is clear that both genetic components as well as environmental elements 
contribute to the risk of developing AMD, it is less clear how these 2 systems interact. 
This interaction is the domain of epigenetics, induced changes in the expression levels 
of genes controlled by outside influences. Epigenetics is a broad term, encompassing 
many possible regulatory mechanisms of gene expression. One type of epigenetic mark 
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that has been explored in a number of studies is the difference in DNA methylation 
patterns between cases and controls.
Epigenetic changes can be observed in peripheral blood leukocytes, which are 
relatively easy to obtain. One study showed a decrease in methylation near the 
IL17RC promotor region, suggesting that this could serve as a potential biomarker for 
AMD.355 However, the finding could not be validated by an independent study with a 
sufficiently powered study design.249
Based on these results, and also because epigenetic mechanisms are likely to be tissue 
specific, the relationship between DNA methylation patterns in peripheral blood 
and retinal tissue was investigated in a recent study.250Although no epigenome-wide 
association peak was observed, the study did report consistent methylation changes 
across multiple samples near the  ARMS2  locus and near the protease serine 50 
(PRSS50) gene.
Despite a limited sample size, the results provided some evidence that methylation 
patterns in blood leukocytes could serve as proxies for retinal changes, implying that 
such studies could deliver additional biomarkers for AMD.250
2.10.4 Circulating microRNAs
A microRNA (miRNA) is a small noncoding RNA molecule that regulates gene 
expression after transcription, thereby influencing biological processes. These miRNAs 
are present in circulation and could potentially serve as biomarkers.229  Because we 
focus on compounds found in body fluids, only the studies that investigate circulating 
miRNAs (cmiRNAs) in serum or plasma are described here.
In a small study by Ertekin and colleagues,84 plasma samples of 33 nAMD patients and 
31 controls were analyzed for the expression of 384 miRNAs. They found 16 miRNAs 
to be differentially expressed between the 2 groups and additionally discovered 10 
miRNAs to be only expressed in nAMD patients.
Grassmann and colleagues identified 203 cmiRNAs in serum, of which 3 (hsa-mir-301-
3p, hsa-mir-361-5p, and hsa-mir-424-5p) were significantly altered in nAMD patients 
(N = 129) compared with control individuals (N = 147).114 No significant association 
was found in GA patients (N = 59), suggesting different mechanisms for advanced 
AMD subtypes. Pathway analysis of the genes that are likely regulated by the altered 
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cmiRNAs implicated the mTOR and TGF-β pathways in nAMD and knockdown of 
these cmiRNAs in  vitro resulted in increased angiogenesis but only significantly for 
hsa-mir-361-5p.
Szemraj and colleagues also reported significant differences in cmiRNA profiles 
between dry and neovascular AMD patients.328 In this study, serum expression levels 
of 377 miRNA genes in 300 AMD patients (150 nAMD/150 dry AMD patients) 
and 200 control individuals were analyzed. This study identified 31 differentially 
expressed miRNAs between patients and controls, including 2 of the 3 previously 
associated114  cmiRNAs (hsa-mir-301-5p and hsa-mir-424-5p). Of the differentially 
expressed miRNAs in this study, 5 were significantly different between patients with 
dry and neovascular AMD. In addition, the correlation between these miRNAs and 
expression of VEGF and VEGFR2 was assessed, and it was suggested that miRNA Let-
7 is implicated in the neoangiogenesis in nAMD.
So far, limited studies on miRNA profiling in AMD have been performed and results 
need to be replicated in larger studies; however, these initial findings emphasize the 
potential of cmiRNAs as biomarkers in AMD.
In general, studies using hypothesis-free techniques demonstrate proof of concept 
that omic analyses are able to identify novel biomarkers for AMD; however, more are 
needed to validate results and to confirm the clinical utility of these biomarkers.
2.11 CONCLUSION AND FUTURE DIRECTIONS
In summary, numerous compounds have been analyzed in relation to AMD. However, 
only a few of these have potential as AMD biomarkers. The most promising biomarker 
candidates belong to the oxidative stress pathway, the complement system, and to 
a lesser extent, lipid metabolism. Finally, the use of hypothesis-free techniques in 
biomarker detection holds great promise. For summarized findings regarding factors 
belonging to the other biological pathways described in this review, we refer to the 
closing paragraphs of the respective chapters. As of yet, none of the biomarkers that 
we have reviewed here are used clinically.
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Many studies reported decreased antioxidant levels and elevated levels of oxidized 
proteins or lipids indicating oxidative stress in AMD. MDA is often used as a marker for 
lipid peroxidation, and increased levels of MDA have been very consistently observed 
in both wet and dry AMD (11 of 11 studies, Section 2.3.1). In addition, most studies 
reported higher levels of homocysteine, an intermediate in the oxidative stress pathway, 
in AMD (12 of 18 studies, Section 2.3.3). Besides dysregulation of the oxidative stress 
pathway, many studies indicate the involvement of the complement system in AMD. 
Products of complement activation and levels of complement activation—described 
by the ratio of C3 and its degradation product C3d (C3d/C3)—were repeatedly 
associated with AMD (Section 2.4.1). In addition, there is clear involvement of lipids in 
AMD from genetic and molecular studies; however, the role of systemic lipids in AMD 
is not fully elucidated, and therefore, they are not yet applicable as robust biomarkers 
for the disease.
In general, many inconsistencies exist between studies evaluating biomarkers and 
their association with AMD. The contradicting results are difficult to interpret due to a 
variety of differences between studies, including methodological differences (fasting 
vs nonfasting blood), different populations (Caucasian/Asian/Mediterranean) with 
different dietary habits, different study designs, different analytical methods, and 
correction factors, but also types of AMD included in the studies. It must be noted that 
compiling and comparison of data deriving from different sources represent a major 
limitation. Therefore, large well-conducted prospective studies are needed to further 
clarify these results.
Although AMD represents a phenotype restricted to the eye, many studies have 
investigated systemic markers in relation to AMD; however, because of the presence 
of the blood-retinal barrier, biomarkers might be only locally dysregulated inside the 
eye without a measurable systemic effect. In addition, some compounds are differently 
expressed between tissues, leading to different results when analyzing different 
matrices. One might therefore argue to measure markers only locally; however, 
because of the invasive character and accompanying ethical issues, systemic markers 
are preferred for implementation as clinical biomarkers.
Until now, most studies have targeted specific single biomarkers in a candidate-driven 
approach. Omic studies with an unbiased view are heavily outnumbered. Future 
biomarker research should therefore combine hypothesis-free as well as candidate-
driven approaches. Quantitative analytical approaches applied in an untargeted and 
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targeted fashion, such as metabolomic or proteomic studies, are necessary to identify 
novel biomarker candidates. Once validated as robust and reliable markers, they can 
offer more insights into the etiology and pathogenesis of AMD and support prediction, 
diagnosis, stratification, monitoring of treatment, and drug development for AMD.
Other biomarker types in AMD such as genetic factors, imaging biomarkers, or visual 
function measurements are currently of key importance for proper clinical diagnosis, 
stratification, and treatment of AMD. In the future, these established clinical 
examinations and diagnostic tests may well be applied in combination with molecular 
biomarkers, an area which is still in a nascent stage.
2.12 METHODS OF LITERATURE SEARCH
A review of literature was performed through a thorough PubMed search in November 
2015. We used the following keywords and their synonyms in various combinations: 
age-related macular degeneration, serum, plasma, blood, urine, tear, aqueous, and 
vitreous. No limitations were set for the time range covered by our search, and 
therefore, all articles published until our search were included.
All abstracts were screened for relevance and full texts of the selected articles were 
studied. We included only articles written in English. Articles cited in the reference 
lists of articles obtained through this search were also included whenever relevant. 
Animal, ex  vivo, and in  vitro studies were excluded. To include the most recent 
developments before submission, the search was repeated in June 2016. An overview 
of our selection process is detailed in Figure 4.
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Figure 4. Flow diagram of literature search. The screening and selection process of studies included for 
this review is depicted in the flow diagram. After the final article selection, all described compounds in these 
studies were grouped based on their common biological function or pathway, and results were discussed 
accordingly. Of note, compounds that were only described once in literature were not mentioned in this 
review to reduce the effect of selective reporting.
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ABSTRACT
Age-related macular degeneration (AMD) is a progressive retinal disorder affecting 
over 33 million people worldwide. Genome-wide association studies (GWASs) for 
AMD identified common variants at 19 loci accounting for 15–65% of the heritability 
and it has been hypothesized that the missing heritability may be attributed to rare 
variants with large effect sizes. Common variants in the complement component 3 
(C3) gene have been associated with AMD and recently a rare C3 variant (Lys155Gln) 
was identified which exerts a large effect on AMD susceptibility independent of the 
common variants. To explore whether additional rare variants in the C3 gene are 
associated with AMD, we sequenced all coding exons in 84 unrelated AMD cases. 
Subsequently, we genotyped all identified variants in 1474 AMD cases and 2258 
controls. Additionally, because of the known genetic overlap between AMD and atypical 
hemolytic uremic syndrome (aHUS), we genotyped two recurrent aHUS-associated 
C3 mutations in the entire cohort. Overall, we identified three rare variants (Lys65Gln 
(P = 0.04), Arg735Trp (OR = 17.4, 95% CI = 2.2–136; P = 0.0003), and Ser1619Arg 
(OR = 5.2, 95% CI = 1.0–25; P = 0.05) at the C3 locus that are associated with AMD in 
our EUGENDA cohort. However, the Arg735Trp and Ser1619Arg variants were not 
found to be associated with AMD in the Rotterdam Study. The Lys65Gln variant was 
only identified in patients from Nijmegen, the Netherlands, and thus may represent a 
region-specific AMD risk variant.
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3.1 INTRODUCTION
Age-related macular degeneration (AMD, MIM 603075) is a retinal disorder that 
causes progressive visual impairment in individuals aged over 50 years.1 AMD 
primarily affects the macula, the central region of the retina, eventually leading to loss 
of central and sharp vision. It has been estimated that more than 33 million people 
suffer from vision loss due to AMD worldwide.2 AMD is a multifactorial disease caused 
by a combination of genetic and environmental factors. GWASs identified common 
variants at 19 loci that influence disease susceptibility, accounting for 15–65% of the 
heritability.3,4
It has been hypothesized that the remaining genetic fraction influencing the risk for 
development of AMD, the so-called missing heritability, may be explained by rare, 
highly penetrant variants.4 Simulation studies suggested that common variants are 
insufficient to account for disease burden in densely affected AMD families and that 
rare penetrant variants would offer a likely explanation.5 In addition, a meta-analysis 
of AMD GWASs suggested that each of the 19 loci may harbour several independent 
variants associated to AMD susceptibility.3 The rare variant hypothesis is supported 
by the identification of rare missense mutations in the fibulin-5 (FBLN5) gene and the 
hemicentin-1 (HMCN1) gene in AMD patients.6,7 In addition, rare, highly penetrant 
variants in the genes encoding complement factor H (CFH), complement factor I (CFI), 
complement component 3 (C3) and complement component 9 (C9) have recently been 
found to be associated with AMD.8-12
Genetic studies have identified an important role for the complement cascade in the 
pathogenesis of AMD.13 Interestingly, recent studies suggested a genetic overlap 
between AMD and atypical hemolytic uremic syndrome (aHUS), a life-threatening 
renal disease caused by chronic, uncontrolled activation of the complement system. 
It has been reported that 4–10% of aHUS patients carry mutations in the C3 gene.14 
Moreover, disease-causing mutations previously identified in aHUS patients, such as 
Arg1210Cys in CFH, Gly119Arg in CFI and Lys155Gln in C3 were found to confer a 
high risk of developing AMD.8-12 However, the precise nature of this genetic overlap 
between two clinically distinct phenotypes remains unknown.
In this study, we explored the role of rare variants in the C3 gene in the pathogenesis 
of AMD. We performed a two-stage analysis to identify rare variants in the C3 
gene. First, sequence analysis was carried out in a discovery set of 84 AMD cases 
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from the EUGENDA cohort, and subsequently the frequencies of these variants 
were determined in replication sets from EUGENDA and from the Rotterdam Study 
consisting of 1474 AMD cases and 2258 controls. In addition, two recurrent aHUS-
associated C3 mutations were genotyped in the entire AMD case-control cohort.15,16
3.2 RESULTS
To investigate the involvement of rare variants in the C3 gene in AMD, the exons and 
flanking introns of C3 were sequenced in a discovery cohort of 84 AMD cases (Table 
1) from the Nijmegen area, the Netherlands. Sequencing identified three rare variants 
(MAF<1%; Lys155Gln/rs147859257, Arg735Trp/rs117793540 and Ser1619Arg/
rs2230210) and two common variants (MAF≥1%; Arg102Gly/rs2230199 and 
Pro314Leu/rs1047286) (Table 2). None of the rare variants were found in 192 
ethnicity-matched and age-matched controls. The Lys155Gln variant, which has 
recently been associated with AMD,10-12 was found in five cases, while variants 
Arg735Trp and Ser1619Arg were found in one case each. Bioinformatic algorithms 
SIFT and PolyPhen predicted the variants Arg102Gly, Lys155Gln, and Pro314Leu not 
to be damaging whereas Arg735Trp and Ser1619Arg were predicted to be damaging 
to the protein function (Table 2).
Table 1. Demographics of studied subjects.
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EUGENDA: a multicenter database comprising participants from Germany and the Netherlands 
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Variables 
EUGENDA cohort Rotterdam Study 
Cases Controls Cases Controls 
Controls (n) 1246 
 
1012 
Intermediate AMD (n) 173 
 
636 
 Advanced AMD (n) 545 
 
120 
 Mean age (±SD) 76 ± 8 70 ± 5.9 80 ± 6.4 77 ± 6.5 
Gender 
    Male 271 532 354 497 
Female 447 714 402 515 
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Next, the frequencies of the rare variants Arg735Trp and Ser1619Arg, as well as the 
common variants Arg102Gly and Pro314Leu were determined, in replication cohorts 
from EUGENDA and from the Rotterdam Study, consisting of 1474 AMD cases 
and 2258 controls of European ancestry (Table 3). In addition, two recurrent aHUS 
mutations (Lys65Gln and Arg161Trp) were included in the analysis (Table 3). The 
common variants Arg102Gly (OR = 1.2 [95% CI 1.1–1.4]; P = 0.001) and Pro314Leu 
(OR = 1.2 [95% CI 1.0–1.4]; P = 0.005) were significantly associated with AMD. In the 
EUGENDA cohort, the rare variant Arg735Trp was found heterozygously in 8 and 
homozygously in one out of 718 AMD cases and heterozygously in one out of 1246 
controls (OR = 17.4 [95% CI 2.2–136]; P = 0.0003). However, in the Rotterdam Study 
the rare variant Arg735Trp was found heterozygously in 1 out of 785 AMD cases and 
heterozygously in 2 out of 1048 controls, and was thus not associated with the disease. 
Rare variant Ser1619Arg was found heterozygously in six out of 718 AMD cases and 
heterozygously in two out of 1244 controls in the EUGENDA cohort (OR = 5.2 [95% 
CI .1.0–25]; P = 0.05). In the Rotterdam Study the rare variant Ser1619Arg was found 
heterozygously in 6 out of 835 AMD cases and heterozygously in 11 out of 1279 
controls, and was thus not associated with AMD. The aHUS mutation Lys65Gln was 
found heterozygously in three out of 717 AMD cases and was not observed in 1246 
controls (P = 0.05) in the EUGENDA cohort, but was not identified in the Rotterdam 
Study. Arg161Trp was found heterozygously in two out of 644 AMD cases and was not 
observed in 1142 controls (P = 0.13) in the EUGENDA cohort. In the Rotterdam Study 
the aHUS mutation Arg161Trp was observed heterozygously in one out of 320 AMD 
cases and heterozygously in one out of 483 controls (P = 1.0) and was not significantly 
associated with AMD in the EUGENDA cohort nor in the Rotterdam Study.
Table 2. C3 variants identified by sequence analysis of 84 AMD cases.
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Table 2. C3 variants identified by sequence analysis of 84 AMD cases. 
SNP ID Sequence variants Genotypes Prediction algorithms 
  Nucleotide change Amino acid change Mm mm SIFT PolyPhen2 
rs2230199 c.304 C>G Arg102Gly 34 11 Tolerated (0.5) Tolerated (0) 
rs1047286 c.941 C>T Pro314Leu 30 10 Tolerated (0.1) Tolerated (0.2) 
rs147859257 c.463 A>C Lys155Gln 5 0 Tolerated (0.2) Benign (0.1) 
rs117793540 c.2203 C>T Arg735Trp 1 0 Deleterious (0) Damaging (1) 
rs2230210 c.4855 A>C Ser1619Arg 1 0 Deleterious (0) Damaging (0.8) 
Major and minor allele indicated in capital and lower case respectively; Reference sequence of C3 (NM_000064) gene; SIFT: Sorting 
Intolerant from Tolerant (Intolerance < 0.05); PolyPhen2: Polymorphism Phenotyping (score 0→1) 
doi:10.1371/journal.pone.0094165.t002 
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To determine whether the identified variants conferred disease risk independent 
of the two known common C3 variants (Arg102Gly/rs2230199 and Pro314Leu/
rs1047286), a conditional logistic regression analysis was performed (Table 4). After 
conditioning on Arg102Gly/rs2230199, Arg735Trp remained associated with disease 
risk in the EUGENDA cohort (OR = 22.1, 95% CI = 2.8–173; P = 0.003). Similarly, after 
conditioning on Pro314Leu/rs1047286, Arg735Trp still showed association with 
disease risk in the EUGENDA cohort (OR = 22.0, 95% CI = 2.8–172; P = 0.003). In 
addition, Arg735Trp was significantly associated with disease risk in the EUGENDA 
cohort (OR = 22.1, 95% CI = 2.8–173; P = 0.003) after conditioning on both variants 
(Arg102Gly and Pro314Leu). Independent association with AMD could not be 
assessed for Lys65Gln and Ser1619Arg because too few data points were available to 
perform a reliable conditional analysis.
Table 4. Conditional analysis of Arg735Trp for SNPs Arg102Gly/rs2230199 and Pro314Leu/rs1047286
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EUGENDA cohort (OR = 22.0, 95% CI = 2.8–172; P = 0.003). In addition, Arg735Trp was 
significantly associated with disease risk in the EUGENDA cohort (OR = 22.1, 95% 
CI = 2.8–173; P = 0.003) after conditioning on both variants (Arg102Gly and Pro314Leu). 
Independent association with AMD could not be assessed for Lys65Gln and Ser1619Arg 
because too few data points were available to perform a reliable conditional analysis. 
Table 4. Conditional analysis of Arg735Trp for SNPs Arg102Gly/rs2230199 and 
Pro314Leu/rs1047286 
Condition EUGENDA cohort 
Combined cohorts (EUGENDA 
and Rotterdam) 
  OR (95%CI) p-value OR (95%CI) p-value 
Arg102Gly/rs2230199 
22.1 (2.8-
173) 0.003 6.2 (1.7-22.5) 0.005 
Pro314Leu/rs1047286 
22.0 (2.8-
172) 0.003 6.2 (1.7-22.4) 0.005 
Arg102Gly & 
Pro314Leu 
22.1 (2.8-
173) 0.003 6.2 (1.7-22.5) 0.005 
EUGENDA: a multicenter database comprising participants from the Cologne area, Germany 
and the Nijmegen area, the Netherlands 
doi:10.1371/journal.pone.0094165.t004 
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3.3 DISCUSSION
In this study, three rare variants (Lys65Gln, Arg735Trp and Ser1619Arg) in the C3 
gene were shown to be associated with AMD disease risk in our EUGENDA cohort. 
However, the Arg735Trp and Ser1619Arg variants were not found to be associated 
with AMD in the Rotterdam Study. The Arg735Trp and Ser1619Arg variants were 
also not associated with AMD in a recent study that analyzed the C3 gene in 2,493 
AMD cases and controls.10 The Lys65Gln variant was only identified in AMD patients 
from the Nijmegen area, while it was not found in the Rotterdam Study, nor in a cohort 
from Boston.10 The Lys65Gln variant may therefore represent a region-specific AMD 
risk variant, being confined to the east of the Netherlands, which is confirmed by the 
occurrence of Lys65Gln in Dutch aHUS patients.10 A fourth variant, Arg161Trp, was 
found in three AMD cases and in one control; therefore it cannot be ruled out that the 
variant is in fact associated with AMD but a larger sample size would be required to 
detect a significant association.
The complement system plays an important role in the pathogenesis of AMD.8-12 The 
C3 gene encodes the complement component 3 protein, a central component of the 
complement cascade that plays a crucial role in clearance of pathogens and immune 
complexes. All three branches of the complement system, the classical pathway, the 
mannose-binding lectin pathway and the alternative pathway, converge at C3. At this 
stage, activation of C3 results in an amplification loop that ultimately forms a cytolytic 
membrane attack complex which targets pathogens. The system is tightly controlled 
by molecules like CFH and CFI. If the complement cascade is improperly regulated, 
host cells may also be subjected to complement attack, resulting in tissue damage and 
a spectrum of complement-mediated diseases.17
The rare variants reported in this study have previously been described for their 
association with aHUS, a chronic renal disorder caused by uncontrolled activation of 
the complement system, often leading to renal failure. Functional experiments have 
been performed in this context to determine the effect of the amino acid substitutions 
on C3 function. The Lys65Gln variant resides in the macroglobulin (MG1) domain of 
C3 and was shown to cause decreased binding to CFH.16 Although not significantly 
associated in our study, the Arg161Trp variant was shown to cause hyperactive C3 
convertase due to increased binding to factor B (CFB), and reduced binding to CFH 
and membrane cofactor protein (MCP; CD46), resulting in higher complement 
activity.15,16,18
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Recombinant protein studies have shown that the Arg735Trp variant performs normal 
in binding and cleavage assays.14 However, since the Arg735Trp residue is located in 
the anaphylatoxin (C3a) domain of C3, it is not likely to show an effect in the performed 
assays that evaluated binding and activation of the C3b fragment. Recent studies in 
animal models suggest that C3a anaphylatoxin has specific functions in the retina and 
retinal pigment epithelium, but it remains unknown how an amino acid substitution in 
C3a may contribute to the development of AMD.19,20
The Lys65Gln variant associated with AMD in this study has previously been associated 
with aHUS, further supporting the genetic overlap between AMD and aHUS. To rule 
out any renal pathology, the medical histories of AMD patients who carried this variant 
were evaluated, but no signs of aHUS or other renal pathologies were reported in 
these patients. Thus, although aHUS and AMD may overlap genetically, in this study no 
clinical overlap was shown, suggesting that compounding (genetic or environmental) 
factors contribute to a particular clinical phenotype. Such a notion is further supported 
by a study that showed that some aHUS patients carry multiple mutations in the 
complement factor genes.21 In order to understand the shared associations, cross-
phenotype studies are warranted to unravel the mechanisms common and unique to 
aHUS and AMD. This will lead to more rational approaches to diagnosis and therapy by 
targeting these specific molecular targets.
The identification of rare penetrant AMD-associated variants may have relevance for 
diagnostic, predictive and therapeutic purposes, although the exact interpretation 
may remain a challenge. Recent studies have identified several highly penetrant rare 
variants (Lys155Gln in C3, Gly119Arg in CFI, Pro167Ser in C9 and Arg1210Cys in 
CFH), to be associated with AMD.8-12 However, not all associations hold true among 
different populations. An example of this is the Arg1210Cys variant in CFH which was 
strongly associated in a North American AMD cohort8 but not in an Icelandic AMD 
cohort11 (Table 5). Genetic drift, founder effects or differences in genetic make-up 
that could compensate for a rare disruptive variant may underlie this phenomenon. 
In addition, the possibility that environmental effects could mask or enhance the 
penetrance of certain alleles between populations may also exist. To date, it remains 
unclear how these observations impact the predictive value of finding such variants in 
individuals. In contrast, variants that were proven to be functionally impaired and that 
are associated with AMD in several populations, such as the Lys155Gln variant in C3, 
have a much stronger predictive value.
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In conclusion, we report a rare variant (Lys65Gln) at the C3 locus in patients with AMD, 
while an association with two other variants (Arg735Trp and Ser1619Arg) was not 
confirmed in other cohorts. This study further supports that rare variants contribute 
to the genetic variance of AMD, which may have implications for predictive testing 
and personalized medicine in AMD.10
3.4 MATERIALS AND METHODS
3.4.1 Cases and controls
Cases and controls included in this study were selected from the population-based 
Rotterdam Study, Rotterdam, The Netherlands and from the European Genetic 
Database (EUGENDA), a multicenter database comprising participants from the 
Cologne area, Germany and the Nijmegen area, the Netherlands. All participants of 
this study underwent extensive retinal imaging which has been described in detail 
elsewhere22,23. In short, AMD staging was performed by grading of stereo fundus 
photographs according to the standard protocol of the Rotterdam grading center and 
Cologne Image Reading Center (CIRCL). All subjects were classified on the basis of 
the eye with the more severe diagnosis. Cases were aged ≥50 years of age and AMD 
was classified by the presence of at least 15 intermediate (63–124 µm) or at least 
one large drusen (≥125 µm) or geographic atrophy or choroidal neovascularization 
secondary to AMD. Control subjects were aged ≥65 years of age and did not have 
AMD (none or only small, hard drusen or only pigmentary abnormalities or less 
than 10 small drusen and pigmentary abnormalities). Written informed consent 
was obtained from all participants. The EUGENDA study was approved by the local 
research ethics committee, Commissie Mensgebonden Onderzoek Regio Arnhem-
Nijmegen, the Netherlands, and Ethics Committee of the University Hospital Cologne, 
Germany. The Rotterdam study was approved by the institutional review board 
(Medical Ethics Committee) of the Erasmus Medical Center and by the review board 
of The Netherlands Ministry of Health, Welfare and Sports. The study was performed 
in accordance with the tenets of the Declaration of Helsinki.
3.4.2 Sequencing
Sanger sequencing of the C3 (NM_000064) gene was performed in the discovery set, 
consisting of 84 AMD patients selected from the EUGENDA database. Primers were 
designed for all 41 coding exons and intron-exon boundaries by Primer3 software 
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(Supplementary Material, Table S1). Polymerase chain reaction (PCR) was performed, 
and PCR amplicons were sequenced using an automated sequencer (BigDye 
Terminator, version 3, 3730 DNA analyzer; Applied Biosystems). Sequences were 
assembled and analyzed using ContigExpress (Vector NTI Advance, Version 11.0, Life 
Technologies). Each newly identified variant was confirmed by a second independent 
PCR and bidirectional Sanger sequencing. The predicted effects of identified missense 
variants were examined using Polymorphism Phenotyping (PolyPhen)24 and Sorting 
Intolerant from Tolerant (SIFT).25
3.4.3 Genotyping in the EUGENDA cohort
Variants (Lys65Gln, Arg102Gly, Arg161Trp, Pro314Leu, and Arg735Trp) were 
genotyped in the EUGENDA cohort using competitive allele-specific PCR assays 
(KASPar SNP Genotyping System, KBiosciences). KASPar genotyping was performed 
according to the manufacturer’s protocol in a volume of 4 µl containing 10 ng of 
genomic DNA, 2.5 µl of 2× reaction mix, and 0.069 µl of assay. Thermal cycling 
conditions included a pre-incubation step at 94°C for 15 min, 20 cycles of 94°C for 
10 s, 57°C for 5 s, 72°C for 10 s, followed by 23 cycles of 94°C for 10 s, 57°C for 20 s, 
72°C for 40 s. Plates were analyzed on a 7900 Fast Real-Time PCR system (Applied 
Biosystems). The Ser1619Arg variant was genotyped in the EUGENDA cohort by 
Amplification Refractory Mutation System (ARMS)26 PCR (Supplementary Material, 
Table S2). PCR reactions were performed in a volume of 12.5 µl using 20 ng genomic 
DNA, 1× buffer, 2.5 mM MgCl2, 1 mM deoxyribonucleotide triphosphates, 0.2 µM of 
each primer, and 0.5 U Taq DNA polymerase (Invitrogen, Life technologies). Thermal 
cycle conditions included a pre-incubation step at 95°C for 5 min, 16 cycles of 95°C 
for 30 s, 69°C for 30 s, 72°C for 45 s, followed by 25 cycles of 95°C for 30 s, 67°C for 
30 s, 72°C for 45 s. PCR amplicons were analyzed by agarose gel electrophoresis. Each 
newly identified variant was confirmed by a second independent PCR and bidirectional 
Sanger sequencing.
3.4.4 Exome sequencing, exome chip analysis and genotyping in 
the Rotterdam Study
The occurrence of the C3 variants Lys65Gln, Arg161Trp, Arg735Trp, and Ser1619Arg 
in the Rotterdam Study (RS) was retrieved from exome chip and exome sequencing 
data. For exome sequencing purposes, genomic DNA of RS participants was prepared 
from blood and fragmented into 200–400 bp fragments using Covaris Adaptive 
Focused Acoustics (AFA) shearing according to the manufacturer’s instructions 
168
Chapter 3 
(Covaris, Inc., Woburn, MA). Illumina TruSeq DNA Library preparation (Illumina, Inc., 
San Diego, CA) was performed on a Caliper Sciclone NGS workstation (Caliper Life 
Sciences, Hopkinton, MA), followed by exome capture using the Nimblegen SeqCap 
EZ V2 kit (Roche Nimblegen, Inc., Madison, WI). This capture targets 44 Mb of exonic 
regions covering 30,246 coding genes, 329,028 exons and 710 miRNAs. Paired-end 
2 ×100 sequencing was performed on Illumina HiSeq2000 sequencer using Illumina 
TruSeq V3 chemistry. Downstream analyses included demultiplexing (CASAVA 
software, Illumina), alignment using the burrows-wheeler alignment tool, followed by 
data processing and filtering with Picard, SAMtools and the Genome Analysis Tool-
Kit.27,28 Finally, variant detection was performed using GATK’s Unified Genotyper. 
For exome chip analysis, DNA samples of the Rotterdam study were included in the 
joint calling experiment of the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium.29 In short, DNA from the study participants was 
processed on the HumanExome BeadChip v1.0 (Illumina, Inc, San Diego, CA) querying 
247,870 variable sites using standard protocols at seven genotyping centers. Each 
center genotyped a common set of 96 HapMap samples to be utilized for quality 
control and determination of batch effects. Raw datafiles for all samples were 
transferred to a central location and assembled into a single joint calling (Illumina 
GenomeStudio v2011.1 software and GenTrain 2.0 clustering algorithm). Call rates 
>99% were used for both study samples as for HapMap controls to define genotype 
clusters. Finally, 8994 variants were excluded for further analyses. Common variants 
(Arg102Gly and Pro314Leu) were genotyped in the RS cohort using Taqman assays 
(Applied Biosystems, Foster city, California, USA).
3.4.5 Statistical analysis
A Fisher’s exact test was performed to assess the association between each variant 
and AMD, and also to check for Hardy-Weinberg equilibrium. P-values were calculated 
two-sided, and values of <0.05 were considered as statistically significant. Logistic 
regression analysis was performed to check for genotype interactions, to estimate the 
odds ratios (OR) with 95% confidence intervals (CI) and to adjust for age. Conditional 
analysis was performed to identify secondary association signals at the C3 locus by 
accounting for two known AMD SNPs. Either Arg102Gly/rs2230199 or Pro314Leu/
rs1047286 was added independently and combined to the regression model as a 
covariate to test the effect of the variant of interest. Data were analyzed using SPSS 
software, version 18.0.
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3.5 SUPPLEMENTARY DATA
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Primers Sequence (5’- 3’) Product (bp)
Exon 1F TGCTCACTCCTCCCCATC 199
Exon 1R AAATGTCTGCTTCCACCCC
Exon 2F GGCGTCTCACATCCGTG 333
Exon 2R GAAGACAGAAGGGGAGGGG
Exon 3F AGATCCGGAAGCTGGACC 444
Exon 3R TTGCCTCTCCTAAGCCTGTG
Exon 4F AGCGGGTACCTCTTCATCC 300
Exon 4R CCTTCCGGTGTGTCTTTCTC
Exon 5-6F TAGACACTGTGCACAGAGAAT 516
Exon 5-6R TTTCTCTGTAGGCTCCACTAT
Exon 7F AAGATCCGAGCCTACTATGAA 311
Exon 7R GTCCCCCACCTGGTCTTCACC
Exon 8-9F GGAGATCCCATTCTCCAGG 455
Exon 8-9R TTTCTCTTCTGACCTGGTCTCC
Exon 10-11F GGAGGTCTAATCCTGAGGGG 500
Exon 10-11R GACCCCACTGTGCAAACAC
Exon 12F CAGGTCTCAGGGATTCGG 349
Exon 12R GAAGGAGTCCCAGGGGTG
Exon 13F GAGGCCAAGATCCGCTACTAC 546
Exon 13R GACAGTTGAGAGACAGAGAGGG
Exon 14F AACCTTTCTGTCTTTCCACTC 422
Exon 14R CATTCCCATCTTCAGCTTCAA
Exon 15-16F CACAGGTGCATATGTGGGG 629
Exon 15-16R TCCCCTCCTCCCTCTCTG
Exon 17F GGGGAAGTCCTCCCTGG 360
Exon 17R TCCCTCCTCAGACAGGAGTC
Exon 18-19F TTTCACCATGTTAGCTAGGCT 662
Exon 18-19R AATGAGATGACACTCAGACAC
Exon 20-21F CTAAGAGCTGAGACCCAGGAG 585
Exon 20-21R GAAGACCAGGAGCCCTCTC
Exon 22-23F TGCTGACCATCTGTGTGTCTG 421
Exon 22-23R AATGAGATGGAATTTGGCTCC
Table S1. List of C3 gene sequencing primers
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Exon 24F AACCCTTTTCACGCCACC 343
Exon 24R GGATCTTAGGGGAGGGATGC
Exon 25F TGAGTCCTTCCCTTTTTAAGG 406
Exon 25R TCCGTGCTTAAGGATGCTTAA
Exon 26F GGTTGACATGGCAGTCTCTG 290
Exon 26R CTCTCGTGTTCATCCTGCG
Exon 27F GATGACTGCCATGTGTGGAC 241
Exon 27R CTGTGCTCTGCATCGGG
Exon 28F AAGTGCTGCTCGAATGATCC 297
Exon 28R CAGTATCTCCCGCCCTGAAC
Exon 29F CTCTTTCTGAGCTTTCTCTGA 386
Exon 29R AACTGATTCTCAACTCCACTG
Exon 30-31F GATTCTAGCCACTTTCCCAGG 495
Exon 30-31R AGAGGAGATGGTCCCTCTGG
Exon 32-33F GACCATCTCCTCTTGTCCCC 432
Exon 32-33R ACTTGGAAAGTACTGAATATCATGG
Exon 34-35F TCCTTGTCCAGGAACAGACC 424
Exon 34-35R CCAGCCAGATAGAGGTCAGG
Exon 36F CAAGACAATGCTGGACTCCC 244
Exon 36R CCCCACAATTCATATATACCTGG
Exon 37-38F TCTTTGGAGGGAGGCCC 504
Exon 37-38R TGACAACCACACCTACCACC
Exon 39-40F TGCCCCTCATGGTCAAC 428
Exon 39-40R ACAATGGTGTGGGCGTG
Exon 41F CCACACCATTGTCACGCC 280
Exon 41R GGCAAAGAACTCCAGACACG
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Table S3. List of kaspar primers
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Table S2. Genotyping probes: 
Ser1619Arg variant, Amplification Refractory Mutation System (ARMS) primer list 
Primers Sequence (5’- 3’) Product (bp) 
Wild type-Forward CCTGACCTGCCATTCTTCCCTCCAGCCTTA 298 
Mutant type-Forward CCTGACCTGCCATTCTTCCCTCCAGCCTTC   
Reverse GGTTTCAAGTAGGATGGAGCTGAGCTGCAGGTG   
 
List of kaspar primers     
Variants Allele X Primer Allele Y Primer Common Primer 
Allel
e X 
Allel
e Y 
Lys65Gln 
GTCCACGACTTCC
CAGGCA 
GTCCACGACTTCCC
AGGCC 
GTCTTCTCACTGGAC
AGCACTAGTT A C 
Arg102Gly/rs2
230199 
CACGGTCACGAAC
TTGTTGCC 
CACGGTCACGAACT
TGTTGCG 
GCCAACAGGGAGTTC
AAGTCAGAAA C G 
Arg161Trp 
CAATGTTGACCAT
GACCGTCCG 
CAATGTTGACCATG
ACCGTCCA 
TTCACCGTCAACCAC
AAGCTGCTA C T 
Pro314Leu/rs1
047286 
CCACCAGGTCTTC
TGCTCGGA 
CACCAGGTCTTCTG
CTCGGG 
TACTGCTGGACGGGG
TGCAGAA A G 
Arg735Trp/rs1
17793540 
GCAACTACATCAC
AGAGCTGC 
CTGCAACTACATCA
CAGAGCTGT 
TGGCCAGGCCCAGGT
GGCT C T 
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Mutant type-Forward CCT ACCTGCCATTCTTCCCTCCAGCCTTC   
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Variants Allele X Primer Allele Y Primer Common Primer 
Allel
e X 
Allel
e Y 
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GTCCACGACTTCC
CAGGCA 
GTCCACGACTTCCC
AGGCC 
GTCTTCTCACTGGAC
AGCACTAGTT A C 
Arg102Gly/rs2
230199 
CACGGTCACGAAC
TTGTTGCC 
CACGGTCACGAACT
TGTTGCG 
GCCAACAGGGAGTTC
AAGTCAGAAA C G 
Arg161Trp 
CAATGTTGACCAT
GACCGTCCG 
CAATGTTGACCATG
ACCGTCCA 
TTCACCGTCAACCAC
AAGCTGCTA C T 
Pro314Leu/rs1
047286 
CCACCAGGTCTTC
TGCTCGGA 
CACCAGGTCTTCTG
CTCGGG 
TACTGCTGGACGGGG
TGCAGAA A G 
Arg735Trp/rs1
17793540 
GCAACTACATCAC
AGAGCTGC 
CTGCAACTACATCA
CAGAGCTGT 
TGGCCAGGCCCAGGT
GGCT C T 
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ABSTRACT
Age-related macular degeneration (AMD) is a common condition that leads to severe 
vision loss and dysregulation of the complement system is thought to be associated 
with the disease. To investigate associations of polymorphisms in AMD susceptibility 
genes with systemic complement activation, 2655 individuals were genotyped for 
32 single nucleotide polymorphisms (SNPs) in or near 23 AMD associated risk genes. 
Component 3 (C3) and its catabolic fragment C3d were measured in serum and AMD 
staging was performed using multimodal imaging. The C3d/C3 ratio was calculated and 
associations with environmental factors, SNPs and various haplotypes of complement 
factor H (CFH) genes and complement factor B (CFB) genes were analyzed. Linear 
models were built to measure the influence of genetic variants on the C3d/C3 ratio. 
The study cohort included 1387 patients with AMD and 1268 controls. Higher C3d/
C3 ratios were found for current smoker (p = 0.002), higher age (p = 1.56×10−7), AMD 
phenotype (p = 1.15×10−11) and the two SNPs in the C3 gene rs6795735 (p = 0.04) and 
rs2230199 (p = 0.04). Lower C3d/C3 ratios were found for diabetes (p = 2.87×10−6), 
higher body mass index (p = 1.00×10−13), the SNPs rs1410996 (p = 0.0001), rs800292 
(p = 0.003), rs12144939 (p = 4.60×10−6) in CFH, rs4151667 (p = 1.01×10−5) in CFB and 
individual haplotypes in CFH and CFB. The linear model revealed a corrected R-square 
of 0.063 including age, smoking status, gender, and genetic polymorphisms explaining 
6.3% of the C3d/C3 ratio. After adding the AMD status, the corrected R-square 
was 0.067. In conclusion, none of the evaluated genetic polymorphisms showed an 
association with increased systemic complement activation apart from two SNPs in 
the C3 gene. Major genetic and non-genetic factors for AMD were not associated with 
systemic complement activation.
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4.1 INTRODUCTION
Age-related macular degeneration (AMD) is a neurodegenerative disease causing 
visual impairment and blindness in the elderly population. Accumulation of drusen 
between Bruch´s membrane and the retinal pigment epithelium characterizes the 
early forms while the two advanced forms show geographic atrophy and choroidal 
neovascularization. Risk is multifactorial including environmental and genetic 
factors. Genetic variation accounts for up to 71% of the disease risk.1 Many genetic 
polymorphisms were found in the alternative pathway of the complement system 
including complement factor H (CFH), complement component 3 (C3), Complement 
factor I (CFI), and complement factor B (C2/CFB locus) 2–8. Complement proteins and 
their activation products have been identified in retinal deposits of AMD patients.3,9-11
The alternative complement pathway is constantly activated by the spontaneous 
hydrolysis of a thioester bond in C3 and a tight regulation including CFH is necessary 
to prevent excessive activation. It is hypothesized that a dysregulation of the 
complement system leads to tissue damage and finally AMD.
The dysregulation of the complement system or their activation fragments were also 
found systemically. In AMD patients, various components of the complement system 
were found at increased levels such as CFB, CFD, C3a, C5a, C3d, and Ba.12,13
While the association of genetic polymorphisms with AMD is well established, only 
polymorphisms in the C3 gene and few haplotypes in the CFH and CFB/C2 gene were 
found to be associated with complement activation products including factor C3d in 
two small cohorts.12,13 The impact of other AMD susceptibility genes on the regulation 
of systemic complement activation remains unclear. In our study, we analyzed the 
association of 32 single nucleotide polymorphisms (SNPs) in or near 23 AMD risk 
genes with the C3d/C3 ratio as a marker for chronic complement activation in a 
Caucasian cohort of 2655 participants.
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4.2 MATERIALS AND METHODS
4.2.1 Study population
2655 participants from the European Genetic Database (EUGENDA, www.eugenda.
org) were included in the study. The study was performed in accordance with the tenets 
of the Declaration of Helsinki and the Medical Research Involving Human Subjects Act 
(WMO) and was approved by the local ethics committee of the University Hospitals in 
Cologne and Nijmegen. Written informed consent was obtained from all participants.
AMD staging was performed by grading of retinal images including stereo fundus 
photographs (FPs), fluorescein angiograms (FAs) and spectral domain optical 
coherence tomograms (SDOCTs) according to the standard protocol of the Cologne 
Image Reading Center (CIRCL) by certified graders (TR, LE). AMD was classified by 
the presence of pigmentary changes together with at least 10 small drusen (<63 µm) 
or the presence of intermediate (63–124 µm) or large drusen (≥125 µm diameter) in 
the Early Treatment Diabetic Maculopathy Study (ETDRS) grid or geographic atrophy 
and/or choroidal neovascularization (CNV) secondary to AMD in at least one eye.
Demographic data and non-genetic parameters including history of smoking 
(current/past/never), regular alcohol intake (yes/no), body mass index (BMI), arterial 
hypertension (yes/no), diabetes (yes/no), rheumatoid arthritis (yes/no), thyroid 
disease (yes/no), kidney disease (yes/no) and history of allergy (yes/no) were obtained 
by standardized interviewer-assisted questionnaires.
4.2.2 Complement component measurements and genetic 
analysis
Serum samples were used for C3d and C3 measurements. Serum was prepared by 
coagulation at room temperature. After centrifugation, the samples were stored at 
−80°C within 1 hour after collection. Complement component C3 and the activation 
fragment C3d were measured in serum samples as described previously.14 The C3d/C3 
ratio was calculated as a measure of C3 activation.
Genomic DNA was extracted from peripheral blood samples using standard 
procedures. Thirty-two SNPs in or near 23 AMD associated risk genes were chosen 
representing the majority of loci associated with AMD. Genotyping of SNPs in the 
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ARMS2 (rs10490924), CFH (rs1061170, rs800292, rs12144939, rs1410996), CFI 
(rs10033900, rs141853578), C2 (rs9332739), C3 (rs2230199, rs433594, rs6795735), 
CFB (rs4151667, rs641153), CFD (rs3826945), LPL (rs12678919), LIPC (rs10468017), 
TIMP3 (rs9621532), APOE2 (rs7412), APOE4 (rs429358), FADS1 (rs174547), 
CETP (rs2230199), TLR (rs4986790, rs3775291), SERPING (rs2511989), ABCA4 
(rs1800555, rs1800553, rs76157638), VEGFA (rs699946), SPRYD7 (rs7995557), 
COL8A1 (rs13081855), COL10A1 (rs3812111), SLC16A8 (rs8135665), ADAMTS9-AS2 
(rs6795735) genes were carried out as previously described.15
4.2.3 Haplotype analysis
In order to analyze the influence of haplotypes on C3d/C3 ratios, the posterior 
probability of each haplotype in the CFH gene including rs1061170, rs800292 and 
rs12144939 and in the CFB gene including rs4151667 and rs641153 was calculated 
using PHASE software, version 2.1.16,17
4.2.4 Statistical analysis
All calculations were performed using SPSS software version 21.0 (IBM Software 
and Systems, Armonk, NY, USA). C3d/C3 ratios are given as median and interquartile 
range (1st quartile – 3rd quartile). Due to the skewed nature of the data, the logarithm 
(log10) of the C3d/C3 ratios was used for analysis. Associations between logarithmic 
C3d/C3 ratios and genetic polymorphisms, haplotypes, phenotype and environmental 
factors were analyzed using t-tests or univariate analysis of variance (ANOVA) 
depending on number of variables. Associations between AMD phenotype and genetic 
polymorphisms were evaluated using logistic regression analysis. Linear models were 
performed to illustrate the influence of the genetic factors on complement activation. 
P-Values <0.05 were considered statistically significant.
4.3 RESULTS
4.3.1 Demographics and non-genetic factors
Mean age of the study population was 73.2±8.0 years (75.8±8.1 years for AMD 
patients and 70.4±6.8 years for controls, p<0.001). Demographic data, phenotype and 
environmental factors are summarized in Table 1. C3d/C3 ratios showed significant 
differences for age with increasing levels (except the youngest group from 50–59 
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and phenotype with higher values for AMD patients. A significant association was also 
found for diabetes, smoking, and BMI. 
Table 1. Median C3d/C3 ratios for non-genetic factors. 
Non-genetic factor N (%) Median C3d/C3 ratio (IQR) T-test/ univariate ANOVA 
Female sex 1547 (58.3) 0.00424 (0.00325-0.00561) 0.90 
Male sex 1108 (41.7) 0.00433 (0.00328-0.00567)  
Age 50-59 years 61 (2.3) 0.00430 (0.00337-0.00598) 1.56x10-7 
Age 60-69 years 879 (33.1) 0.00408 (0.00312-0.00550)  
Age 70-79 years 1140 (42.9) 0.00426 (0.00324-0.00547)  
Age 80-89 years 474 (17.9) 0.00462 (0.00356-0.00591)  
Age 90-99 years 97 (3.7) 0.00488 (0.00374-0.00705)  
No AMD 1268 (47.8) 0.00403 (0.00309-0.00536) 1.15x10-11 
AMD 1387 (52.2) 0.00449 (0.00348-0.00586)  
No arterial hypertension 1600 (63.6) 0.00428 (0.00328-0.00563) 0.24 
Arterial hypertension 917 (36.4) 0.00425 (0.00321-0.00556)  
No diabetes 2268 (90.8) 0.00430 (0.00330-0.00567) 2.87x10-6 
Diabetes 231 (9.2) 0.00390 (0.00295-0.00495)  
No rheumatoid arthritis 2353 (93.5) 0.00426 (0.00327-0.00559) 0.35 
Rheumatoid arthritis 164 (6.5) 0.00433 (0.00304-0.00564)  
No thyroid disease 2119 (84.2) 0.00426 (0.00326-0.00559) 0.77 
Thyroid disease 398 (15.8) 0.00429 (0.00325-0.00559)  
No kidney disease 2403 (95.5) 0.00426 (0.00326-0.00559) 0.92 
Kidney disease 114 (4.5) 0.00447 (0.00320-0.00572)  
No allergy 1984 (78.8) 0.00428 (0.00325-0.00562) 0.75 
Allergy 533 (21.2) 0.00425 (0.00328-0.00552)  
Never smoker 1029 (43.0) 0.00431 (0.00325-0.00572) 0.002 
Past smoker 1164 (48.6) 0.00415 (0.00320-0.00545)  
212 
 
Current smoker 201 (8.4) 0.00451 (0.00355-0.00584)  
BMI <25 930 (40.1) 0.00464 (0.00360-0.00611) 1.00x10-13 
BMI 25-29 1084 (46.7) 0.00408 (0.00312-0.00531)  
BMI ≥30 308 (13.3) 0.00376 (0.00287-0.00493)  
IQR = interquartile range (1st quartile – 3rd quartile).  
doi:10.1371/journal.pone.0093459.t001 
 
Associations of C3d/C3 levels with genetic polymorphisms 
Significant associations of C3d/C3 levels were found in the CFH gene for the SNPs 
rs1410996, rs800292 and rs12144939, in the CFB gene for rs4151667 and in the C3 
gene for rs6795735 and rs2230199. In all SNPs of the CFH and CFB gene, these 
variants showed lower C3d/C3 ratios than the reference alleles, only variants in C3 
revealed higher values. After stratification in AMD cases and controls, associations for 
the major risk variants in rs1061170 (CFHY402H, p = 0.35 for no AMD; p = 0.55 for AMD) 
and rs10490924 (ARMS2, p = 0.75 for No AMD, p = 0.25 for AMD) with the C3d/C3 ratio 
could not be observed. A detailed analysis is outlined in Table 2.
Table 1. Median C3d/C3 ratios for non-genetic factors.
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years) and phenotype with higher values for AMD patients. A significant association 
was also found for diabetes, smoking, and BMI.
4.3.2 Associations of C3d/C3 levels with genetic polymorphisms
Significant associations of C3d/C3 levels were found in the CFH gene for the SNPs 
rs1410996, rs800292 and rs12144939, in the CFB gene for rs4151667 and in the 
C3 gene for rs6795735 and rs2230199. In all SNPs of the CFH and CFB gene, these 
variants showed lower C3d/C3 ratios than the reference alleles, only variants in C3 
revealed higher values. After stratification in AMD cases and controls, associations 
for the major risk variants in rs1061170 (CFHY402H, p = 0.35 for no AMD; p = 0.55 for 
AMD) and rs10490924 (ARMS2, p = 0.75 for No AMD, p = 0.25 for AMD) with the C3d/
C3 ratio could not be observed. A detailed analysis is outlined in Table 2.
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For the SNPs rs1061170, rs800292 and rs12144939 in the CFH gene and the SNPs 
rs4151667 and rs641153 in the CFB gene, haplotypes were associated with C3d/
C3 levels (Table 3). All haplotypes were associated with lower C3d/C3 levels than the 
reference haplotype (Figure 1 and 2).
4.3.3 Associations of genetic polymorphisms with AMD
Performing logistic regression analysis, protective effects were found for variants 
in CFH rs1410996, CFH rs800292, CFH rs12144939, CFB rs641153 and FADS1 
rs174547. Variants in CFB rs4151667, TIMP3 rs9621532 and APOE4 rs429358 
showed a trend for a protective effect on AMD without reaching statistical significance, 
which may be due to low minor allele frequencies or smaller effects of those SNPs.
Variants in ARMS2 rs10490924, CFH rs1061170, C3 rs2230199, C3 rs6795735 and 
CETP rs2230199 were found to be associated with significantly higher risk for AMD 
(Table 4). Variants in VEGFA rs699946, SLC16A8 rs8135665 and ADAMTS9-AS2 
rs6795735 also showed a trend for a higher AMD risk without statistical significance, 
which also may be due to a smaller effect on AMD development for each of those SNPs 
compared to ARMS2 rs10490924 or CFH rs1061170.
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Table 3. Haplotypes for CFH/CFB and median C3d/C3 ratios. 
Haplotype CFH n Haplotype frequency MedianC3d/C3 ratio (IQR) T-test 
TGG 728 0.20 0.00456 (0.00345–0.00608) -* 
CGG 1544 0.42 0.00420 (0.00324–0.00550) 1.40×10−8 
TAG 755 0.20 0.00405 (0.00314–0.00530) 3.61×10−12 
TGT 620 0.17 0.00386 (0.00300–0.00504) 1.03×10−13 
CAG 21 0.008 0.00396 (0.00339–0.00507) -** 
TAT 18 0.005 0.00386 (0.00317–0.00513) -** 
Haplotype CFB n Haplotype frequency MedianC3d/C3 ratio (IQR) T-test 
TG 3337 0.89 0.00424 (0.00325–0.00559) -* 
TA 279 0.07 0.00408 (0.00310–0.00546) 0.15 
AG 152 0.04 0.00356 (0.00292–0.00471) 9.96×10−6 
For CFH single nucleotides polymorphisms rs1061170, rs800292, and rs12144939 and for CFB 
rs4151667 and rs641153 were chosen. 
*T- test with comparison to reference haplotypes TGG and TG; **Due to small number of cases 
excluded from analysis; IQR  =  interquartile range (1st quartile – 3rd quartile). 
doi:10.1371/journal.pone.0093459.t003 
 
Associations of genetic polymorphisms with AMD 
Performing logistic regression analysis, protective effects were found for variants in CFH 
rs1410996, CFH rs800292, CFH rs12144939, CFB rs641153 and FADS1 rs174547. 
Variants in CFB rs4151667, TIMP3 rs9621532 and APOE4 rs429358 showed a trend for 
a protective effect on AMD without reaching statistical significance, which may be due to 
low minor allele frequencies or smaller effects of those SNPs. 
Variants in ARMS2 rs10490924, CFH rs1061170, C3 rs2230199, C3 rs6795735 and 
CETP rs2230199 were found to be associated with significantly higher risk for AMD 
(Table 4). Variants in VEGFA rs699946, SLC16A8 rs8135665 and ADAMTS9-AS2 
rs6795735 also showed a trend for a higher AMD risk without statistical significance, 
Table 3. Haplotypes for CFH/CFB and median C3d/C3 ratios
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Figure 1. Logarithmic C3d/C3 ratios for haplotypes in the CFH gene rs1061170, rs800292 and rs12144939.
https://doi.org/10.1371/journal.pone.0093459.g001
Figure 2. Logarithmic C3d/C3 ratios for haplotypes in the CFB gene rs4151667 and rs641153.
https://doi.org/10.1371/journal.pone.0093459.g002
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Table 4. Logistic regression analysis between AMD and single nucleotide polymorphisms SNPs+.
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which also may be due to a smaller effect on AMD development for each of those SNPs 
compared to ARMS2 rs10490924 or CFH rs1061170. 
Table 4. Logistic regression analysis between AMD and single nucleotide 
polymorphisms SNPs+. 
SNP Heterozygous variant Homozygous variant 
 
OR 95% CI P-value OR 95% CI P-value 
ARMS2 rs10490924 2.32 1.90–2.84 1.00×10−13 8.13 5.66–11.69 1.00×10−13 
CFH rs1061170 1.57 1.27–1.95 3.16×10−5 3.70 2.82–4.85 1.00×10−13 
CFH rs1410996 0.36 0.27–0.48 5.05×10−12 0.23 0.15–0.36 1.28×10−13 
CFH rs800292 0.61 0.49–0.75 5.38×10−6 0.70 0.44–1.10 0.12 
CFH rs12144939 0.57 0.47–0.71 6.71×10−7 0.51 0.28–0.91 0.02 
CFI rs10033900 1.07 0.85–1.35 0.59 0.99 0.76–1.28 0.93 
CFI rs141853578 1.17 0.96–1.43 0.12 -* -* -* 
C2 rs9332739 0.70 0.42–1.17 0.17 -* -* -* 
C3 rs2230199 1.17 0.96–1.42 0.11 2.17 1.42–3.31 0.0004 
C3 rs433594 0.98 0.80–1.21 0.88 0.91 0.67–1.23 0.52 
C3 rs6795735 1.10 0.89–1.36 0.37 2.06 1.27–3.33 0.03 
CFB rs4151667 0.74 0.52–1.05 0.08 -* -* -* 
CFB rs641153 0.72 0.54–0.96 0.02 -* -* -* 
CFD rs3826945 1.01 0.76–1.34 0.94 0.76 0.48–1.22 0.26 
LPL rs12678919 1.02 0.80–1.29 0.89 1.11 0.51–2.43 0.79 
LIPC rs10468017 0.94 0.78–1.14 0.53 0.63 0.43–0.93 0.19 
TIMP3 rs9621532 0.86 0.52–1.42 0.56 -* -* -* 
APOE2 rs7412 1.21 0.84–1.76 0.31 -* -* -* 
APOE4 rs429358 0.84 0.60–1.17 0.30 -* -* -* 
FADS1 rs174547 0.88 0.72–1.06 0.18 0.64 0.46–0.88 0.006 
CETP rs2230199 1.39 1.15–1.70 0.001 1.38 1.02–1.87 0.04 
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TLR rs4986790 1.08 0.71–1.64 0.71 0.53 0.08–3.36 0.50 
TLR3 rs3775291 1.00 0.75–1.34 0.99 0.78 0.48–1.27 0.32 
SERPING rs2511989 1.10 0.81–1.50 0.53 0.79 0.54–1.16 0.22 
ABCA4 rs1800555 0.96 0.33–2.82 0.94 -* -* -* 
ABCA4 rs1800553 0.88 0.12–6.58 0.90 -* -* -* 
ABCA4 rs76157638 2.14 0.98–4.67 0.06 -* -* -* 
VEGFA rs699946 1.08 0.81–1.44 0.61 1.47 0.75.2.89 0.27 
SPRYD7 rs7995557 1.01 0.73–1.40 0.95 0.57 0.23–1.43 0.23 
COL8A1 rs13081855 1.03 0.80–1.33 0.82 0.53 0.16–1.74 0.30 
COL10A1 rs3812111 1.04 0.84–1.28 0.73 1.02 0.75–1.40 0.89 
SLC16A8 rs8135665 1.21 0.98–1.49 0.08 1.39 0.87–2.21 0.17 
ADAMTS9-AS2 rs6795735 1.21 0.98–1.51 0.08 1.30 0.98–1.72 0.07 
+Adjusted for age and gender; *analysis not performed due to small group size. 
doi:10.1371/journal.pone.0093459.t004 
 
Linear Models 
Linear models were composed based on univariate analysis of covariance (ANCOVA) 
with the logarithmic C3d/C3 ratio as dependent variable to evaluate the influence of 
various factors on the C3d/C3 ratio. In the first model, we included all SNPs (rs1410996, 
rs800292, rs12144939 in CFH, rs4151667 in CFB, rs6795735 and rs2230199 in C3) that 
had reached statistical significance in the individual analysis and the two major AMD risk 
SNPs risk ARMS2 rs10490924 and CFH rs1061170. Additionally, age, gender, and 
smoking status was included. The corrected R-square was 0.063. Adding the AMD 
status to the model, the corrected R-square was 0.067. 
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4.3.4 Linear Models
Linear models were composed based on univariate analysis of covariance (ANCOVA) 
with the logarithmic C3d/C3 ratio as dependent variable to evaluate the influence 
of various factors on the C3d/C3 ratio. In the first model, we included all SNPs 
(rs1410996, rs800292, rs12144939 in CFH, rs4151667 in CFB, rs6795735 and 
rs2230199 in C3) that had reached statistical significance in the individual analysis 
and the two major AMD risk SNPs risk ARMS2 rs10490924 and CFH rs1061170. 
Additionally, age, gender, and smoking status was included. The corrected R-square 
was 0.063. Adding the AMD status to the model, the corrected R-square was 0.067.
In the second model, CFH haplotypes, age, gender, and smoking status were included. 
The corrected R-square was 0.038.
4.4 DISCUSSION
Dysregulation of the alternative complement pathway is thought to play a key role in 
AMD pathogenesis, which is also reflected by increased systemic complement levels.
In this study we analyzed the association of genetic AMD risk polymorphisms with 
systemic complement activation. We identified only a few variants in the CFH, CFB, 
and C3 gene that showed an association with systemic complement activation, while 
for all other genetic polymorphisms associations were not observed.
While the association with genetic polymorphisms was weak, we found a significant 
association of the phenotype AMD with an increased C3d/C3 ratio which is in line 
with other smaller studies.12,13 Our linear model including the AMD phenotype, the 
two major non-genetic risk factors age and smoking, and eight relevant SNPs could 
only explain 6.7% of the variation in the C3d/C3 ratio, indicating that these AMD risk 
polymorphisms do not explain sufficiently increased systemic complement activation 
found in AMD patients. The inclusion of CFH haplotypes in the model revealed an 
even lower explanation of the C3d/C3 ratio of only 3.8%.
Our analysis concentrated on C3d as a marker of chronic complement activation 
because it is a relatively stable protein with a long half-life. To correct for differences 
in the concentration of the precursor protein, we also measured C3 in the plasma.
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CFH, CFB, and C3 influence the regulation of the alternative pathway of the complement 
system. CFH acts as the major regulator of complement activation controlling the 
alternative pathway in blood and on cell surfaces18, and accelerates the decay of the 
alternative C3 convertase (C3bBb).19
CFH is also a cofactor of CFI-mediated cleavage and inactivation of C3b.20 The 
formation of C3d, a polypeptide fragment generated during alternative C3 convertase 
cleaves C3 to C3b, is also CFH dependent.21 Alterations in the CFH gene may change 
the regulating characteristics of CFH resulting in an up or down regulation of the CFH 
dependent elements of the alternative complement pathway. In our cohort, SNPs 
rs1410996, rs800292, and rs12144939 in the CFH gene were associated with lower 
C3d/C3 ratios and a lower risk for AMD, whereas the most common AMD risk variant 
rs1061170 was not associated with the C3d/C3 ratio even after stratification in AMD 
patients and controls. Additionally, CFH haplotypes showed lower C3d/C3 ratios in all 
cases compared to the reference haplotype. Therefore, CFH SNPs were not associated 
with increased systemic complement activation.
CFB is an acute phase protein involved in the alternative complement pathway as a 
precursor of C3 convertase. CFB is cleaved to Bb which combines with C3b to form 
the alternative pathway C3 convertase C3bBb. An acute phase response-mediated 
up-regulation may result in elevated systemic plasma levels of CFB in AMD patients 
and may contribute to an enhanced systemic complement activity.12,13,22 In our study 
we observed lower C3d/C3 ratios for the operatively protective CFB variants for 
AMD indicating that individuals with these polymorphisms show less complement 
activation.
Among all analyzed SNPs, only variants in the C3 gene were associated with higher 
systemic C3d/C3 ratios which aligns with the results by Hecker et al.11 The alternative 
pathway of the complement system starts with spontaneous hydrolysis of C3 and 
variants with a higher risk for AMD seem to influence this part of the complement 
cascade resulting in elevated systemic complement activation. Scholl et al did not 
observe a correlation between genetic variants in C3 and systemic C3d levels12 
underlining that the systemic effects of AMD susceptibility genes on complement 
activation are only weak.
In our study, slightly higher C3d/C3 levels were found in AMD patients. In order to 
not miss a combined effect of multiple SNPs, we performed linear models to illustrate 
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the effect of the combination of SNPs on complement activation. These models could 
not explain the C3d/C3 ratio, showing that there have to be other systemic effects 
than AMD phenotype or genetic variants influencing systemic complement activation. 
Hecker et al also showed in a small cohort that risk haplotypes in CFH did not alter 
complement levels, whereas protective haplotypes reduced complement levels 
including C3d.12
A limitation of our study is the analysis of only two components of the complement 
system, which is accompanied by several strengths including a large cohort of well-
balanced AMD patients and controls, a high number of investigated SNPs and the use 
of multimodal imaging that avoids misclassification of phenotypes.
In summary, we showed that the major AMD risk polymorphisms in CFH and ARMS2 
are not associated with increased systemic complement activation as measured by the 
C3d/C3 ratio. Few SNPs were associated with lower levels of systemic complement 
activation, particularly the CFH and CFB polymorphisms that are protective against 
AMD. Only variants in C3 were associated with elevated complement levels. 
Furthermore, a model including major genetic and non-genetic factors for AMD was 
not able to explain complement activation.
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ABSTRACT
The complement system is the first line of defense against foreign intruders, and 
deregulation of this system has been described in multiple diseases. In age-related 
macular degeneration (AMD), patients have higher complement activation levels 
compared to controls. Recently, a combination of three single nucleotide polymorphisms 
(SNPs) in genes of the complement system, referred to as a complotype, has been 
described to increase complement activation in vitro. Here we describe a novel 
complotype composed of CFB (rs4151667)-CFB (rs641153)-CFH (rs800292), which is 
strongly associated with both AMD disease status (p = 5.84 x 10−13) and complement 
activation levels in vivo (p = 8.31 x 10−9). The most frequent genotype combination 
of this complotype was associated with the highest complement activation levels in 
both patients and controls. These findings are relevant in the context of complement-
lowering treatments for AMD that are currently under development. Patients with a 
genetic predisposition to higher complement activation levels will potentially benefit 
the most of such treatments.
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5.1 INTRODUCTION
The complement system is part of our innate immunity where it acts as a first line 
of defense against foreign intruders1 and as a surveillance system to discriminate 
between healthy host tissue, cellular debris and apoptotic cells2. The complement 
system can be triggered through one of its three pathways: the classical pathway (CP), 
the lectin pathway (LP) and the alternative pathway (AP). All three pathways converge 
at the level of complement component 3 (C3), which is cleaved into C3a (a potent 
proinflammatory molecule) and C3b (an opsonin).1
After C3 cleavage, a subsequent cascade of enzymatic reactions lead to the formation 
of the membrane-attack-complex, which is responsible for disrupting the target cell 
membrane by forming transmembrane pores3. Unlike the CP and the LP, which need 
certain triggers to become activated, the AP is always at a low level of activation 
via a process called “tick-over”,4 a spontaneous conversion of C3 to a bioactive form 
C3(H
2
O)5. This conversion leads to a conformational change that allows for the binding 
of complement factor B (FB), similar to C3b5 and, through a series of subsequent steps, 
forms the initial C3 convertase C3(H
2
O)Bb1. This convertase cleaves C3 molecules 
into C3a and C3b5,6. In plasma, AP amplification is controlled by complement factor 
H (FH), which inactivates the C3 convertase and catalyses complement factor I (FI) 
degradation of C3b7. Dysregulation of the AP is associated with a number of diseases8, 
a strong example being age-related macular degeneration (AMD).9,10,11,12
AMD is a progressive retinal disease that leads to vision loss in the elderly population13. 
It is a multifactorial disease caused by both genetic and environmental factors. Several 
lines of evidence support the involvement of the complement system in the pathology 
of AMD. Some of the highest genetic risk for AMD is conferred by single nucleotide 
polymorphisms (SNPs) in or near genes of the complement system.14 Additionally, 
complement activation levels in plasma/serum are significantly higher in patients 
compared to controls9,10,11,12 and complement components have been described in the 
composition of retinal deposits called drusen, which are a hallmark of the disease.15
Currently, AMD therapies that aim to inhibit or lower complement activation are being 
developed,16,17 but it has been suggested that one of these inhibitors, lampalizumab, 
is effective only in a subset of patients that carry a specific genotype.18 Therefore, 
it is important to understand the genetic risk factors that influence complement 
activation in order to identify those individuals that would benefit the most from such 
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treatments.
Several studies have evaluated the effect of SNPs on complement activity, and only 
moderate effects have been observed.19,20,21 In vitro studies show that complement 
activity can increase six-fold when multiple SNPs in the complement system 
interact together.20 Such combinations of SNPs in the complement system are called 
complotypes. Harris et al. defined the complotype as any inherited pattern of genetic 
variants in complement genes which alters risk for both inflammatory disorders 
and infectious diseases involving the complement system.22 Until now, the best 
studied complotype in vitro is composed of three functional variants from the AP: C3 
(rs2230199 p.R102G), CFB (rs641153 p.R32Q) and CFH (rs800292 p.V62I). All three 
SNPs are individually associated with AMD.23,24,25 Although the presence of all three 
SNPs led to markedly higher complement activity in vitro, the effect of the complotype 
has so far neither been investigated in human plasma samples, representative of the in 
vivo situation, nor been associated with any disease.
In a recent study, we have found another functional SNP in CFB (rs4151667) to be 
more strongly associated with complement activation9 than the individual SNPs in the 
most studied complotype (C3 (rs2230199), CFB (rs641153) and CFH (rs800292)). The 
aims of this study, therefore, are: 1) to expand the complotype with the CFB variant 
(rs4151667) we found to be highly associated with complement activity; 2) to evaluate 
the relation of the complotype with complement activation in human plasma samples, 
representative of the in vivo situation; and 3) to investigate the association between 
the complotype and AMD.
5.2 RESULTS
The study was performed in three consecutive steps. First, the individual associations of 
CFH (rs800292), CFB (rs4151667), CFB (rs641153) and C3 (rs2230199) with AMD and 
with complement activation were verified. Next, we determined the most informative 
complotype for complement activation. Finally, we analyzed the association of the 
resulting complotype with the disease and with complement activation.
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5.2.1 Individual association of CFH (rs800292), CFB (rs4151667), 
CFB (rs641153) and C3 (rs2230199) with AMD and complement 
activation
In a previous study, CFH rs800292, CFB rs4151667, CFB rs641153 and C3 rs2230199 
were tested for their association with AMD in 2,655 individuals9. For the purpose of 
this study, 387 additional individuals were genotyped, amounting to a total of 3,042 
subjects (1,615 AMD and 1,427 Controls). The mean age was 75 for AMD and 70 for 
controls. The gender distribution was: 41% males to 59% females. All four SNPs were 
significantly associated with AMD (Supplementary Table S1). SNPs CFH rs800292 
(minor allele A), CFB rs4151667 (minor allele A) and CFB rs641153 (minor allele A) are 
protective, whereas the C3 rs2230199 (minor allele C) infers increased risk of AMD.
To determine the association of these SNPs with complement activation levels, CFH 
(rs800292), CFB (rs4151667), CFB (rs641153) and C3 (rs2230199) were included 
in a single general linear model, corrected for age, gender, body mass index (BMI) 
and disease status. The model revealed significant independent associations with 
complement activation levels for all four SNPs. Figure 1 illustrates P-values, mean 
log-transformed complement activation levels and genotype distribution for the four 
tested SNPs.
When we looked at the difference in mean complement activation level between 
the genotypes for each SNP, the high-risk C3 (rs2230199) genotype (GG) showed 
higher complement activation levels than the heterozygous (CG) and ancestral (CC) 
genotype. The protective CFH (rs800292) genotype (AA) showed lower complement 
activation levels than the other genotypes (Figure 1). However, a statistically 
significant difference in mean complement levels was only observed between the 
heterozygous genotype (GA) and the major genotype (GG) (p = 0.002), presumably 
due to the limited number of individuals carrying the AA genotype. The protective 
CFB (rs641153) genotype (AA) and the heterozygous (GA) genotype displayed 
lower mean complement activation levels than the ancestral (GG) genotype. For 
CFB (rs4151667), the homozygous protective genotype for AMD (AA) could not be 
statistically compared to the homozygous ancestral genotype (TT), due to low number 
of individuals in this genotype group. The observed effects are driven by the difference 
in mean complement activation levels between the heterozygous (TA) genotype and 
the ancestral (TT) genotype (Figure 1).
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Figure 1. Plasma complement activation levels (log-transformed C3d/C3 ratio) for C3, CFH and CFB genotype 
groups. Each genotype per SNP is plotted on the X axis in an individual dot plot. The homozygous genotypes 
conferring increased risk for AMD are indicated in red; the homozygous genotypes that are protective 
for AMD are indicated in green. The number of individuals carrying a specific genotype is indicated below 
each genotype. The Y axis represents the Log-transformed C3d/C3 ratio level as a measure of complement 
activation. The p-values represent the overall significance for each SNP included in the model.
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5.2.2 The most informative SNP combination in determining 
complement activation or AMD status
As all four SNPs were individually and independently associated with both complement 
activation and AMD status, the next step aimed to assess which combination of 
SNPs best predicted these associations. It was impossible to introduce genotype 
combinations of all 4 SNPs into the model because of the very low samples number 
of individuals in each of the resulting groups. For this reason, only combinations of 3 
SNPs were considered.
In order to determine which combination of SNPs could best explain complement 
activation and disease status, two random forest analyses were performed. In the 
first analysis, the ratio of C3d/C3 as a measure of complement activation was used as 
the dependent variable, whereas the second analysis was classified on AMD disease 
status. Variable importance analyses in both tests revealed that the SNP combination 
composed of CFB (rs4151667)-CFB (rs641153)-CFH (rs800292) was the strongest 
predictor for both complement activation and AMD status (Table 1). For the purpose 
of clarity, this combination of SNPs will be referred to as the novel complotype in the 
remainder of the manuscript.
5.2.3 Association of the novel complotype with AMD
Mathematically, there are 27 possible genotype combinations for a complotype 
composed of three SNPs. To ensure a meaningful interpretation of the statistical 
analyses, we included only those genotype combinations that were represented 
by at least ten individuals in both the patients and controls group. In our cohort, we 
observed seven genotype combinations that met these criteria. The distribution of all 
genotype combinations in our cohort is shown in Supplementary Table S2.
To determine the association of the novel complotype with AMD, a logistic regression 
analysis was performed. A strong overall association of the novel complotype with 
AMD (p = 5.84 x 10−13) was observed. In our analysis of the genotype combinations 
within the novel complotype, the most frequent genotype combination found in 
controls (TT-GG-GG) was set as reference. The logistic regression analyses corrected 
for age and gender revealed that, in comparison to TT-GG-GG, the other six genotype 
combinations were protective for AMD (Table 2).
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Table 1. Variable importance scores of C3, CFB and CFH genotypes and genotype 
combinations on complement activation levels and AMD status 
Variables %IncMSE  
IncNode 
Purity 
Mean 
Decrease 
Accuracy 
Mean 
Decrease 
Gini 
C3 (rs2230199) 5.33 0.06 6.59 1.85 
CFB (rs4151667) 13.24 0.20 2.51 0.92 
CFB (rs641153) 5.77 0.11 6.08 2.41 
CFH (rs800292) 6.07 0.15 13.24 6.57 
C3 (rs2230199) - CFB (rs4151667) - CFB 
(rs641153) 8.83 0.34 8.71 5.07 
C3 (rs2230199) - CFB (rs4151667) - CFH 
(rs800292) 9.08 0.35 13.12 9.66 
C3 (rs2230199) - CFB (rs641153) - CFH 
(rs800292) 10.88 0.33 13.84 11.85 
CFB (rs4151667) - CFB (rs641153) - CFH 
(rs800292) 18.58 0.62 18.47 17.28 
C3 (rs2230199) - CFB (rs4151667) - CFB 
(rs641153) - CFH (rs800292) 10.25 0.49 14.07 15.36 
Mean decrease accuracy and mean decrease Gini measure variable importance in predicting 
disease status. %IncMSE and IncNode Purity are measures for variable importance in predicting 
complement activation. For all variables, the highest values represent the best predictors. 
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Association of the novel complotype with AMD 
Mathematically, there are 27 possible genotype combinations for a complotype 
composed of three SNPs. To ensure a meaningful interpretation of the statistical 
analyses, we included only those genotype combinations that were represented by at 
least ten individuals in both the patients and controls group. In our cohort, we observed 
seven genotype combinations that met these criteria. The distribution of all genotype 
combinations in our cohort is shown in Supplementary Table 2. 
To determine the association of the novel complotype with AMD, a logistic regression 
analysis was performed. A strong overall association of the novel complotype with AMD 
(p = 5.84*10−13) was observed. In our analysis of the genotype combinations within the 
novel complotype, the most frequent genotype combination found in controls (TT-GG-
GG) was set as reference. The logistic regression analyses corrected for age and 
gender revealed that, in comparison to TT-GG-GG, the other six genotype combinations 
were protective for AMD (Table 2). 
Table 2. Association between the novel complotype and AMD 
Genotype 
combination for 
the novel 
complotype 
N 
P OR 
95% CI 
Contols AMD Lower Upper 
TT - GG - GG 607 916 5.84*10-13 - - - 
TA - GG - GA 47 23 1.01*10-5 0.3 0.174 0.51 
TA - GG - GG 55 65 0.131 0.74 0.494 1.096 
TT - GA - GA 74 47 6.65*10-7 0.36 0.237 0.535 
TT - GA - GG 112 106 3.2*10-4 0.57 0.422 0.775 
TT - GG - AA 59 48 0.007 0.56 0.373 0.856 
TT - GG - GA 406 370 7.32*10-9 0.58 0.48 0.696 
The model was established by logistic regression analysis, corrected for age and gender. 
Bonferroni corrected threshold for statistical significance is p<0.008. 
Table 1. Variable importance scores of C3, CFB and CFH genotypes and genotype combinations on 
complement activation levels and AMD status
Table 2. Association between the novel complotype and AMD
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5.2.4 Association of the novel complotype with complement 
activation
Finally, to determine the association of the novel complotype with complement 
activation, a general linear model was built, corrected for age, gender, BMI and 
disease status. This model showed that the novel complotype was highly associated 
with complement activation levels (p = 8.31 x 10−9). When we compared the different 
genotype combinations with one another, the TT-GG-GG combination was associated 
with the highest mean complement activation levels (Figure 2). The difference in mean 
complement activation levels between all genotype combinations, tested in a post-
hoc Bonferroni corrected manner, are presented in Supplementary Table S3. When 
comparing complement activation levels between AMD patients and controls, we only 
observed a significant difference for genotype combination TT-GG-GA (Figure 2).
5.3 DISCUSSION
In a large case-control study, we show that carrying multiple AMD protective 
genotypes for CFB (rs4151667), CFB (rs641153) and CFH (rs800292) leads to lower 
levels of complement activation in plasma compared to the most frequent genotype 
combination of these SNPs in control individuals. This novel complotype was identified 
as the most predictive SNP combination for determining both complement activation 
levels and AMD status. This combination of SNPs, drawn from an in vivo setting, is 
different from what has previously been suggested on the basis of in vitro data.20
It is well established that SNPs in complement components C3, CFB and CFH influence 
the risk for AMD.24,25,26 In this study, we confirmed that four common functional SNPs, 
CFH (rs800292), CFB (rs4151667), CFB (rs641153) and C3 (rs2230199) are associated 
with AMD. The minor alleles of the CFH and the CFB SNPs are protective,23,24 whereas 
the minor allele of the C3 SNP confers increased risk of AMD25. The well-known AMD 
SNP CFH (rs1061170; Tyr402His) was not included in this study because it was not 
associated with complement activation in our previous study9. This SNP was not 
described to alter AP convertase regulation, but rather it displays differential binding 
to C-reactive protein27 and malondialdehyde28.
Higher levels of systemic complement activation in patients compared to controls have 
been described in multiple studies.9,10,12,29 As the proteins encoded by CFH, CFB and C3 
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Figure 2. Mean C3d/C3 level and frequency of genotype combinations in AMD patients and controls. The 
blue and green bars represent the percentage of individuals carrying a specific genotype combination 
within their own disease status. The green triangles and blue squares represent mean C3d/C3 values for 
the corresponding genotype combination. The only genotype combination showing a significant difference 
in complement levels between AMD patients and controls was observed for TT-GG-GA with a p-value of 
3*10−4 (after Bonferroni correction statistical significance is achieved at p < 0.007).
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are key components of the AP of the complement system,30 the contribution of these 
SNPs to disease susceptibility possibly comes from their impact on AP activation.
FH is a major regulator of the AP31. One of the ways in which it down-regulates 
complement activity is to bind C3b as a cofactor for its inactivation.32 The A allele (p.62I) 
of the CFH (rs800292, p.V62I) SNP is a gain of function variant. In vitro experiments 
showed that the resulting protein binds more efficiently to C3b than the protein 
resulting from the G allele (p.V62) of this SNP,19 thus leading to more complement 
inhibition. This is in line with our results, demonstrating that the CFH (rs800292) GG 
genotype was associated with decreased risk for AMD and lower levels of complement 
activation than the AA genotype.
FB binds hydrolyzed C3(H
2
O) or C3b, which is then cleaved by complement factor D 
to form the AP C3 convertase that cleaves C3 to C3a and C3b,22 thus fueling the AP 
amplification loop. The A (p.32Q) allele of rs641153 (p.R32Q) leads to a FB protein with 
decreased potential to form the C3 convertase and amplify complement activation33. 
The second CFB SNP (rs4151667) (p.L9H) resides in the signal peptide, and it has 
been proposed that it could alter CFB secretion.24 In this study, the A alleles of both 
CFB SNPs were found to be protective for AMD and to lead to lower complement 
activation levels, even in heterozygous state, than the major homozygous genotype. 
The homozygous protective genotypes for CFB (rs4151667) were too rare for any 
reliable conclusions to be drawn.
C3 plays a central role in the complement system.34 The G (p.102G) allele of C3 
(rs2230199, p.R102G) decreases the efficiency of regulation of C3b by FH, thus 
leading to an increase in complement activation. These observations are in accordance 
with the results in the present study, where the GG genotype is associated with risk 
for AMD and displays higher levels of complement activation than the CC genotype 
(Figure 1A). Even though it plays such an important role, it was not part of the most 
predictive complotype in the present study.
Several in vitro studies have shown that having multiple SNPs in complement genes 
would lead to higher complement activation.20,35 In the present study, the novel 
complotype composed of CFB(rs4151667)-CFB(rs641153)-CFH(rs800292) had a 
larger effect on complement activation than the initially studied complotype C3 
(rs2230199)-CFB (rs641153)-CFH (rs800292)20 (Table 1). The higher predictive 
value of the newly described complotype with respect to AMD might be related to 
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the fact that it is composed of protective SNPs only rather than of a combination of 
polymorphisms with opposing effects on AMD susceptibility. When comparing the 
strongest effect (OR = 0.3) of this new complotype on the risk of AMD with the odds 
ratios of the 38 individual loci described in the newest AMD GWAS36, we notice that 
the effect size is close to both the CFH (OR = 0.38) and the ARMS2 (OR = 2.81), albeit 
reverse, locus. It is worth mentioning that the OR of 0.3 for the complotype it is seen 
when comparing TA-GG-GA to TT-GG-GG which has only two alleles difference out of 
the six.
This study is the first to analyze this specific complotype combination for its association 
with AMD and complement activity. Although it would have been interesting to study 
the simultaneous presence of all four genotyped SNPs, cohorts even larger than ours 
are needed to avoid the problem of small genotype combination groups that cannot be 
reliably compared.
Intriguingly, the homozygous genotypes associated with the highest complement 
activation levels in all three SNPs (TT-GG-GG) in the novel complotype are found 
most frequently in both AMD patients and controls. This is in contrast to what was 
proposed in the theoretical model from22, where the extreme genotype combinations 
were expected to be at the lower end of the carrier frequency spectrum. With fewer 
than ten individuals for patients or controls, the combination of all heterozygous 
genotypes was rare. The combination where all SNPs had the homozygous protective 
genotypes (AA-AA-AA) was not present in our cohort at all. In our study, therefore, the 
frequency distribution is skewed towards complement-raising genotypes.
This could potentially be explained by the fact that our cohort has a mean age of 
73 years and might be enriched, therefore, for alleles that promote survival. In this 
case, the alleles that give higher complement activation could offer better lifetime 
protection against infection. However, these same genetic variants would potentially 
induce low-grade inflammation, and its effect would only be observed later in life, as 
is the case for AMD, a disease that is prevalent in the elderly population. In support 
of this hypothesis, immune genes have been described to have the highest rate of 
positive selection.37 Upon examination of the amino acid conservation of the SNPs 
in the present study, in humans three complement-raising variants are the reference 
amino acid, compared to only one in primates (Supplementary Table S4).
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A significant difference in complement levels was observed between AMD patients and 
controls carrying the TT-GG-GA genotype combination. Although the highest mean 
difference was observed between the groups carrying the TT-GA-GG combination, 
this difference was not significant due to the high standard error.
The four most prevalent genotype combinations are all associated with high levels 
of complement activation in AMD patients with only minor differences between the 
groups. The three genotype combinations that are least prevalent are associated with 
lower complement activity. If we look at the specific genotype combinations, some 
interesting observations can be made.
First of all, the TT-GG-GG genotype combination is associated with the highest 
complement activation levels and is more prevalent in AMD patients (57.3%) than in 
controls (43.3%). The TA-GG-GG genotype, which is only different with respect to 1 risk 
allele in CFB rs4151667, is at the lower end of complement activation. The only other 
genotype combination with TA instead of TT for CFB rs4151667 is also associated with 
lower complement activation. This suggests that this SNP might be the most important 
of the three SNPs in the novel complotype and is the driving force behind the influence 
on complement activation. This is also evident in the results from the random forest 
analyses, where CFB rs4151667 is the strongest predictor for complement activation 
compared to the other individual SNPs. Another interesting observation from Figure 
1 is the difference in complement activation between genotype combinations TT-GG-
AA and TT-GA-GA. Both combinations include four risk alleles and two protective 
alleles, but the difference in complement activation is striking, especially in the AMD 
group. Perhaps the presence of two protective alleles in one SNP, as in the TT-GG-
AA genotype combination, has a stronger influence on complement activity than the 
combination of two heterozygous SNPs (TT-GA-GA). Observations like ours may help 
to clarify this and warrant further research, preferentially in an even larger dataset.
One of the major strengths of this study is the use of the large EUGENDA dataset. 
To the best of our knowledge, this is one of the largest datasets of complement 
activation to date. For the evaluation of mean differences in complement activation 
at a population level, as we have done in this study, a single measurement of C3 and 
C3d in each individual is sufficient. However, if complement activation would be used 
on an individual basis, such as for the selection of patients for clinical trials, multiple 
measurements over time would be preferred to correct for individual variations in 
complement activation.
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In conclusion, the current study has demonstrated that a novel complotype composed 
of CFB (rs4151667) in combination with CFB (rs641153) and CFH (rs800292) is 
strongly associated with complement activation and AMD status. These findings are 
relevant in the context of future complement-lowering treatments for AMD. In the 
era of personalized medicine, we are moving towards a more individualized approach 
to the treatment of diseases. To evaluate new treatment strategies, we need detailed 
information to determine how subgroups of patients with a higher treatment response 
potential should be defined. In this case, genotype-based patient stratification may 
identify those individuals that are genetically predisposed to having the highest 
complement levels, potentially making them the best candidates for complement-
inhibiting therapies in AMD.
5.4 MATERIALS AND METHODS
5.4.1 Study population
In this study, 3042 participants from the European Genetic Database (EUGENDA, 
www.eugenda.org), over the age of 50 years, were included. The study was performed 
in accordance with the tenets of the Declaration of Helsinki and the Medical Research 
Involving Human Subjects Act (WMO) and was approved by the local ethics committee 
of the University Hospitals in Cologne and Nijmegen. Written informed consent was 
obtained from all participants.
AMD and control status were assigned by multimodal image grading that included 
stereo fundus photographs, fluorescein angiograms and spectral domain optical 
coherence tomograms. The grading was performed according to the standard 
protocol of the Cologne Image Reading Center (CIRCL) by certified graders (TR, LE) as 
previously described38.
Age, gender and BMI were obtained by standardized interviewer-assisted 
questionnaires.
5.4.2 Complement measurements and genetic analysis
Complement component C3 and the activation fragment C3d were measured in serum 
samples as previously described9, and the C3d/C3 ratio was calculated as a measure 
of complement activation. The complement activation data were skewed and had 
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several outliers at the high end of the value range. In order to reduce the risk of outlier 
effects distorting the data, five percent of the highest values from the entire dataset 
were excluded from our analysis. After the exclusion of the outliers, the remaining 
skewedness of the C3d/C3 data was normalized by Log10 transformation.
Genomic DNA was extracted from peripheral blood samples using standard 
procedures. Four SNPs, CFH (rs800292), CFB (rs4151667), CFB (rs641153) and C3 
(rs2230199) were genotyped using the KASPar SNP Genotyping System by LGC 
Genomics.
5.4.3 Statistical analysis
All associations were calculated using SPSS software version 20.0 (IBM Software and 
Systems, Armonk, NY, USA). Associations with complement activation were analyzed 
using General Linear Models with C3d/C3 as the dependent variable. The models 
were corrected for age, gender, BMI and disease status.
The associations between AMD phenotype and the individual SNPs or the complotype 
were evaluated using logistic regression. To determine if the SNPs were independently 
associated with the disease, all four SNPs were included in the logistic regression 
model at once.
To avoid being relevant only to our sample set (overfitting), the most informative 
complotype combination was determined by calculating the variable importance 
in a random forest analysis using the R package (RandomForest version 4.6-10). In 
the first analysis, C3d/C3 was included as the dependent variable for the regression 
type random forest test. In the second analysis, the disease status was defined as the 
classifier for a classification type of random forest. For both analyses the number of 
predictors sampled for splitting at each node was set to two. All other options were 
left at default setting.
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5.5 SUPPLEMENTARY DATA
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Table S1. Association between AMD and SNP genotypes in the CFH, CFB and C3 genes
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Supplementary material 
Supplementary Table 1. Association between AMD and SNP genotypes in the CFH, 
CFB and C3 genes 
SNP 
cDNA 
change 
Protein 
change Genotype 
N  
P-value OR 
95% C.I.for 
EXP(B) 
AMD Control Lower Upper 
CFH 
rs800292 c.134G>A p.V62I 
GG 1101 801 7.4*10-11 
  
  
GA 445 539 0.015 0.63 0.435 0.913 
AA* 62 77 2.4*10-11 0.564 0.477 0.667 
CFB 
rs4151667 c.26T>A p.L9H 
TT* 1511 1291 0.02 
  
  
TA 99 127 0.904 0.828 0.038 17.888 
AA 1 1 0.005 0.654 0.486 0.881 
CFB 
rs641153 c.95G>A p.R32Q 
GG* 1436 1195 3*10-4 
  
  
GA 171 217 0.387 0.545 0.138 2.152 
AA 4 7 7.9*10-5 0.623 0.492 0.788 
C3 
rs2230199 c.304G>C p.R102G 
CC* 911 901 2.4*10-6 
  
  
CG 570 471 0.046 1.183 1.003 1.396 
GG 117 47 7.8*10-7 2.59 1.775 3.777 
Analyses were performed by logistic regression analysis. The genotypes marked with * are the 
ancestral variants. Variables entered in the model: CFH rs800292, CFB rs4151667, CFB 
rs641153, C3 rs2230199, age and gender. Bonferroni corrected threshold for statistical 
significance is p<0.004. 
  
Table S2. Genotype combination frequency for the novel complotype
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Supplementary Table 2. Genotype combination frequency for the novel complotype 
CFB (rs4151667) - CFB 
(rs641153) - CFH (rs800292) 
Control AMD 
Total 
n % n % 
AA - GG - GG 1 0.1 1 0.1 2 
TA - GA - AA 0 0.0 2 0.1 2 
TT - AA – GA 1 0.1 1 0.1 2 
TA - GA - GA 5 0.4 1 0.1 6 
TT - AA - GG 6 0.4 3 0.2 9 
TA - GG - AA 7 0.5 3 0.2 10 
TA - GA - GG 10 0.7 5 0.3 15 
TT - GA - AA 11 0.8 9 0.6 20 
TA - GG - GA 47 3.4 23 1.4 70 
TA - GG - GG 55 3.9 65 4.1 120 
TT - GG - AA 59 4.2 48 3.0 107 
TT - GA - GA 74 5.3 47 2.9 121 
TT - GA - GG 112 8.0 106 6.6 218 
TT - GG - GA 406 29.0 370 23.1 776 
TT - GG - GG 607 43.3 916 57.3 1523 
Total 1401 100 1600 100 3001 
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Table S3. Differences in mean complement activation levels between genotype combinations
248 
 
Supplementary Table 3. Differences in mean complement activation levels between 
genotype combinations 
 CFB (rs4151667) - CFB (rs641153) - 
CFH (rs800292) Mean Difference 
(I-J) 
Std. 
Error P-value 
TA - GG - GA 
TA - GG - GG -0.024 0.026 1 
TT - GA - GA -0.041 0.027 1 
TT - GA - GG -0.085* 0.024 0.011 
TT - GG - AA -0.06 0.027 0.524 
TT - GG - GA -0.079* 0.022 0.006 
TT - GG - GG -0.100* 0.021 6.1*10-5 
TA - GG - GG 
TA - GG - GA 0.024 0.026 1 
TT - GA - GA -0.017 0.024 1 
TT - GA - GG -0.061 0.021 0.074 
TT - GG - AA -0.036 0.023 1 
TT - GG - GA -0.055* 0.018 0.043 
TT - GG - GG -0.076* 0.017 1.9*10-4 
TT - GA - GA 
TA - GG - GA 0.041 0.027 1 
TA - GG - GG 0.017 0.024 1 
TT - GA - GG -0.044 0.021 0.843 
TT - GG - AA -0.019 0.024 1 
TT - GG - GA -0.038 0.018 0.826 
TT - GG - GG -0.059* 0.018 0.019 
TT - GA - GG 
TA - GG - GA 0.085* 0.024 0.011 
TA - GG - GG 0.061 0.021 0.074 
TT - GA - GA 0.044 0.021 0.843 
TT - GG - AA 0.025 0.021 1 
TT - GG - GA 0.006 0.014 1 
TT - GG - GG -0.015 0.014 1 
TT - GG - AA 
TA - GG - GA 0.06 0.027 0.524 
TA - GG - GG 0.036 0.023 1 
TT - GA - GA 0.019 0.024 1 
TT - GA - GG -0.025 0.021 1 
TT - GG - GA -0.019 0.018 1 
TT - GG - GG -0.04 0.018 0.464 
TT - GG - GA 
TA - GG - GA 0.079* 0.022 0.006 
TA - GG - GG 0.055* 0.018 0.043 
TT - GA - GA 0.038 0.018 0.826 
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TT - GA - GG -0.006 0.014 1 
TT - GG - AA 0.019 0.018 1 
TT - GG - GG -0.021 0.008 0.215 
TT - GG - GG 
TA - GG - GA 0.100* 0.021 6.1*10-5 
TA - GG - GG 0.076* 0.017 1.9*10-4 
TT - GA - GA 0.059* 0.018 0.0189 
TT - GA - GG 0.015 0.014 1 
TT - GG - AA 0.04 0.018 0.464 
TT - GG - GA 0.021 0.008 0.215 
*The mean difference is significant at the 0.05 level. All p-values were adjusted for multiple 
comparisons: Bonferroni. The general linear model was corrected for age, gender, BMI and 
disease status. 
 
 
Supplementary Table 4. Amino acid conservation for CFH (rs800292, p.V62I) - CFB 
(rs4151667, p.L9H) - CFB (rs641153, p.R32Q) - C3 (rs2230199, p.R102G) 
Species CFH CFB CFB C3 
p.V62I p.L9H p.R32Q p.R102G 
Human V L R R 
Chimp I L Q R 
Mouse I L R G 
Dog I L A G 
Cat 
 
L G G 
Caw 
 
L G G 
 
 
Statistical Syntax used for the models built in SPSS and the R script used to run 
the Random forest analyses: 
SPSS syntax for the statistical models: 
UNIANOVA Log_C3d_C3 BY Gender Disease_status Complotype_SNP2_SNP3_SNP4 WITH 
Age_Blooddate Q14_BMI 
  /METHOD=SSTYPE(3) 
  /INTERCEPT=INCLUDE 
  /EMMEANS=TABLES(Complotype_SNP2_SNP3_SNP4) WITH(Age_Blooddate=MEAN 
Q14_BMI=MEAN) COMPARE  
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5.5.1 Statistical Syntax used for the models built in SPSS and the R script 
used to run the Random forest analyses:
SPSS syntax for the statistical models:
UNIANOVA Log_C3d_C3 BY Gender Disease_status Complotype_SNP2_SNP3_SNP4 
WITH Age_Blooddate Q14_BMI
  /METHOD=SSTYPE(3)
  /INTERCEPT=INCLUDE
/EMMEANS=TABLES(Complotype_SNP2_SNP3_SNP4)
WITH(Age_Blooddate=MEAN Q14_BMI=MEAN) COMPARE 
ADJ(BONFERRONI)
 /PRINT=ETASQ PARAMETER
 /CRITERIA=ALPHA(.05)
/DESIGN=Gender Disease_status Complotype_SNP2_SNP3_SNP4 Age_Blooddate 
Q14_BMI.
LOGISTIC REGRESSION VARIABLES Disease_status
  /METHOD=ENTER Complotype_SNP2_SNP3_SNP4 Age_Blooddate Gender 
  /CONTRAST (Complotype_SNP2_SNP3_SNP4)=Indicator
  /CLASSPLOT
  /PRINT=CI(95)
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5).
249 
 
TT - GA - GG -0.006 0.014 1 
TT - GG - AA 0.019 0.018 1 
TT - GG - GG -0.021 0.008 0.215 
TT - GG - GG 
TA - GG - GA 0.100* 0.021 6.1*10-5 
TA - GG - GG 0.076* 0.017 1.9*10-4 
TT - GA - GA 0.059* 0.018 0.0189 
TT - GA - GG 0.015 0.014 1 
TT - GG - AA 0.04 0.018 0.464 
TT - GG - GA 0.021 0.008 0.215 
*The mean difference is significant at the 0.05 level. All p-values were adjusted for multiple 
comparisons: Bonferroni. The general linear model was corrected for age, gender, BMI and 
disease status. 
 
 
Supplementary Table 4. Amino acid conservation for CFH (rs800292, p.V62I) - CFB 
(rs4151667, p.L9H) - CFB (rs641153, p.R32Q) - C3 (rs2230199, p.R102G) 
Species CFH CFB CFB C3 
p.V62I p.L9H p.R32Q p.R102G 
Human V L R R 
Chimp I L Q R 
Mouse I L R G 
Dog I L A G 
Cat 
 
L G G 
Caw 
 
L G G 
 
 
Statistical Syntax used for the models built in SPSS and the R script used to run 
the Random forest analyses: 
SPS  syntax for the statis ical models: 
UNIANOVA Log_C3d_C3 BY Gender Disease_status Complotype_SNP2_SNP3_SNP4 WITH 
Age_Blooddate Q14_BMI 
  /METHOD=SSTYPE(3) 
  /INTERCEPT=INCLUDE 
  /EMMEANS=TABLES(Complotype_SNP2_SNP3_SNP4) WITH(Age_Blooddate=MEAN 
Q14_BMI=MEAN) COMPARE  
Table S4. Amino acid conservation for CFH (rs800292, p.V62I) - CFB (rs4151667, p.L9H) - CFB (rs641153, 
p.R32Q) - C3 (rs2230199, p.R102G)
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The R script used for the random forest analyses 
library(randomForest)
setwd(“”)
data <- read.table(“file.txt”, header=T)
View(data)
Combi3_4_SNPs <- data[,(2:11)]
attach(Combi3_4_SNPs)
set.seed(4)
complotype.rf <- randomForest(Log_C3d_C3 ~ ., data=Combi3_4_SNPs, mtry=2, 
importance=TRUE)
print(complotype.rf)
round(importance(complotype.rf), 2)
library(randomForest)
setwd(“”)
data <- read.table(“file2.txt”, header=T)
View(data)
selected_colums <- data[, (2:11)]
names(selected_colums)
attach(selected_colums)
sink(“results_randomeForest_on_disease_status.txt”)
set.seed(4)
complotype_on_AMD.rf <- randomForest(Disease_status ~ ., data=selected_colums, 
importance=TRUE, proximity=TRUE)
print(complotype_on_AMD.rf)
round(importance(complotype_on_AMD.rf), 2)
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ABSTRACT
Purpose Genetic variants in genes encoding components of lipid metabolism have 
been associated with AMD. The aims of this study were to evaluate the relation of 
these genetic variants with serum lipid levels in AMD in a large case-control cohort (n 
= 3070) and to test for correlations between lipids and complement activation.
Methods Single nucleotide polymorphisms (SNPs) in eight lipid metabolism genes, 
previously described to be associated with AMD, were genotyped and tested for their 
association in our case-control cohort. Serum apolipoprotein B (ApoB), apolipoprotein 
AI (Apo-AI), cholesterol, triglycerides (TG), high-density lipoprotein–cholesterol 
(HDLC), and complement activation levels (C3d/C3) were measured and tested for 
association with AMD. Non-HDL cholesterol and LDL were inferred based on the 
measurements of the other lipids and lipoproteins. General linear models and χ2 tests 
were used to evaluate the relation of SNPs and lipids/lipoproteins to the disease as 
well as their interrelations.
Results Significant genotypic associations with AMD were observed for SNPs in 
CETP, APOE, and FADS1. The serum levels of Apo-AI and HDLC were significantly 
higher in patients compared with controls. Triglycerides (TG) levels were lower in 
AMD compared with controls. A cumulative effect was observed for APOE and CETP 
genotypes on HDLC and Apo-AI levels. Complement activation levels correlated 
positively with HDLC and Apo-AI, and negatively with TG. Both the lipids/lipoproteins 
and the complement activation levels associate independently to AMD.
Conclusions This study bridges the gap between genetic associations and 
physiological lipid levels in AMD. Additionally, the observed correlations between 
complement activation and lipid levels link two major systems that previously were 
always assessed independently.
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6.1 INTRODUCTION
Age-related macular degeneration (AMD) is a multifactorial, progressive disease and a 
leading cause of blindness in the elderly population.1,2 The strong genetic underpinnings 
of AMD based on genome-wide association studies (GWAS) broadly point toward the 
involvement of three systems in the pathogenesis of AMD: the complement system, 
lipid metabolism, and the extracellular matrix.3 Investigating the pathways identified 
by genetic associations has proven to be a fruitful research strategy in the past. A 
higher rate of systemic complement activation levels was demonstrated in patients 
compared with controls,4,5 bringing systemic physiological consequences in line with 
the genetic associations. For the second major system involved in AMD, the lipid 
metabolism, such congruency is not immediately apparent. 
Lipids, due to their insoluble nature, are transported through the circulation by 
lipoproteins.6 Two major lipoproteins of this process are low-density lipoprotein 
(LDL) and high-density lipoprotein (HDL).7 Low-density lipoprotein is responsible 
for transporting cholesterol from the liver to the periphery, while HDL transports 
peripheral cholesterol back to the liver in a process called reverse cholesterol 
transport (RCT).8 
In a recent GWAS on AMD, three genes involved in the lipoprotein transport system 
(CETP, APOE, and LIPC) reached genome-wide significance.3 In addition, two earlier 
association studies also reported associations for LPL, FADS1, and ABCA1.9,10 All of 
the proteins encoded by these genes, are either enzymes, coenzymes, or transporters 
within the lipid metabolism. Thus, ample genetic evidence exists for the involvement 
of lipid metabolism in the etiology of AMD. 
In the pathology of AMD, aberrant lipid homeostasis has also been observed. Particularly, 
approximately 40% of drusen composition (one of the major hallmarks of AMD) is 
made up of esterified cholesterol, unesterified cholesterol, and phosphatidylcholine.11 
However, it has proven to be challenging to attribute risk scores for the development 
of AMD to systemic measurements of HDL or LDL. Studies directly investigating the 
levels of HDL/HDLC and LDL report conflicting results, with some presenting higher 
levels of HDL/HDLC in AMD patients compared with controls,12–18 whereas others 
describe the opposite.19–21 Yet other reports, including those that combined multiple 
of the previous studies, did not observe any significant differences between patients 
and controls.1,22–26 
227
Genetic variants and systemic complement activation levels are associated 
with serum lipoprotein levels in age-related macular degeneration
6
It is important to clarify the role of HDL and other lipids/lipoproteins in AMD and their 
relation to the established AMD-associated lipid genes, as this may shed more light on 
the pathogenesis of AMD. Such insights potentially could lead to targeted and more 
efficient approaches toward treatment regimens for AMD. Therefore, the primary 
aim of this study was to investigate the relation of single nucleotide polymorphisms 
(SNPs) genotypes in the AMD-associated lipid genes and serum lipid levels in AMD in a 
large case-control cohort (N = 3070). The secondary aim was to determine if there is a 
correlation between the previously described complement activation4 and lipid levels. 
6.2 MATERIALS AND METHODS
6.2.1 Study Population
From the European Genetic Database (EUGENDA, in the public domain, www.
eugenda.org), 3070 participants above the age of 50 years were included in the study. 
The study was performed in accordance with the tenets of the Declaration of Helsinki 
and the Medical Research Involving Human Subjects Act (WMO), and was approved 
by the local ethics committee of the University Hospitals in Cologne and Nijmegen. 
Written informed consent was obtained from all participants. 
Age-related macular degeneration and control status were assigned by multimodal 
image grading that included stereo fundus photographs, fluorescein angiograms, and 
spectral-domain optical coherence tomograms. The grading was performed according 
to the standard protocol of the Cologne Image Reading Center (CIRCL) by certified 
graders (TR, LE). The classification of AMD was performed as described previously.27 
Demographic data and nongenetic parameters including smoking status (current/
past/never), regular alcohol intake (current/past/never), body mass index (BMI), 
exercise/physical activity (never, almost never, 1–2 times a week, 3 or more times a 
week), and daily fat consumption (more than 35 g oil per day: Yes/No) were obtained 
by standardized interviewer-assisted questionnaires. 
6.2.2 Serum Measurements and Genetic Analysis
Serum samples were used for the various lipid and systemic complement measurements. 
Serum was obtained by a standard coagulation/centrifugation protocol, after which 
the samples were stored at −80°C within 1 hour after collection. Serum levels of 
228
Chapter 6 
apolipoprotein B (Apo-B), apolipoprotein AI (Apo-AI), total cholesterol, triglycerides 
(TG), and HDL-cholesterol (HDLC) were measured in all patients and controls using 
standard procedures by a clinical chemistry laboratory (Architect Analyzer; Abbott 
Diagnostics Hoofddorp, The Netherlands). Non-HDL cholesterol (NHDL) was 
calculated by subtracting HDLC from total cholesterol; and low-density lipoprotein 
(LDL) cholesterol was calculated using the Friedewald formula.28 
Complement component C3 and the activation fragment C3d were measured in 
serum samples as previously described29 and C3d/C3 was calculated as a measure of 
complement activation. 
Genomic DNA was extracted from peripheral blood samples using standard 
procedures. Eight SNPs in the LIPC, CETP, APOE, FADS1, LPL, and ABCA1 genes (see 
Supplementary Table S1) were genotyped using the KASPar SNP Genotyping System 
by LGC Genomics. 
6.2.3 Statistical Analysis
All calculations were performed using SPSS software version 20.0 (IBM Software and 
Systems, Armonk, NY, USA). Associations between lipid levels, SNP genotypes and 
disease status were analyzed using general linear models with each lipid, in turn, set as 
the dependent variable. The first model was built to find the association between lipids 
and disease status, the model was corrected for all possible confounders (see Table 3). 
The second model was built to find the association between lipids and SNP’s, again the 
model corrected for all possible confounders (see Table 4). In literature smoking status, 
alcohol intake, BMI, and dietary fat intake are reported to significantly influence lipid 
and lipoprotein levels,30–34 for this reason they were selected as correction factors for 
the models to eliminate any possible confounding. Additionally, age, sex, and exercise/
physical activity were significantly different between patients and controls, thus they 
were also added as correction factors. 
In order to assess the cumulative effect of CETP and APOE SNPs on lipid/lipoprotein 
levels, a new variable was created that had all nine possible genotype combinations (see 
Table 4). The association with the lipid/lipoprotein levels was tested in a general linear 
model also corrected for age, sex, BMI, smoking status, alcohol intake, exercise/physical 
activity, daily fat consumption, and disease status. The significance threshold was 
corrected for multiple testing, P values less than or equal to 0.006 (0.05/8 associations 
per experiment) were considered statistically significant for the associations to AMD 
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of both SNP genotypes and serum lipid levels. For the associations of the SNPs and 
serum lipid levels we have corrected for 12 associations (4 genetic variables against 
3 lipid/lipoprotein levels). The P values less than or equal to 0.004 (0.05/12 studied 
associations) were considered significant. 
Associations between AMD phenotype and genotypes were evaluated using cross 
tabulation, P values were calculated with Pearson χ2 and odds ratios were generated 
using logistic regression. Pearson correlations were used to investigate the relationship 
between lipids and complement activation levels. 
All power calculations were performed using CaTS - Power Calculator v0.0.2 (Center 
for Statistical Genomics, University of Michigan, Ann Arbor, MI, USA) as previously 
described.35 For the calculation we assumed a multiplicative model, a disease 
prevalence of 10% and a significance level of 0.006 (0.05/8 SNPs). The disease allele 
frequency and genotype relative risk were extracted from the papers that first 
described the associations (Supplementary Table S1). 
6.3 RESULTS
Summary of the demographics for the subjects included in the present study are 
shown in Table 1.
Eight SNPs in genes of the lipid metabolism, previously shown to be associated with 
AMD, were selected from literature (see Supplementary Table S1). Out of the eight 
SNPs that were analyzed, genotypes in CETP (rs3764261; P = 0.002), APOE (rs4420638; 
P = 0.005), and FADS1 (rs174547; P = 0.005), were significantly associated with AMD 
after correcting for multiple testing (P < 0.006). A summary of all associations and 
genotype frequencies are presented in Table 2.
Mean serum levels of Apo-B, Apo-AI, total cholesterol, HDLC, LDL, NHDL, and 
triglycerides of AMD patients compared to controls are presented in Table 3. 
After adjusting for age, sex, BMI, smoking status, alcohol intake, exercise/physical 
activity, and daily fat consumption, AMD patients had significantly higher Apo-AI 
(P = 0.002) and HDLC levels (P = 4.4 × 10−5) compared with controls. In contrast, 
patients had significantly lower serum levels of TG (P = 1.9 × 10−4) compared with 
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controls. Significant positive correlations were observed between Apo-AI and HDLC, 
and negative correlations between HDLC and TG (Supplementary Figure S1). The 
association between Apo-AI and AMD was independent of HDLC and TG. Similarly, the 
association of TG with AMD was independent of HDLC and Apo-AI. When correcting 
for Apo-AI and TG, the association of HDLC with AMD was negated, which is in line 
with the correlation of HDLC with Apo-AI and TG levels. No significant associations 
were found for any of the other measurements. 
Table 1. Baseline characteristics of study subjects.
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Table 1. Baseline characteristics of study subjects. 
    EUGENDA 
 
 AMD (n=1491) Control (n = 1579) 
Female sex, %   60 58 
Mean age ± SD, y   74.7 ± 8.4 69 ± 7.6 
Age range, y   50-101 50-100 
Mean BMI ± SD   25.82 ± 3.8 25.79 ± 3.9 
Smoking status, %    
current  10.2 8.5 
past  47.6 47.5 
never  42.2 44 
Regular alcohol intake, %    
current  57.6 56.4 
past  5 4.2 
never  37.4 39.4 
Exercise/physical activity, %    
never  24 20.1 
almost never  14.6 6.8 
1-2 times a week  44.2 47 
3 or more times a week  17.2 26.1 
Daily fat consumption, %    
yes  28.8 30.6 
no  71.2 69.4 
Significant differences between the two groups were only for age (p=1.98x10-114), sex (p=0.043) 
and exercise/physical activity (p=9.9x10-25) 
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the intermediate AMD stage. The observed effect directions were similar to the 
comparison of all AMD stages versus controls, with only Apo-AI, HDLC, and TG being 
significantly associated with intermediate AMD after correction for multiple testing 
(Supplementary Table S2). 
The SNPs that were significantly associated with AMD in the EUGENDA cohort, were 
analyzed for association with the lipid/lipoprotein levels that significantly differed 
between patients and controls. Only APOE (rs4420638) and CETP (rs3764261) 
genotypes displayed significant associations with Apo-AI and HDLC serum levels. 
APOE (rs4420638) genotypes were moderately associated with TG levels (P = 0.026), 
however the association did not remain significant after correcting for multiple testing. 
A summary of the results is presented in Table 4. 
Table 2. Association of genotypes in lipid metabolism genes with AMD.
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Eight SNPs in genes of the lipid metabolism, previously shown to be associated with 
AMD, were selected from literature (see Supplementary Table S1). Out of the eight 
SNPs that were analyzed, genotypes in CETP (rs3764261; P = 0.002), APOE 
(rs4420638; P = 0.005), and FADS1 (rs174547; P = 0.005), were significantly associated 
with AMD after correcting for multiple testing (P < 0.006). A summary of all associations 
and genotype frequencies are presented in Table 2. 
 
Table 2. Association of genotypes in lipid metabolism genes with AMD. 
    Status (%)   
SNP Gene P* Genotype Control AMD OR 95% C.I. 
rs493258 LIPC 0.388 TT 21.1 19.6   
   CT 49.0 48.6 1.07 0.89-1.27 
   CC 29.9 31.8 1.14 0.94-1.38 
rs10468017 LIPC 0.161 TT 8.2 7.7   
   CT 41.9 39.1 0.99 0.76-1.28 
   CC 49.9 53.2 1.13 0.88-1.46 
rs3764261 CETP 0.002 GG 47.8 42.3   
   GT 41.2 44.2 1.21 1.05-1.40 
   TT 10.9 13.5 1.40 1.12-1.74 
rs2075650 APOE 0.043 GG 1.6 1.4   
   GA 23.5 20.1 0.96 0.54-1.69 
   AA 74.9 78.5 1.18 0.68-2.05 
rs4420638 APOE 0.005 GG 3.0 1.9   
   GA 28.6 25.3 1.41 0.89-2.21 
   AA 68.3 72.8 1.70 1.09-2.65 
rs12678919 LPL 0.579 AA 80.7 79.3   
   AG 18.1 19.4 1.10 0.92-1.30 
   GG 1.3 1.2 0.99 0.54-1.81 
rs174547 FADS1 0.005 CC 11.8 8.5   
   CT 43.1 43.8 1.41 1.12-1.79 
   TT 45.1 47.7 1.47 1.16-1.86 
rs3758294 ABCA1 0.982 TT 63.1 62.9   
   TC 32.6 32.8 1.03 0.73-1.45 
   CC 4.3 4.2 1.02 0.73-1.42 
 * after correction for multiple testing significance is reached at P ≤ 0.006  
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Because both CETP and APOE SNP genotypes were significantly associated with Apo-
AI and HDLC serum levels, the cumulative effect of carrying multiple risk genotypes on 
the lipid levels was investigated. Mean levels for each genotype combination of CETP 
and APOE are displayed in Table 4 and visualized in Figure 1. In both cases, carriers of 
double high-risk genotypes for CETP and APOE showed significantly elevated levels of 
Apo-AI and HDLC compared with low-risk genotype carriers.
To exclude the possibility that the associations of HDLC and Apo-AI with AMD were 
mainly a consequence of the underlying genetic associations of CETP and APOE that 
drive HDLC and Apo-AI levels, all lipid analyses were corrected for CETP and APOE 
genotypes and all the other genotyped SNPs. After doing so, HDLC and Apo-AI 
remained significantly associated with AMD, independent of the genotypes (P = 1.4 × 
10−4 and 0.003, respectively).
Table 3. Association of mean serum lipid/lipoprotein levels with AMD*.
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Table 3. Association of mean serum lipid/lipoprotein levels with AMD*. 
Lipid Status Mean SE P 
Apo-B, mg/l 
Control 954.98 9.50 
0.788 
AMD 957.44 9.41 
Apo-AI, mg/l 
Control 1615.76 11.43 
0.002 
AMD 1649.35 11.32 
Total Cholesterol, mM 
Control 5.60 0.05 
0.155 
AMD 5.66 0.05 
HDLC, mM 
Control 1.40 0.01 
4.6x10-5 
AMD 1.45 0.01 
LDL, mM 
Control 3.83 0.04 
0.739 
AMD 3.85 0.04 
NHDL, mM 
Control 4.20 0.05 
0.819 
AMD 4.21 0.04 
Triglycerides, mM 
Control 1.76 0.03 
1.9x10-4 
AMD 1.65 0.03 
* General linear models were built with each lipid/lipoprotein as the dependent variable. The 
models tested for the association to disease status and were all corrected for age, sex, BMI, 
smoking status, alcohol intake, exercise/physical activity and daily fat consumption. 
Threshold for statistical significance p<0.006. 
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Finally, because serum complement activation levels were previously shown to be 
associated to AMD,4 we tested whether a relation exists between lipid levels and 
complement activation levels (C3d/C3 ratio). This analysis revealed significant 
positive correlations between Apo-AI, HDLC, and complement activation and a 
significant negative correlation for TG (Figure 2). All P values were less than 1.9 × 10−9. 
A general linear model corrected for disease status and other variables confirmed the 
association of C3d/C3 to lipids/lipoproteins (P = < 1.9 × 10−9) and revealed that the 
association to disease status is independent of lipid levels (P = 9 × 10−6).
Table 4. Association of AMD SNPs with serum lipid/lipoprotein levels.*
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Table 4. Association of AMD SNPs with serum lipid/lipoprotein levels.* 
    Lipid/lipoprotein 
  Apo-AI, mg/L HDLC, mM TG, mM 
     
SNP Genotype Mean SE Mean SE Mean SE 
CETP rs3764261 
GG 1601.6 12.1 1.37 0.01 1.71 0.03 
GT 1645.9 12.0 1.46 0.01 1.71 0.03 
TTa 1704.6 17.8 1.54 0.02 1.73 0.05 
Sig. 2.8x10-9 6.50x10-20 0.950 
APOE rs4420638 
GG 1555.7 35.9 1,32 0.04 1.95 0.09 
GA 1612.6 13.8 1.42 0.02 1.73 0.04 
AAa 1643.6 11.0 1.44 0.01 1.71 0.03 
Sig. 0.003 0.012 0.026 
FADS1 rs174547 
CC 1620.4 18.6 1.44 0.02 1.75 0.05 
TC 1632.8 12.1 1.43 0.01 1.74 0.03 
TTa 1638.5 12.0 1.43 0.01 1.69 0.03 
Sig. 0.595 0.832 0.137 
CETP/APOE 
GG/GG 1531.3 48.8 1.26 0.06 2.1 0.13 
GG/GA 1561.4 18.0 1.33 0.02 1.7 0.05 
GG/AA 1619.0 13.1 1.39 0.02 1.7 0.04 
GT/GG 1590.9 54.6 1.41 0.06 1.8 0.14 
GT/GA 1651.7 18.2 1.48 0.02 1.7 0.05 
GT/AA 1644.2 13.0 1.45 0.02 1.7 0.03 
TT/GG 1530.6 123.3 1.29 0.14 2.2 0.36 
TT/GA 1660.3 29.7 1.51 0.03 1.8 0.08 
TT/AA 1725.3 20.7 1.56 0.02 1.7 0.05 
  Sig. 1.3x10-9 4.4x10-19 0.118 
*The model was corrected for age, sex, BMI, smoking status, alcohol intake, 
exercise/physical activity, daily fat consumption and disease status. Threshold for statistical 
significance p<0.004. Sig., significance. 
a. Risk allele for AMD in our cohort 
 
Mean serum levels of Apo-B, Apo-AI, total cholesterol, HDLC, LDL, NHDL, and 
triglycerides of AMD patients compared to controls are presented in Table 3. After 
adjusting for age, sex, BMI, smoking status, alcohol intake, exercise/physical activity, 
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Figure 1. Mean lipid levels with standard error bars for CETP/APOE homozygous high-risk genotypes, 
heterozygous and homozygous low-risk genotypes. All P values are Bonferroni-corrected. (A) Levels for 
Apo-AI; (B) levels for HDLC.
Figure 2. Scatterplots showing the correlations of lipid levels with complement activation levels represented 
by the log transformed ratio of C3d/C3. Direction of the correlations is indicated by the black regression 
line. (A) Positive correlation of Apo-AI and logC3d/C3; (B) positive correlation of HDLC with logC3d/C3; (C) 
negative correlation of TG and logC3d/C3. 
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6.4 DISCUSSION
The genetic analyses from the present case-control study confirm previously described 
associations for CETP (rs3764261), APOE (rs4420638), and FADS1 (rs174547) with 
AMD. However, no associations were observed for APOE (rs2075650), LIPC (rs493258 
and rs10468017), LPL (rs12678919), and ABCA1 (rs3758294). The SNPs were selected 
from recent large GWAS3,9,10,36,37 (see Supplementary Table S1). For the SNPs in ABCA1 
(rs1883025) and LIPC (rs493258 and rs10468017) our study was underpowered with 
52%, 59%, and 53% chance of detection, respectively. Therefore, we cannot exclude 
the possibility that these SNPs may be associated to AMD in a larger cohort. On the 
other hand, for LPL (rs12678919) this study had 77% detection power, suggesting that 
not all genetic associations may be reliably replicated between different populations. 
In this study, we observed significant differences in the serum levels of Apo-AI, HDLC, 
and TG of AMD patients compared with controls. Triglycerides were significantly 
lower, while Apo-AI and HDLC were significantly higher in patients compared with 
controls. No statistically significant associations with AMD were detected for any of 
the other measured lipids/lipoproteins. 
In the literature, there are inconsistent associations of AMD with serum lipid 
levels. Comparing the mean lipid/lipoprotein levels observed in the present study 
with values previously reported (Supplementary Table S3), is challenging since the 
measurements were performed differently across the various reports, different 
correction factors were applied, and different populations were studied. All of these 
factors can influence the mean levels, making it difficult to pinpoint the cause of the 
different study outcomes. However, if we compare the main effects, our findings 
of high HDLC levels in patients compared with controls are consistent with several 
previous studies.12–18 The positive association of HDLC with only the intermediate 
AMD stage confirms the finding reported by Cougnard-Grégoire et al.12 On the other 
hand, other publications have reported inverse or no association between HDLC 
and AMD.19–23,25,26 When results were pooled in a meta-analysis, no associations 
have been detected.1,24,38 To our knowledge, for Apo-AI this is the first large study to 
report a positive association with AMD, and for TG other studies reported opposite 
or no associations with AMD.12,20,26 The reasons for these inconsistencies are not fully 
understood, however in a recent publication high levels of HDLC were associated 
with risk for AMD only after a stringent multivariate correction.12 Because our study, 
and others,39–41 show a clear effect of genotype on lipid levels, correcting for these 
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genotypes may improve the insight into the associations of lipid levels with AMD and 
the direction of their effect. This is especially important because our study, although 
appropriately powered, had failed to detect associations with LPL (rs12678919), 
suggesting that population- or cohort-specific genetic substructures may account 
partly for the observed inconsistencies. Another reason could be related to sample 
size, which in some studies might not be large enough to allow for the necessary 
adjustments and still have sufficient power to detect significant associations. In our 
cohort, higher levels of Apo-AI and HDLC were associated with risk genotypes in CETP 
(rs3764261; TT) and APOE (rs4420638; AA). A cumulative effect was observed for 
these two SNPs, with a risk-allele dose dependent increase in both HDLC and Apo-AI 
serum levels (Figure 1). The CETP and APOE loci have previously been linked to lipid 
metabolism in cardiovascular studies.40 In the context of AMD, few studies have looked 
into the relation of AMD lipid SNPs and serum lipid levels. Our results for CETP were 
consistent with a recent report from the Alienor study.12 Another study observed that 
in individuals carrying the LPL (rs12678919) GG genotype, TG levels were significantly 
lower and HDLC levels were significantly higher.42 Moreover, one study reported that 
the LIPC (rs10468017) T allele was associated with higher levels of HDLC.43 Our study 
does not describe an association of LPL and LIPC genotypes with lipid levels, because 
no significant difference between patients and controls was observed. 
CETP encodes for cholesterol ester transfer protein (CETP), which promotes the 
transfer of excess cholesterol ester (CE) to the liver through the RCT pathway.44 Several 
studies have shown that lower CETP activity leads to higher HDLC levels.41,45,46 APOE 
encodes for apolipoprotein E (ApoE), which plays a major role in the metabolism of 
cholesterol and TG by mediating the clearance of chylomicrons and very low-density–
lipoprotein (VLDL) from the bloodstream.47,48 ApoE has been described to have a 
direct relation with CETP by enhancing the CE and TG transfer between VLDL and 
HDL in a CETP-dependent manner.49 Despite the direct impact of ApoE and CETP on 
HDLC metabolism, understanding how the risk genotypes of the studied SNPs could 
have the cumulative HDLC raising effect is not directly obvious, mainly because both 
rs3764261 and rs4420638 are located in intergenic regions. One possibility may be a 
consequence of an effect on CETP expression levels that was reported for rs3764261.50 
Traditionally, rs4420638 is reported as an APOE SNP, because it is considered a proxy 
for rs429358, one of the two coding variants that determine the APOE isoforms (ε2, ε3, 
and ε4) reported to attenuate binding affinity to the (LDL)-receptor,51 and thus affect 
the entire cholesterol metabolism. However, the r2 value for the linkage disequilibrium 
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of these two SNPs is 0.63,3 indicating that there is not a complete coinheritance. Also, 
its genomic position is closer to the APOC1 gene, a potent inhibitor of CETP activity,52 
thus we cannot exclude the possibility of rs4420638 for being a proxy for a regulatory 
variant of APOC1 instead. 
Understanding the local involvement of lipid and lipoprotein systems at AMD disease 
sites in the eye is made difficult by the lack of information regarding eye specific 
function of these molecules. Nevertheless, if we focus on HDLC metabolism, clues 
can be found. First, key components of the RCT pathway for which the main player is 
HDLC,53 are expressed in the retina.54–56 In addition, during the normal aging process, an 
accumulation of Apo-B of unusual composition takes place in the Bruch’s membrane, 
forming a precursor of basal linear deposit, called the “lipid wall.”57 Moreover, the 
macromolecular conductivity of the Bruch’s membrane reduces 10-fold between the 
first and ninth decades of life, which is significant because lipoproteins need to cross 
the Bruch’s membrane in order to mediate lipid efflux from the RPE.58,59 Furthermore, 
in vitro, HDL has been observed to mediate efflux of photoreceptor outer segment 
lipids from the basal surfaces of RPE cells.60 Finally, a retention of cholesterol in drusen, 
the major lesions of AMD, has been reported.61 
Besides the involvement of HDL in lipid and lipoprotein transport, this system has 
recently been implicated in immune function.62 Recent proteomic analyses revealed 
several types of HDL particles containing complement system components C4a, C4b, 
C9, and vitronectin63,64 in healthy subjects, and C3 in patients with coronary artery 
disease.63 In our study, we offer support for this emerging concept by demonstrating a 
significant correlation between HDLC and complement system activation, although it 
remains to be determined whether the effect is direct or indirect. 
One possible limitation of our study may be that the lipid/lipoprotein levels were 
not overnight fasted blood measurements, which could induce possible artifacts 
for certain lipids like the TG. However, the fact that HDLC and Apo-AI levels are not 
severely affected by food intake,65 and the great number of participants in this study, 
negate this potential drawback. 
In our study, the genetic and environmental factors explain 31%, 84%, and 27% of the 
Apo-AI, HDLC, and TG variation, respectively. Our findings indicate that other factors 
must be associated with them, which might relate to the AMD disease pathogenesis. 
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In conclusion, the results of our study indicate that patients with high risk CETP/APOE 
genotypes and high HDLC levels have higher risk of developing AMD, suggesting that 
they could potentially benefit from HDLC lowering regimens. Further studies are 
needed to investigate the role of HDL subfractions and the observed correlation of 
HDLC with complement activation in the disease pathogenesis of AMD. 
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6.5 SUPPLEMENTARY DATA
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Supplementary Data 
Supplementary Table 1. Lipid associated SNPs and the papers they were selected 
from: 
 
 
 
 
 
 
 
 
 
  
SNP Gene Reference 
rs493258 LIPC 9 
rs10468017 LIPC 9 
rs3764261 CETP 3, 9, 10 
rs2075650 APOE 64, 65 
rs4420638 APOE 3 
rs12678919 LPL 9, 10 
rs174547 FADS1 9 
rs3758294 ABCA1 9, 10 
Table S1. Lipid associated SNPs and the papers they were selected from:
Figure S1. Correlations of Apo-AI and TG with HDLC in the EUGENDA cohort. The direction of the 
correlations is indicated by the black regression line. A. positive correlation between Apo-AI and HDLC 
levels; B. negative correlation between TG and HDLC levels.
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ABSTRACT
Purpose To identify genetic variants associated with complement activation, which 
may help to select age-related macular degeneration (AMD) patients for complement-
inhibiting therapies.
Design Genome-wide association study (GWAS) followed by replication and meta-
analysis.
Participants AMD patients and controls (n = 2245).
Methods A GWAS on serum C3d-to-C3 ratio was performed in 1548 AMD patients 
and controls. For replication and meta-analysis, 697 additional individuals were 
genotyped. A model for complement activation including genetic and non-genetic 
factors was built, and the variance explained was estimated. Haplotype analysis 
was performed for 8 SNPs across the CFH/CFHR locus. Association with AMD was 
performed for the variants and haplotypes found to influence complement activation.
Main Outcome Measures Normalized C3d/C3 ratio as a measure of systemic 
complement activation.
Results Complement activation was associated independently with rs3753396 
located in CFH (Pdiscovery = 1.09 × 10−15; Pmeta = 3.66 × 10−21; β = 0.141; standard 
error [SE] = 0.015) and rs6685931 located in CFHR4 (Pdiscovery = 8.18 × 10−7; Pmeta 
= 6.32 × 10−8; β = 0.054; SE = 0.010). A model including age, AMD disease status, 
body mass index, triglycerides, rs3753396, rs6685931, and previously identified 
SNPs explained 18.7% of the variability in complement activation. Haplotype analysis 
revealed 3 haplotypes (H1–2 and H6 containing rs6685931 and H3 containing 
rs3753396) associated with complement activation. Haplotypes H3 and H6 conferred 
stronger effects on complement activation compared with the single variants (P = 2.53 
× 10−14; β = 0.183; SE = 0.024; and P = 4.28 × 10−4; β = 0.144; SE = 0.041; respectively). 
Association analyses with AMD revealed that SNP rs6685931 and haplotype H1–2 
containing rs6685931 were associated with a risk for AMD development, whereas 
SNP rs3753396 and haplotypes H3 and H6 were not.
Conclusions The SNP rs3753396 in CFH and SNP rs6685931 in CFHR4 are 
associated with systemic complement activation levels. The SNP rs6685931 in 
CFHR4 and its linked haplotype H1–2 also conferred a risk for AMD development, 
and therefore could be used to identify AMD patients who would benefit most from 
complement-inhibiting therapies.
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7.1 INTRODUCTION
The complement system is an integral part of our innate immunity. Its best known 
physiologic functions are host defense against foreign intruders and homeostasis 
maintenance.1 It consists of more than 30 plasma proteins and cellular components 
that interact in proteolytic cascades for an efficient and rapid activation leading 
to inflammation, opsonization, and targeted cytolysis.2 The complement system 
can be activated by 3 different pathways: the classical pathway, the lectin pathway, 
and the alternative pathway (AP). The classical pathway is activated by antibody–
antigen complexes and the lectin pathway is activated by lectin or ficolin binding 
to carbohydrates, both present on the surfaces of pathogens. In contrast, the AP is 
activated constitutively at a low level in a process known as tick-over.3
All 3 pathways lead to the formation of complement component 3 (C3) convertases 
that catalyze a proteolytic cleavage of complement C3 into the potent anaphylatoxin 
C3a, and C3b, an opsonization molecule that can be further cleaved into C3d. 
Complement component 3b also can bind the cleaved form of factor B (Bb) to form 
the AP C3 convertase (C3bBb) that will cleave more C3, initiating an amplification 
loop. Downstream in the cascade, complement component 5 convertases are formed, 
initiating the terminal pathway with the subsequent formation of additional activation 
products as well as the membrane-attack complex that is responsible for cytolysis.4 
The complement system can be amplified rapidly, and therefore several inhibitory 
proteins such as complement factor H (FH) and complement factor I are in place 
regulating complement activity.4
Deregulation and deficiencies of the complement system have been reported to 
be associated with numerous inflammatory, autoimmune, neurodegenerative, and 
infectious disorders.5 A prime example of a multifactorial disease associated with a 
deregulation of the complement system is age-related macular degeneration (AMD). 
Age-related macular degeneration is characterized by a progressive degeneration of 
the central retina and is responsible for most cases of vision loss in the elderly with a 
pooled prevalence of 8.9%.6,7 Age-related macular degeneration constitutes a major 
health problem as by 2020, the number of people affected by a form of this disease is 
projected to be 196 million, rising to 288 million by 2040.8 Several lines of evidence 
point toward an overactivation of the complement system in AMD, mainly through 
a dysregulation of the AP. Multiple genetic variants in or near complement genes 
(CFH, C3, CFI, C2/CFB locus, and C9) have been associated strongly with AMD.9,10 
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Moreover, complement components have been described in drusen, the hallmark of 
the disease,11,12,13,14 and complement activation fragments in plasma or serum such 
as Ba, C3a, C3d, and component C5a have been found to be elevated significantly in 
AMD patients compared with controls.15,16,17,18,19,20,21 Currently, there is no treatment 
available for most forms of AMD, nor is there an effective means to halt AMD 
progression. Therefore, therapies for AMD, as well as for other diseases involving 
complement deregulation, are being developed aiming to inhibit or lower complement 
activation.22,23,24
Systemic complement activation levels demonstrate considerable variation among 
individuals.16,17,18,19,20 As a consequence, patients who have higher levels of complement 
activation may benefit more than others from the upcoming therapies. A better 
understanding of the factors that influence complement activation would facilitate 
the selection of the most suitable patients for complement-inhibiting therapies. 
Genetic markers are robust biomarkers that could be included in prediction models 
for complement activation. Several studies have previously evaluated the effect of 
genetic variation on complement activity; however, these studies were restricted to a 
limited number of single nucleotide polymorphisms (SNPs).16,17,18,19,21,25
The aim of this study was to perform the first genome-wide association study (GWAS) 
on systemic complement activation levels. Identification of genetic variants explaining 
complement activation levels will contribute to a better understanding of the molecular 
mechanisms of complement-related diseases, will pinpoint potential drug targets, and 
will facilitate the selection of patients for complement-inhibiting therapies.
7.2 MATERIALS AND METHODS
7.2.1 Study Population
This study included 2245 participants from the European Genetic Database (www.
eugenda.org). The European Genetic Database is a multicenter database for the 
clinical and molecular analysis of AMD collected at the Radboud University medical 
center, Nijmegen, The Netherlands, and at the University Hospital of Cologne, 
Cologne, Germany. The study participants were separated into 2 cohorts: a discovery 
cohort comprising 1548 individuals and a replication cohort of 697 individuals.
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The study was performed in accordance with the tenets of the Declaration of Helsinki 
(seventh revision) and the Medical Research Involving Human Subjects Act. Approval 
of the local ethics committee of both University hospitals was obtained, and written 
informed consent was acquired from all participants. All the individuals included in the 
study agreed to the performed serum measurements and genotyping. All participants 
were of European descent and older than 50 years. Age-related macular degeneration 
and control status were assigned by multimodal image grading according to the 
standard protocol of the Cologne Image Reading Center by certified graders. Age, 
sex, height, and weight measurements were obtained by standardized interviewer-
assisted questionnaires.
7.2.2 Serum Complement and Lipid Measurements
Serum was obtained by a standard coagulation and centrifugation protocol, and 
within 1 hour after collection, the samples were stored at −80°C. Triglycerides and 
high-density lipoprotein cholesterol were measured using standard procedures by 
a clinical chemistry laboratory (Architect Analyzer; Abbott Diagnostics, Hoofddorp, 
The Netherlands). Complement component 3 was assessed by radial immunodiffusion 
(or Mancini method) using monospecific polyclonal rabbit antisera, and C3d was 
measured by rocket electrophoresis, as previously described.21 Complement 
component 3d is a fragment of C3 generated upon activation of the system, and 
therefore a direct measurement of complement turnover.4 Moreover, C3d has the 
longest half-life of all C3 split products.26 The C3d-to-C3 ratio is a sensitive way of 
assessing the activation of the complement system independently of the baseline 
individual C3 concentration.27,28,29 The C3d-to-C3 ratio has been described previously 
to be a robust biomarker for complement activation in AMD studies.19 The different 
measurements were performed for all samples in a single assay.
7.2.3 Genotyping
Genomic DNA was extracted from peripheral blood samples using standard procedures. 
The discovery cohort was genotyped with a custom-designed HumanCoreExome 
array by Illumina (Illumina Inc., San Diego, CA) within the International AMD Genetics 
Consortium. All the details regarding the design of the array, annotation, imputation, 
and quality control of the genotypic data have been described previously.9
Imputed lead variants in GWAS peaks that reached significance, rs6685931 and 
rs3130572, were confirmed by polymerase chain reaction and Sanger sequencing. 
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The SNP rs6685931 was evaluated in 12 individuals representing the 3 genotypes, 
and a 100% of concordance with the imputed genotypes was achieved. The SNP 
rs3130572 (chromosome 6) was located in a highly repetitive region and specific 
primers could not be designed; therefore, this SNP was excluded from further analysis. 
In the replication cohort, CFH rs3753396 and CFHR4 rs6685931 were genotyped 
using competitive allele-specific polymerase chain reaction assays according to the 
manufacturer instructions (KASP Genotyping Chemistry; LGC, Hoddesdon, UK).
7.2.4 Statistical Analysis
Natural log transformation was applied to normalize the skewed distribution of C3d/
C3 measurements. A general linear model for ln(C3d/C3) including as independent 
variables the environmental factors collected was used to determine potential 
confounders. The R2 and adjusted R2 statistics were estimated for the model. 
Additionally, the R2 statistic was estimated for each of the independent factors 
individually, performing separate models. Analyses were carried out using SPSS 
software version 20.0 (IBM Software and Systems, Armonk, NY).
A power calculation for the GWAS was performed using the Genetic power calculator.30 
Association tests in the GWAS and replication analyses were performed by means of a 
linear Wald test from EPACTS software (http://genome.sph.umich.edu/wiki/EPACTS) 
using allele dosages. Linear regression models adjusted for age, sex, body mass index 
(BMI), triglycerides, clinic site, and the first 2 ancestry principal components were 
used. Manhattan and Q-Q plots were generated using the ‘qqman’ R package (version 
0.1.2; R Foundation for Statistical Computing, Vienna, Austria). The regional plots for 
chromosome 1 were generated using LocusZoom.31 Meta-analysis of fixed effects 
based on effect size estimates and standard errors was performed using METAL 
software (version 2-11-03-25).32
Evaluation of an interaction between the identified SNPs and clinic or AMD status 
was performed including an interaction parameter on the general linear model and 
assessing nominal significance. Comparisons of systemic complement activation 
levels between the genotype groups were performed using a general linear model 
adjusted for age, BMI, triglycerides, and clinic sites including both the discovery and 
the replication cohorts. SPSS software version 20.0 (IBM Software and Systems, 
Armonk, NY) was used for these analyses.
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To estimate how much of the variation in systemic complement activation could be 
explained by the identified factors, general linear models for systemic complement 
activation were performed using SPSS software version 20.0. Only the 1548 individuals 
from the discovery cohort were included to accommodate the CFH rs800292 and C2 
rs9332739 SNPs, which were not analyzed in the replication cohort. The adjusted R2 
statistic was estimated for the models.
Haplotype analysis was carried out for the 1548 patients genotyped with exome-arrays 
using the haplo.glm function of the R library ‘haplo.stats’ (version 1.7.7). Analysis was 
performed based on a general linear model adjusted for age, sex, BMI, triglycerides, 
clinic site, and the first 2 ancestry principal components.
Single-variant and haplotype association analyses with AMD were performed for the 
1548 individuals of the discovery cohort. Single-variant analyses were performed 
using a Firth bias-corrected likelihood-ratio test with EPACTS software. Haplotype 
analyses were based on chi-squared tests including haplotypes with a predicted 
probability of 0.75 or more using SPSS software version 20.0.
Risk scores for AMD-associated variants were calculated as a sum of the number of 
AMD risk-increasing alleles. Two risk scores were calculated: the first risk score included 
the 52 AMD-associated variants described in Fritsche et al,9 and the second risk score 
included the 19 variants located in or near complement genes of these 52. The variants 
included in the complement risk score were: rs10922109, rs570618, rs121913059, 
rs148553336, rs187328863, rs61818925, rs35292876, and rs191281603 from the 
CFH locus; rs10033900 and rs141853578 from the CFI locus; rs62358361 from the 
C9 locus; rs116503776, rs144629244, rs114254831, and rs181705462 from the 
C2/CFB/SKIV2L locus; rs11080055 from the TMEM97/VTN locus; and rs2230199, 
rs147859257, and rs12019136 from the C3 locus. The risk scores were included in 
linear models for ln(C3d/C3) that included age, BMI, triglycerides, and clinic site as 
covariates, and the effect of the risk score was estimated. The 1548 individuals from 
the discovery phase, genotyped with the HumanCoreExome array, were included 
in these analyses. Figures including graphs were generated using Graphpad Prism 
version 5.03 (GraphPad Software, La Jolla, CA).
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7.3 RESULTS
7.3.1 Characteristics of the Study Cohorts
We evaluated the association of genetic variants with systemic complement 
activation levels through a GWAS in a discovery cohort of 1548 individuals, followed 
by replication in an independent cohort of 697 individuals. For both cohorts, 
demographics and information about AMD disease status, BMI, triglycerides, and 
high-density lipoprotein cholesterol was collected (Table 1).
7.3.2 Genome-Wide Association Study Identifies 2 Independent 
Signals at the CFH/CFHR Locus to Be Associated with Systemic 
Complement Activation
We carried out a GWAS of normalized C3d/C3 levels as a measure of systemic 
complement activation. After quality control, a total of 1548 individuals and 9 972 920 
variants were included in the analysis. The study had more than 80% of power to 
detect common variants (minor allele frequency ≥5%), explaining ≥2.6% or more of 
variance in complement activation levels.
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levels through a GWAS in a discovery ohort of 1548 individuals, followed by replication 
in an independent cohort of 697 individuals. For both cohorts, demographics and 
information about AMD disease status, BMI, triglycerides, and high-density lipoprotein 
cholesterol was collected (Table 1). 
 
Table 1. Demographics and other characteristics of the discovery and replication 
cohorts 
 
Discovery cohort 
(n=1,548) 
Replication cohort 
(n=697) 
Complement activation ln(c3d/c3), mean 
(SD) 1.459 (0.407) 1.464 (0.398) 
Age, mean (SD) 73.2 (7.8) 73.3 (7.7) 
Female sex (%)  60 58.8 
AMD disease status, control (%) 53.7 37.4 
BMI (kg/m2), median (quartiles) 25 (23 – 28) 25 (23 – 28) 
Triglycerides (mmol/l), median (quartiles) 1.620 (1.170 - 2.220) 1.620 (1.165 - 2.210) 
HDL cholesterol (mmol/l), mean (SD) 1.489 (0.377) 1.478 (0.403) 
Clinic site-Radboud university medical 
center, % 53.5 63 
 
AMD= age-related macular degeneration; BMI=body mass index, HDL=high-density lipoprotein, 
SD=standard deviation. 
Higher complement activation levels were associated independently with older age, AMD 
disease status, lower BMI, and lower triglyceride levels as previously described.21, 33 
Differences also were observed between the sample collection clinics (Table S2, available at 
www.aaojournal.org). Therefore, these factors were included as covariates in all consecutive 
analyses. 
Table 1. Demographics and other characteristics of the discovery and replication cohorts
AMD = age-related macular degeneration; BMI = body mass index, HDL = high-density lipoprotein, 
SD = standard deviation.
Higher complement activation levels were associated independently with older age, AMD disease 
status, lower BMI, and lower triglyceride levels as previously described.21, 33 Differences also were 
observed between the sample collection clinics (Table S1). Therefore, these factors were included as 
covariates in all consecutive analyses.
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A total of 280 variants reached genome-wide significance (Manhattan plot, Figure 
1A; QQplot, Figure S1; λGC = 0.999). All variants, except for one, were located on 
chromosome 1 at the CFH/CFHR locus (chromosome 1, 196.643.724–197.061.086). 
The only variant outside of this locus was located on chromosome 6 near the 
PSORS1C1 gene, but could not be verified by Sanger sequencing. The SNP rs3753396 
(c.2016A→G, p.Gln672Gln) located in exon 14 of the complement factor H (CFH) gene 
showed the strongest association with complement activation levels (P = 1.09 × 10−15; 
β = 0.145; standard error [SE], 0.018; Table 2; locus zoom depicted in Figure 1B).
Conditional analysis on the lead SNP revealed a second independent signal with a P 
value close to genome-wide significance for which the strongest associated variant 
was rs6685931. This SNP was also located at the CFH/CFHR locus, specifically in 
intron 1 (c.59–4315T→C) of the complement factor H related 4 (CFHR4) gene (P = 
8.18 × 10−7; β = 0.068; SE, 0.014; Table 2; locus zoom depicted in Figure 1C).
Variants shown to be associated with complement activation fragments in previous 
studies were extracted from the GWAS results.17,18 The SNP rs800292 in CFH and 
the 2 SNPs in linkage disequilibrium rs4151667 in CFB and rs9332739 in C2 were 
associated nominally with systemic complement activation levels in the current study, 
showing the same direction of the effect. The SNP rs2230199 in C3 and the SNP 
rs10490924 in ARMS2 could not be replicated (Table S2).
7.3.3 Replication in an Independent Cohort Confirms the Effect 
of rs3753396 in CFH and rs6685931 in CFHR4 on Systemic 
Complement Activation
Replication analysis of rs3753396 in CFH and rs6685931 in CFHR4 in an independent 
cohort of 697 study participants confirmed both variants to be associated significantly 
with systemic complement activation levels (rs3753396: P = 1.39 × 10−6; β = 0.131; 
SE, 0.027; and rs6685931: P = 8.62 × 10−3; β = 0.038; SE, 0.014; Table 2). Subsequent 
meta-analysis showed associations for both rs3753396 (P = 3.66 × 10−21; β = 0.141; 
SE, 0.015) and rs6685931 (P = 6.32 × 10−8; β = 0.054; SE, 0.010), confirming that 2 
independent signals at the CFH/CFHR locus are associated with higher complement 
activation levels (Table 2). Sensitivity analyses adjusting for AMD disease status 
showed comparable results (Table S3), and neither an interaction between clinic site 
and the identified SNPs (Prs3753396 × clinic = 0.436; Prs6685931 × clinic = 0.676), 
nor an interaction between AMD status and the identified SNPs (Prs3753396 × AMD 
status = 0.557; Prs6685931 × AMD status = 0.658) was detected.
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Figure 1. Graphs showing that the genome-wide association study identified 2 independent signals at the 
CFH/CFHR locus associated with systemic complement activation levels. A, Manhattan plot illustrating 
the P values of each individual single nucleotide polymorphism (SNP) tested for association with systemic 
complement activation. The red horizontal line indicates the threshold considered for genome-wide 
significance (P = 5 × 10−8). B, Locus zoom plot showing a detailed view of the chromosome 1 signal. The 
lead SNP rs3753396 is located in the CFH gene. The SNPs are colored based on their linkage disequilibrium 
estimate (r2) to the lead SNP. C, Locus zoom plot showing a detailed view of the signal on chromosome 1 
(chr1) after conditioning the association analysis for rs3753396. Here, the lead SNP rs6685931 is located 
in the CFHR4 gene. The SNPs are colored based on their linkage disequilibrium estimate (r2) to the lead SNP.
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Next, mean complement activation levels in the genotype groups of rs373396 and 
rs6685931 were analyzed. For rs3753396 in CFH, the heterozygous AG genotype 
group showed higher complement activation levels compared with the reference AA 
genotype group (P = 6.23 × 10−18; β = 0.152; SE, 0.018), and for the homozygous GG 
group, these levels were even higher (P = 2.39 × 10−7; β = 0.267; SE, 0.052; Figure 2A). 
In the case of rs6685931 in CFHR4, a similar effect was observed: the heterozygous 
TC genotype group had higher complement activation levels than the reference TT 
genotype (P = 10−3; β = 0.063; SE, 0.019) and for the homozygous CC group, the levels 
were even higher (P = 3.62 × 10−7; β = 0.118; SE, 0.023; Figure 2B). Analysis of the 
cumulative effect of both SNPs showed that the main effect on systemic complement 
activation levels is driven by rs3753396 in CFH, and rs6685931 in CFHR4 introduces 
additional variation to the rs3753396 genotypes (Figure 2C).
7.3.4 A Model of Genetic and Nongenetic Variables Explains 
18.7% of the Variability in Complement Activation
General linear models were built to determine how much of the variation could be 
explained by factors found to be associated with systemic complement activation. 
A model including only non-genetic factors (age, AMD disease status, BMI, and 
triglycerides) explained 12.6% of the variability in systemic complement activation. 
With the addition of SNP rs3753396 to the model, 16.3% of the variability could 
be explained, and by including SNP rs6685931, a total of 17.3% was explained. We 
additionally incorporated SNPs associated with complement activation fragments 
in a previous study that replicated in our GWAS: rs800292 in CFH and rs9332739 in 
C2.18 Only rs9332739 remained associated independently with systemic complement 
activation levels, and the variance explained by the model rose to 18.7% (adjusted R2; 
Table 3).
7.3.5 Haplotypes across the CFH/CFHR Locus Show Stronger 
Effects on Systemic Complement Activation Levels Compared 
with Individual Variants
To assess whether more variants at the CFH/CFHR locus influence systemic 
complement activation and to determine the cumulative effect of several variants on 
the same haplotype, we evaluated the effect of distinct haplotypes across the CFH/
CFHR locus on systemic complement activation. Haplotypes previously described for 
AMD already included rs3753396, the lead variant associated in the GWAS,34 and 
were expanded by adding rs668593, the second independent signal. In total, 7 SNPs 
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Figure 2. Graphs showing systemic complement activation levels stratified by rs3753396 and rs6685931 
genotypes: rs6685931 introduced additional variation on the main effect of rs3753396. The y-axes 
represent the ln-transformed complement C3d/C3 ratio as a measure of systemic complement activation. 
Horizontal bars indicate the mean values for each genotype group. The complement-raising alleles for both 
single nucleotide polymorphisms are indicated in red. Association analyses included the 2245 individuals 
from the discovery and the replication cohorts. A, Distribution of complement activation levels for each 
genotype of rs3753396 in CFH. B, Distribution of complement activation levels for each genotype of 
rs6685931 in CFHR4. P values were calculated adjusting the model for rs3753396. C, Distribution of 
complement activation levels over the genotype combinations of rs3753396 in CFH and rs6685931 in 
CFHR4.
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across the CFH/CFHR locus yielded 9 different haplotypes with a predicted population 
frequency higher than 1% (Table 4; Table S4).
Haplotype association analyses with age-related macular degeneration were 
performed for the 1548 individuals in the discovery cohort. Haplotypes are coded 
as in Hageman et al.34 If 2 different subhaplotypes based on the extra allele in single 
nucleotide polymorphism rs6685931 were found, the Hageman haplotypes were 
recoded as 1 or 2. Alleles associated with higher complement levels are underlined. 
The reference haplotype was set to the most common haplotype not carrying any 
complement-raising allele for rs3753396 or rs6685931.
Association with systemic complement activation levels revealed haplotypes with 
stronger effects on complement activation compared with the single SNPs identified 
in the GWAS. Haplotypes H1–2, H3, and H6 were associated with higher systemic 
complement activation levels. Haplotype H3 carrying the complement-raising allele of 
rs3753396 (G) had a stronger effect on complement activation levels (P = 2.53 × 10−14; 
β = 0.183; SE, 0.024) compared with the complement-raising allele of rs3753396 in the 
single variant analysis (β = 0.141; SE, 0.015). Haplotypes H1–2 and H6 both carried the 
complement-raising allele for rs6685931 (C). Haplotype H6 showed a stronger effect 
on complement activation levels (P = 4.82 × 10−4; β = 0.144; SE, 0.041) compared with 
the single variant analysis for rs6685931 (β = 0.054; SE, 0.010; Table 4; Table S4).
Table 3. A model of genetic and non-genetic variables explains 18.7% of the variability in systemic 
complement activation
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A Model of Genetic and Nongenetic Variables Explains 18.7% of the Variability in 
Complement Activation 
General linear models were built to determine how much of the variation could be 
explained by factors found to be associated with systemic complement activation. A 
model including only non-genetic factors (age, AMD disease status, BMI, and 
triglycerides) explained 12.6% of the variability in systemic complement activation. With 
the addition of SNP rs3753396 to the model, 16.3% of the variability could be explained, 
and by including SNP rs6685931, a total of 17.3% was explained. We additionally 
incorporated SNPs associated with complement activation fragments in a previous study 
that replicated in our GWAS: rs800292 in CFH and rs9332739 in C2.18 Only rs9332739 
remained associated independently with systemic complement activation levels, and the 
variance explained by the model rose to 18.7% (adjusted R2; Table 6). 
Table 6. A model of genetic and non-genetic variables explains 18.7% of the variability 
in systemic complement activation 
 
 β SE (β) P-value 
CFH rs3753396                           AG 0.196 0.023 8.772x10
-17 
GG 0.330 0.066 6.461x10-7 
CFHR4 rs6685931                              TC 0.070 0.024 0.003 CC 0.125 0.033 1.620x10-4 
CFH rs800292                              GA -0.011 0.023 0.639 AA 0.027 0.046 0.555 
C2 rs9332739                              GC -0.185 0.034 4.674x10
-8 
CC 0.168 0.213 0.431 
Age (years) 0.004 0.001 0.005 
Disease status (AMD) 0.035 0.020 0.089 
BMI (kg/m2) -0.012 0.003 2x10-6 
Triglycerides (mmol/l) -0.131 0.011 1.177x10-33 
AMD = age-related macular degeneration; BMI = body mass index. 
R2 = 0.193 (adjusted R2 = 0.187). The model included the 1548 individuals from the discovery 
phase. 
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7.3.6 The Single Nucleotide Polymorphism rs6685931 in CFHR4 
and Haplotype H1–2 Confer a Risk for Age-Related Macular 
Degeneration
To identify genetic biomarkers that are relevant in the context of disease, we explored 
whether the SNPs and haplotypes associated with systemic complement activation 
levels also associate with AMD. The SNP rs3753396 in CFH was not associated with 
AMD (P = 0.76). In contrast, the complement-raising allele of rs6685931 in CFHR4 (C) 
was associated with an increased risk for AMD (P = 5.89 × 10−12; odds ratio = 1.631; 
95% confidence interval, 1.489–1.772; Table 5). These results are in concordance with 
the largest GWAS on AMD reported to date (rs3753396, P = 3 × 10−3; rs6685931, P = 
1.02 × 10−495; odds ratio >1).9
In agreement with the single variant analysis of CFH rs3753396, the haplotype H3 that 
gave the highest risk for higher systemic complement activation was not associated 
with AMD (P = 0.80). Haplotype H6 carries the CFHR4 rs6685931 complement-
raising allele (C), but did not reach significance in the association with AMD (P = 0.14); 
however, the frequency of H6 was relatively low (3%). Haplotype H1–2, the most 
Table 4. Association of haplotypes across the CFH/CFHR locus with systemic complement activation levels 
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Haplotypes across the CFH/CFHR Locus Show Stronger Effects on Systemic 
Complement Activation Levels Compared with Individual Variants 
To assess whether more variants at the CFH/CFHR locus influence systemic 
complement activation and to determine the cumulative effect of several variants on the 
same haplotype, we evaluated the effect of distinct haplotypes across the CFH/CFHR 
locus on systemic complement activation. Haplotypes previously described for AMD 
already included rs3753396, the lead variant associated in the GWAS,34 and were 
expanded by adding rs668593, the second independent signal. In total, 7 SNPs across 
the CFH/CFHR locus yielded 9 different haplotypes with a predicted population 
frequency higher than 1% (Table 7; Table S8, available at www.aaojournal.org). 
Table 7. Association of haplotypes across the CFH/CFHR locus with systemic 
complement activation level   
Haplotype 
CFH rs3753396 and CFHR4 
rs6685931 Alleles  
 
Haplotype  
Frequency β 
Standard 
Error (β) P value 
H2 A-T 0.18 Reference Reference Reference 
H1-2 A-C 0.36 0.062 0.019 1.148x10-3 
H3 G-T 0.14 0.183 0.024 2.531x10-14 
H4 A-T 0.10 0.013 0.026 0.607 
H5 A-T 0.04 -0.058 0.038 0.128 
H1-1 A-T 0.03 -0.053 0.043 0.218 
H6 A-C 0.03 0.144 0.041 4.823x10-4 
H7 A-C 0.03 0.060 0.046 0.192 
H8 A-T 0.03 -0.007 0.048 0.890 
 
Haplotype association analyses with age-related macular degeneration were performed for the 
1548 individuals in the discovery cohort. Haplotypes are coded as in Hageman et al.34 If 2 
different subhaplotypes based on the extra allele in single nucleotide polymorphism rs6685931 
were found, the Hageman haplotypes were recoded as 1 or 2. Alleles associated with higher 
complement levels are underlined. The reference haplotype was set to the most common 
haplotype not carrying any complement-raising allele for rs3753396 or rs6685931. 
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common haplotype carrying the CFHR4 rs6685931 complement-raising allele (C), 
showed a strong risk-conferring association with AMD (P = 1.38 × 10−12; odds ratio = 
1.318; 95% confidence interval, 1.223–1.420; Table 5; Figure 3).
Finally, we determined whether other AMD-associated variants are associated with 
systemic complement activation levels. For this purpose, we extracted the 52 AMD-
associated variants reported in the largest AMD study performed so far from the 
GWAS on complement activation levels.9 However, no variants outside of the CFH/
CFHR locus were found to be associated with systemic complement activation levels 
at the genome-wide significance level, or at a significance level of P < 0.05/52 = 0.001 
(Table S5). Interestingly, a risk score based on the 52 AMD risk-conferring alleles was 
associated with higher levels of complement activation (P = 0.043; β = 0.004; SE(β) = 
0.002). A similar risk score including only the variants located in or near complement 
genes was associated more strongly with higher levels of complement activation (P 
= 0.022; β = 0.009; SE(β) = 0.004). This complement risk score included 3 nominally 
associated variants: 2 common variants located in the CFH and the C2/CFB/SKIV2L 
loci—rs10922109 and rs116503776, respectively—and a rare variant located in the 
CFI gene, rs141853578 or p.Gly119Arg. However, the effects of these genetic risk 
scores are smaller compared with the single variant effects in the model for systemic 
complement activation described in Table 3.
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Table 5. Association of complement-raising SNPs and haplotypes with AMD: SNP rs6685931 and haplotype 
H1-2 confer a risk for AMD
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Table 9. Associati n of complement-raising SNPs and haplotypes with AMD: SNP 
rs6685931 and haplotype H1-2 confer a risk for AMD  
 Odds Ratio Confidence Interval P value SNP rs3753396 1.031 0.839 - 1.223 0.756 
SNP rs6685931 1.631 1.489 - 1.772 5.889x10-12 
Haplotype H3 1.015 0.911 - 1.130 0.795 
Haplotype H6                                 0.828 0.637 - 1.075 0.135 
Haplotype H1-2 1.318 1.223 - 1.420 1.382x10-12 
SNP = single nucleotide polymorphism. 
Single variant and haplotype association analyses with age-related macular degeneration were 
performed for the 1548 individuals from the discovery cohort. Haplotype analyses were based on 
chi-squared tests that compared the frequency of the analyzed haplotypes in patients versus 
controls. 
 
In agreement with the single variant analysis of CFH rs3753396, the haplotype H3 that 
gave the highest risk for higher systemic complement activation was not associated with 
AMD (P = 0.80). Haplotype H6 carries the CFHR4 rs6685931 complement-raising allele 
(C), but did not reach significance in the association with AMD (P = 0.14); however, the 
frequency of H6 was relatively low (3%). Haplotype H1–2, the most common haplotype 
carrying the CFHR4 rs6685931 complement-raising allele (C), showed a strong risk-
conferring association with AMD (P = 1.38 × 10−12; odds ratio = 1.318; 95% confidence 
interval, 1.223–1.420; Table 9; Fig 4). 
Figure 3. Graph showing complement activation levels stratified by common haplotypes across the CFH/
CFHR locus. The AMD risk haplotype H1–2 shows high complement activation levels, and the non–AMD-
associated H3–1 haplotype shows the highest. Horizontal bars indicate the mean values for each haplotype 
carrier group. Haplotype carriers included in the graph had a posterior probability higher than 0.75. The 
haplotype group colors indicate the association with AMD: orange, protective; blue, risk conferring; grey, 
not associated. Association analyses were carried out for the 1548 patients genotyped with exome array.
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7.4 DISCUSSION
We conducted a GWAS on systemic complement activation levels, evaluating for an 
unbiased approach the genetic risk factors involved in the activation of this essential 
component of the immune system. We identified and replicated 2 common variants, 
rs3753396 and rs6685931, that lead to higher systemic complement activation levels 
independently of age, sex, AMD disease status, triglycerides, and BMI. These 2 variants 
were included in a model for systemic complement activation, which explained 18.7% 
of its variability.
The SNP rs3753396 (c.2016A→G, p.Gln672Gln) is a coding, synonymous variant 
located in exon 14 of the CFH gene, and therefore this variant, or the linked causal 
variant(s), may regulate complement activation levels through FH. Factor H is a key 
negative regulator of the AP and the amplification loop of the complement cascade, 
which is expressed constitutively in the liver and locally by other cell types, such as 
retinal pigment epithelial and endothelial cells.35, 36, 37 Evidence to support the theory that 
rs3753396 exerts an effect on complement activation through FH comes from genetic 
studies on other diseases. The SNP rs3753396 has been reported to be associated 
with atypical hemolytic uremic syndrome, known to be caused by mutations in CFH.38, 
39 Moreover, reduced susceptibility to meningococcal disease also has been associated 
with rs3753396. Meningococcal disease is caused by Neisseria meningitides, which 
binds FH to avoid complement-mediated killing.40 The SNP rs3753396 is in linkage 
disequilibrium with rs1065489, also located in CFH (c.2808G→T, p.Glu936Asp), 
which was proposed to be the causal variant for meningococcal disease based on in 
silico pathogenicity predictions.41
The SNP rs6685931 (c.59–4315T→C) is located in intron 1 of the CFHR4 gene. Factor 
H related 4 (FHR-4) is a glycoprotein that, in contrast to the attenuating effects of FH, 
seems to promote complement activation. It binds the complement fluid-phase C3b 
and forms an additional AP C3 convertase (FHR4-C3bBb), which is less susceptible to 
FH-mediated decay.42 However, because rs6685931 is in high linkage disequilibrium 
(r2 > 0.8) with several variants located in the CFH gene, either FH or FHR-4 could be 
responsible for the effects observed on complement activation.
We analyzed the association of genetic variants with systemic complement activation 
levels in a hypothesis-free manner. The results indicate that with our study design, the 
genetic variants with the largest effect on complement activation levels are rs3753396 
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and rs668593, located at the CFH/CFHR locus. Moreover, other previously associated 
variants in CFH and C2/CFB could be replicated.18 Haplotype analysis at the CFH/CFHR 
locus revealed 2 haplotypes with stronger effects on complement activation levels 
compared with the individual SNPs. These findings suggest that additional variants 
at the CFH/CFHR locus play a role in the activation of the complement system. Indeed, 
several rare coding variants in the CFH gene have been shown to lead to increased 
complement activity.10 Genetic variants in other genes that influence systemic 
complement activation levels may be uncovered with larger sample sizes that would 
allow for the detection of rarer variants and smaller effects. A compelling rare variant 
candidate that may merit further investigation is CFI rs141853578 (p.Gly119Arg), 
which was found to be nominally significant in our study. This variant has been 
associated previously with lower factor I levels in plasma and a lower ability to degrade 
C3d on the cell surface and C3b in the fluid phase.43
In this study, AMD was associated with systemic complement activation, which is in 
agreement with previous reports.15,16,17,18,20 In our analysis, rs6685931 in CFHR4 was 
associated with both systemic complement activation and AMD. Haplotype analyses 
were in line with these results; we observed that the complement-raising allele of SNP 
rs6685931 (C) was located mainly on the H1–2 haplotype, which associated with a 
higher risk for AMD development. Thus, this SNP and its linked haplotype could serve 
as a robust biomarker for complement activation in the context of AMD and could be 
used to identify AMD patients who would benefit most from complement-inhibiting 
therapies.
We noted that the rare haplotype H6 (with a frequency of 3%), also containing 
rs6685931, had a larger effect on complement activation levels compared with the 
single variant rs6685931. However, haplotype H6 was not associated significantly 
with AMD, probably because of statistical power limitations. Studies with larger 
cohort sizes may clarify the role of the H6 haplotype in AMD and may identify other 
rare haplotypes that associate with AMD and have larger effects on complement 
activation levels.
Strikingly, the genetic variant that was associated most strongly with systemic 
complement activation, rs3753396 in CFH, and its main haplotype (H3) did not 
associate with AMD. However, the SNP rs3753396 and haplotype H3 have been 
described to confer risk for atypical hemolytic uremic syndrome development. Atypical 
hemolytic uremic syndrome is a complement system-related disease that leads to 
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systemic thrombotic microangiopathy and renal endothelial injury.39,44 This finding 
suggests that the effect of the haplotypes may be different systemically compared 
with the AMD disease site, possibly through a tissue-specific effect of the genetic 
variants. Consequently, systemic complement activation may not always reflect 
complement activation in the disease tissue, and therefore, it may not be the most 
appropriate measure for AMD studies. Genetic biomarkers such as SNP rs6685931 
and haplotype H1–2 are robust markers that, together with the C3d-to-C3 ratio, 
could serve as biomarkers for complement activity studies in AMD. This is supported 
by a recent study demonstrating that complement activation levels in aqueous humor 
are higher than in plasma samples of AMD patients.45 As a consequence, the effect 
of rs6685931 and H1–2 on local complement activation may be even larger than the 
effect seen on systemic levels.
Our results also could further the understanding of other complement-related 
diseases, as well as be used in the context of personalized medicine involving FH 
supplementation therapy and other complement-targeting therapies.46,47,48 Besides 
N. meningitidis, a number of bacteria, fungi, parasites, and viruses bind FH to avoid 
elimination by the alternative pathway of the complement system.49 Also, some 
cancer cells express FH to avoid being targeted by the immune system.50,51,52 Other 
FH-related diseases for which our results may be of interest include hemolytic uremic 
syndrome, atypical hemolytic uremic syndrome, encephalomyelitis, atherosclerosis, 
insulin resistance, immunoglobulin A nephropathy, Alzheimer’s disease, cisplatin 
nephropathy, as well as severe dengue, for which variants in the CFH gene have been 
shown to be protective.53
In conclusion, we identified 2 common variants located at the CFH/CFHR locus, 
rs3753396 and rs668593, which strongly influence systemic complement activation 
levels. Moreover, our haplotype studies suggest that other genetic variants in the 
CFH/CFHR locus influence systemic complement activation. Genetic and nongenetic 
factors identified in this and other studies explain up to 18.7% of the variability in 
systemic complement activation levels. The common variant rs6685931 in CFHR4, 
and its associated haplotype H1–2, could be used, together with other environmental 
factors as well as rare genetic variants, to select AMD patients who would benefit 
from complement-inhibiting therapies.
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Supplementary data 
 
 
Figure S2. Q-Q plot of the GWAS on systemic complement activation levels 
Shown as black dots are the observed P-values (–log10(P)). Lack of population stratification was confirmed by 
a genomic inflation factor (λ) for the trend of 0.999. 
 
Table S2. General linear model for systemic complement activation levels including environmental 
factors 
  β SE (β) P-value R2 
Age (years) 0.003 0.001 0.002 0.010 
Sex (female) -0.025 0.018 0.155 0 
Disease status (AMD) 0.074 0.017 6.700x10-5 0.013 
BMI (kg/m2) -0.012 0.002 8.635x10-8 0.034 
Triglycerides (mmol/l) -0.130 0.010 5.723x10-39 0.101 
HDL cholesterol (mmol/l) 0.015 0.026 0.545 0.024 
Clinic (University Hospital of Cologne) -0.064 0.016 6.800x10-5 0.005 
 
BMI=Body mass index, HDL=High-density lipoprotein, SE=standard error.  
R2=0.141 (adjusted R2=0.138). 
  
Table S1. General linear model for systemic complement activation levels including environmental factors
Figure S1. Q-Q plot of the GWAS on systemic complement activation levels. Shown as black dots are the 
observed P-values (–log10(P)). Lack of population stratification was confirmed by a genomic inflation 
factor (λ) for the trend of 0.999.
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Table S5. Association of the 52 AMD variants with systemic complement activation levels
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Table 10. Association of the 52 AMD variants with systemic complement activation levels 
 
Variant* 
AMD risk-
increasing 
allele  
Locus name AF† β† SE (β) † P-value† P-value†‡ 
rs10922109 C CFH 0.629 0.089 0.013 5.389x10-11 1.406x10-9 
rs570618 T CFH 0.421 -0.002 0.013 0.876 0.629 
rs121913059§ T CFH - - - - - 
rs148553336 T CFH 0.995 -0.128 0.097 0.186 0.219 
rs187328863 T CFH 0.042 0.028 0.036 0.445 0.668 
rs61818925 G CFH(CFHR3/CFHR1) 0.637 0.015 0.015 0.306 0.187 
rs35292876 T CFH 0.016 0.031 0.052 0.550 0.648 
rs191281603 G CFH 0.01 0.041 0.088 0.639 0.578 
rs11884770 C COL4A3 0.738 -0.022 0.015 0.146 0.176 
rs62247658 C ADAMTS9-AS2 0.417 0.007 0.013 0.616 0.475 
rs140647181 C COL8A1 0.018 -0.092 0.057 0.109 0.106 
rs55975637 A COL8A1 0.129 -0.015 0.020 0.473 0.427 
rs10033900 T CFI 0.495 0.004 0.014 0.762 0.664 
rs141853578 T CFI 0.003 0.292 0.133 0.028 0.042 
rs62358361 T C9 0.014 0.025 0.057 0.668 0.742 
rs114092250 G PRLR/SPEF2 0.975 -0.046 0.045 0.300 0.297 
rs116503776 G C2/CFB/SKIV2L 0.872 0.059 0.020 0.003 0.005 
rs144629244 A C2/CFB/SKIV2L 0.010 0.067 0.065 0.300 0.360 
rs114254831 G C2/CFB/SKIV2L 0.242 -0.01 0.015 0.508 0.426 
rs181705462 T C2/CFB/SKIV2L 0.008 -0.008 0.075 0.921 0.877 
rs943080 T VEGFA 0.510 -0.026 0.013 0.056 0.075 
rs1142 T KMT2E/SRPK2 0.371 0.002 0.014 0.883 0.948 
rs7803454 T PILRB/PILRA 0.184 -0.01 0.017 0.574 0.484 
rs79037040 T TNFRSF10A 0.518 0.011 0.013 0.411 0.338 
rs10781182 T MIR6130/RORB 0.301 -0.008 0.015 0.594 0.701 
rs71507014 G TRPM3 0.421 -0.005 0.014 0.732 0.724 
rs1626340 G TGFBR1 0.793 -0.009 0.017 0.598 0.468 
rs2740488 A ABCA1 0.740 -0.009 0.015 0.555 0.403 
rs12357257 A ARHGAP21 0.238 -0.001 0.016 0.927 0.915 
rs3750846 C ARMS2/HTRA1 0.297 0.01 0.014 0.468 0.866 
rs3138141 A RDH5/CD63 0.210 0.046 0.021 0.030 0.045 
rs61941274 A ACAD10 0.013 0.003 0.072 0.971 0.980 
rs9564692 C B3GALTL 0.727 -0.008 0.015 0.618 0.506 
rs61985136 T RAD51B 0.619 0.007 0.014 0.620 0.541 
rs2842339 G RAD51B 0.095 0 0.023 0.994 0.975 
rs2043085 T LIPC 0.616 0.029 0.014 0.036 0.039 
rs2070895 G LIPC 0.800 -0.03 0.017 0.071 0.062 
rs5817082 C CETP 0.745 0.017 0.016 0.284 0.402 
rs17231506 T CETP 0.326 -0.001 0.014 0.924 0.723 
312 
 
rs72802342 C CTRB2/CTRB1 0.929 0.003 0.028 0.914 0.932 
rs11080055 C TMEM97/VTN 0.503 0.015 0.013 0.246 0.206 
rs6565597 T NPLOC4/TSPAN10 0.391 0.003 0.015 0.824 0.862 
rs2230199 G C3 0.224 -0.034 0.017 0.044 0.060 
rs147859257 G C3 0.006 0.098 0.089 0.270 0.385 
rs12019136 G C3(NRTN/FUT6) 0.958 -0.012 0.035 0.740 0.689 
rs67538026 C CNN2 0.556 0.001 0.015 0.960 0.900 
rs429358 T APOE 0.883 0.022 0.021 0.311 0.294 
rs73036519 G APOE(EXOC3L2/MARK4) 0.697 0.012 0.015 0.453 0.477 
rs142450006 TTTTC MMP9 0.858 0.009 0.020 0.667 0.705 
rs201459901 T C20orf85 0.948 -0.024 0.030 0.425 0.444 
rs5754227 T SYN3/TIMP3 0.871 -0.003 0.020 0.895 0.796 
rs8135665 T SLC16A8 0.210 0.003 0.016 0.853 0.973 
 
AF= Allele frequency, SE= Standard error. 
*Location of the SNP as in Fritsche et al., 2016, †Refers to the AMD risk-increasing allele, ‡Analysis adjusted 
for AMD disease status, §Variant not found in the study cohort.  
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GENERAL DISCUSSION
The overarching aim of this thesis was to better understand the molecular drivers of 
age-related macular degeneration (AMD). In this final chapter the obtained results are 
discussed in a broader perspective, considering the current state of the AMD research 
field.
AMD is a multifactorial disease for which the pathogenesis is not yet fully understood. 
Outside influences like diet, smoking, physical fitness and sun exposure interact 
with a person’s genetic blueprint and the combination of these factors establishes 
a certain predisposition to develop AMD in a person’s lifetime. Multiple biological 
pathways and physiological networks have been associated with the disease, such 
as the complement system, lipoprotein homeostasis, extracellular matrix biology, 
angiogenesis and altered redox states 1. Because of strong genetic and physiological 
evidence, the complement system has been the focus of intense investigation and has 
also been a target for potential novel therapies for AMD in the last several years. 
8.1 WHY INVESTIGATE FACTORS INVOLVED IN COMPLEMENT 
ACTIVATION?
Since the discovery of higher complement activation levels in patients with AMD 
compared to controls 2-5 we have focused our attention on understanding which 
factors influence complement activation in the context of AMD.
Besides generating novel scientific insights into how complement activation is 
regulated, in recent years, these research questions became increasingly relevant 
because of their translational implications. Several clinical trials using complement 
inhibitors in AMD have been initiated to investigate their potential in slowing 
down disease progression (Table 1).  Unfortunately, these inhibitors were largely 
unsuccessful in phase II and/or III trials. 
In part, the disappointing outcomes of most of these trials may be explained by the 
fact that complement activation levels can vary considerably among individuals. In line 
with this observation, initially we hypothesized that patients who have higher levels 
of complement activation may benefit more than others from therapies targeting an 
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over-active complement system. In order to identify the most suitable patients for 
complement-inhibiting therapies, we would first need to gain a better understanding 
in the factors that influence complement activation. 
The complement activation cascade is triggered through classical, mannose-binding 
lectin or alternative pathways, which were described in the introduction of this thesis. 
Importantly, the amplitude of the response, in part, is influenced by genetic and 
non-genetic factors, although the exact nature of these influencing factors were not 
known, nor was it clear how these factors interacted. We followed several strategies 
to uncover which genetic factors are central to complement regulation, which are 
covered in section 8.2, while some of the non-genetic factors, like interactions with 
lipids/lipoproteins are discussed in section 8.5.
Table 1. Clinical trials for complement system modulators in AMD.
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have been initiated to investigate their potential in slowing down disease progression 
(Table 1).  Unfortunately, these inhibitors were largely unsuccessful in phase II and/or III 
trials.  
 
Table 1. Clinical trials for complement system modulators in AMD. 
Drug Target Status 
Eculizumab, Complement component 5 
Phase II has been completed and it did not decrease the 
growth rate of GA significantly 6 
Lampalizumab Complement factor D 
Two phase III clinical trials. One did not meet its primary 
endpoint of reducing mean change in GA lesion area 7 
while the results from the other have not been shared yet. 
Avacincaptad 
pegol 
Complement 
component 5 Phase II/III clinical trial has started. 
Tesidolumab, 
LFG316 
Complement 
component 5 
Phase II clinical trial completed but the results have not 
been published yet. 
CLG561 Properdin Phase II clinical trial has started 
POT4 Complement component 3 Phase II/III terminated by management NCT01603043 
APL2 Complement component 3 Phase II clinical trial has started 
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8.2 WHICH GENETIC FACTORS INFLUENCE COMPLEMENT 
ACTIVATION? 
Before we started our studies, there was evidence that at least parts of the 
complement system are under genetic control. Bayesian variance components models 
had previously shown that serum levels of certain complement components like C3 
and C4 have 40-45% heritability 8,9. Therefore, we hypothesized that complement 
activation levels might also be genetically driven. To uncover the genetic variants 
that influence complement activation we undertook several approaches. In Chapter 
4 a targeted approach was used to investigate the effect of AMD-associated SNPs on 
complement activation. 
The selected SNPs for this study came from GWAS studies that had identified 
several complement-related variants to be associated with AMD 10. To test whether 
these SNPs would also explain the observed elevation in complement activation in 
patients we performed univariate and multivariate association analyses. Significant 
associations with complement activation were found for three SNPs in the CFH gene 
(rs1410996, rs800292 and rs12144939), one SNP in CFB (rs4151667) and two SNPs 
in the C3 gene (rs6795735 and rs2230199). All SNPs in the CFH and CFB genes showed 
lower complement activation levels compared to the reference alleles, while the SNPs 
in C3 were associated with higher values. Including the SNPs in a model together with 
age, smoking status, gender and disease status explained only about 6.7% of the total 
variability in complement activation (Chapter 4).
Several other studies have also evaluated the effect of genetic variation on complement 
activity; however, all these studies were restricted to a limited number of SNPs. 3,4  In 
chapter 5 we identified a novel complotype, which is in essence a combination of minor 
functional genetic variants that can accumulate to large effects because they are all 
part of the same cascade. The complotype we reported was associated with both AMD 
and systemic complement activation. Both this complotype and other previously 
described complotypes were composed of three SNPs. 11 This is very little considering 
the large number of SNPs in complement genes that have been found to be associated 
with AMD. In an ideal situation, all of them would be tested in one model, however this 
is impractical, because of the enormous amount of possible genotype combinations 
that would require very large patients datasets that are not currently available. The 
notion of using a complotype has a number of other limitations. A major shortcoming 
of this targeted approach is that it does not take into account all the other variants 
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that might occur in the genome that could exert some influence on the overall activity 
of the complement cascade. A secondary concern is that genetic functional variants in 
the complement system can either increase or decrease complement activation and 
unexpected interactions between these variations are not accounted for. 
To tackle this issue, in Chapter 7 we performed the first GWAS in an effort to identify in 
an unbiased manner the genetic loci that determine systemic complement activation 
levels. This approach revealed two independent signals that were significant at a 
genome-wide threshold level (P <1×10−8). Both signals were situated in the CFH-
CFHR gene cluster on chromosome 1. Including the top SNPs (rs3753396 in CFH and 
rs6685931 in CFHR4) from these loci in a model together with age, AMD disease 
status, body mass index, triglycerides and the previously identified SNPs, explained 
18.7% of variability in complement activation, which is a considerable percentage for 
any biological trait. 
This model may be even further improved if other complement influencing factors 
are identified and included, such as oxidative stress levels as we discussed in Chapter 
2. Also, reducing variability itself within the actual measurement of complement 
activation would improve the accuracy of the model. At this time, the model is based 
on measurements taken from patients and controls at one time point and does not 
take into account variation through the day nor any clinical or subclinical signs of 
infection.  In part, these issues can be resolved by using multiple complement activation 
measurements for each subject over an extended period of time and also enrolling 
fasting patients could potentially reduce some of the variability. An important next 
step is to validate this model in other cohorts that have the same variables available so 
that it can be determined how reproducible these observations are and to what extent 
they can be used in clinical practice. 
8.3 IS AMD DRIVEN BY LOCAL OR SYSTEMIC COMPLEMENT 
ACTIVATION?
Systemic complement activation is associated with AMD, but it might not be the main 
driver of the disease. It is not clear yet whether AMD is a local disease manifestation 
of a systemic phenomenon or the result of locally produced factors within the aging 
macula. A recent study highlighted that, in contrast to monogenic eye disorders where 
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the genes are often uniquely expressed in the retina, the genes involved in AMD are 
mostly ubiquitously expressed throughout the body. 12 Also, the genetic loci identified 
in AMD are shared between several other complex diseases such as cardiovascular, 
autoimmune and neurological disorders among others 13, indicating that the genetic 
risk for AMD is not limited to an eye phenotype. 
In contrast to this, there is evidence to suggest that risk factors associated to the 
disease are more pronounced in the eye itself compared to the systemic circulation. 
One example comes from a recent study that revealed significantly increased levels 
of complement activation products in aqueous humor of neovascular AMD patients 
compared to controls 14 whereas in plasma measurements these differences were 
far less obvious. Additionally, upregulation of complement pathway genes have been 
observed in transcriptome profiles of AMD retinal tissue versus control, demonstrating 
active local transcription, rather than systemic influx. 15  Also, Bruch’s membrane/
choriocapillary extracts from advanced AMD eyes were found to have elevated 
CFB, C3, C3a, and CFD levels compared to tissue from eyes lacking macular drusen. 
16 Furthermore,  reductions in MCP/CD46, a cofactor for CFI-mediated cleavage of 
C3b and C4b, were observed in early AMD and GA donor eyes, preceding atrophy 
and correlating with disease severity 17,18. Finally, only certain systemic complement 
proteins are able to diffuse from the choriocapillaris through the BrM into the eye. 19 
Considering all of this information, future research should be focused more on local 
precipitating events in the eye that lead to the development of AMD.
8.4  WHY IS THE TOP SNP IN THE COMPLEMENT GWAS NOT 
ASSOCIATED WITH AMD?
The apparent paradox between systemic complement activation and local disease is 
also illustrated by the outcomes of our GWAS. The main SNP identified in the GWAS 
we performed and described in Chapter 7, rs3753396 located in CFH, is associated 
with the highest levels of systemic complement activation, yet has no association with 
AMD. 
The CFH gene is 22 exons long and it encodes complement factor H (FH), one of the 
major inhibitors of the complement system. This gene has two alternative transcripts: 
one encodes a full-length FH which is translated from all 22 exons, and the second 
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encodes a shorter isoform called FHL-1, which stops after splicing of an alternative 
10th exon 20. The top SNP from the GWAS presented in Chapter 7 (rs3753396) was 
located in the fourteenth exon of CFH, making it solely part of the full-length FH. It is 
an adenine to a guanine change at cDNA position 2016 (c.2016A>G), which at protein 
level leads to a synonymous amino acid substitution at position 672 (p.Gln672=). 
This position is located in the 11th complement control protein (CCP) module, which 
together with the neighboring modules forms a compact arrangement, consistent with 
a hinge-like structure 21. However, being a synonymous change makes it very difficult 
to explain how it affects complement activation levels. One possibility is that it is a 
proxy for a different variant that actually does alter protein expression or function and 
thus influences complement activation. 
A possible explanation for  the lack of association with AMD,  may come from the fact 
that that full-length FH does not pass the blood-eye barrier, but only the truncated 
form (FHL-1) does. 19 Thus any SNP located exclusively in the full-length part of the 
protein, like rs3753396, would not influence local complement activation in the eye. 
Moreover, the variant located in CFHR4 that is associated both with complement 
activation and with AMD is interesting for follow-up studies, since the role of FHR4 
in AMD has not yet been investigated in great detail. It would be interesting to test 
how the FHR protein family in general and FHR4 in particular is linked to AMD in the 
context of what we already know of the involvement of complement components in 
the disease. 
8.5 WHAT ARE THE INTERACTIONS OF COMPLEMENT WITH OTHER 
PATHWAYS?
Interestingly, we reported a number of non-genetic associations with complement 
activation such as age, AMD disease status, body mass index, triglyceride levels and 
high density lipoprotein cholesterol (HDL-C) (Chapter 6). Of particular interest is 
the observation that complement activation is related to factors that are modifiable 
in nature, in relationship with diet and exercise. Even though genetic markers are 
robust and have the benefit of not being dynamic, having more knowledge about 
how complement interacts with other biological systems such as the lipoprotein 
metabolism may open up avenues that in the future could lead to novel treatments 
that are complementary to the ones being developed now.
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Besides its well known role in innate immunity, there is convincing evidence that 
complement is involved in metabolic events and pathologies. 22 Diseases like metabolic 
syndrome (MetS) and diabetes as well as cardiovascular dysfunction have been 
linked to complement components, such as C3 and C4. 23,24 These two complement 
components have been strongly linked to BMI and fat distribution, in particular 
through the actions of a direct degradation product of C3, C3-des-Arg, also known 
as acylation stimulating protein (ACP), which coordinates energy supply and fat 
storage. 25 In Chapter 6 we also show significant correlations between complement 
activation and HDL-C, apolipoprotein A1 (ApoA1) and triglycerides. Another link 
between complement and the lipid metabolism comes from the fact that adipocytes 
can synthesize alternative pathway components (C3, factor B, and factor D) and after 
activation, these cells can trigger the cleavage of C3 into C3b and C3a.22,26 
Multiple types of lipoprotein classes have been linked functionally and/or structurally 
to the complement system. The largest and least dense particles are chylomicrons 
(CMs). The major cargo of CMs are triglycerides, but they are also known to carry 
transthyretin, which has been shown to stimulate complement C3 (C3) and ACP/ 
C3desArg synthesis in a dose-dependent manner. 27 At the other end of the density 
spectrum in the lipid metabolism, HDL-C is connected with the complement system in 
multiple ways. Firstly, apolipoprotein components of HDL-C can regulate complement 
activity. ApoA1 and ApoA2, the two main components of HDL-C, were shown to 
inhibit complement-mediated lysis. 28 Another component of HDL-C that inhibits 
complement-mediated lysis is ApoJ, also known as clusterin. 29 Finally, ApoE can also 
be present on HDL and it influences complement activation by binding to FH, one of 
main complement regulators. 30
In addition to this, proteomic studies have shown that HDL-C carries multiple 
complement proteins such as C3, complement factor C4B, Factor B, complement C5 
and to a lesser extent complement C1 subcomponents and complement C2 31. Why 
lipoproteins carry complement components is not yet understood. Another proteomic 
study in a different lipoprotein subclass, Lipoprotein(a) (Lp(a)), also reported detection 
with high confidence of C3 and C4A 32. Furthermore, specific complement components 
or regulators are reported to be carried by specific subsets of HDL-C. One study 
observed that all of the FHR1 in plasma is located in one lipoprotein fraction 33. This 
lipoprotein fraction was identified to be a small subfraction of HDL-C (about 2% of 
APOA1 containing HDL-C) 33,34. Later, also dimerized forms of FHR4 35 and FHR5 36 
were found to be associated with triglyceride-rich lipoproteins. 
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From studies done in other diseases, it is apparent that the complement protein 
content of the HDL-C particle is not static, but dynamic. For example, in coronary 
artery disease (CAD), complement complements C3 and C4 were elevated in the 
HDL-C from patients compared to controls, while clusterin was reduced 37. Under 
the influence of statins and niacin, the composition of HDL-C could be remodeled to 
resemble HDL-C normally found in healthy individuals 38. Also, in rheumatoid arthritis, 
changes in the complement composition of HDL-C were reported (factor B, C3 and C9 
were increased) 39. 
The precise function of the presence of complement components and regulators in the 
lipoprotein fractions is not yet fully understood, however it does reveal an intimate link 
between the two systems. For AMD the relevance of these findings is strengthened by 
the fact that drusen from eyes of AMD patients have a composition of >40% lipids, the 
rest being an array of complement components, TIMP3, vitronectin, β-amyloid, and 
apolipoproteins (E, B, A1, C-I, and C-II), plus zinc and iron ions. 40-42
Taken together, these studies suggest that circulating lipoprotein levels and their 
composition and biological activity might be important in the pathogenesis of AMD.
Another pathway that has been associated with AMD and which interacts with the 
complement system is that of oxidative stress. Increased oxidative stress is thought 
to be one of the key factors in the occurrence of AMD. The high metabolic activity 
and high PUFA content in the membranes of photoreceptors primes the macula 
to high oxidative stress. 43 Malondialdehyde (MDA) is one of the reactive carbonyl 
compounds originating from PUFA oxidation, and its presence is often used to 
measure lipid peroxidation levels in blood or serum samples. 44-46 In Chapter 2 we 
have seen that increased systemic levels of MDA have been consistently observed in 
both wet and dry AMD. MDA is a highly reactive molecule that forms covalent bonds 
with endogenous proteins. These MDA modifications can be recognized by factors 
of the immune system, thus triggering a proinflammatory response by increasing 
the expression of the inflammation factor interleukin (IL)-8. 47 FH can neutralize 
the proinflammatory response generated by MDA. Interestingly in this context, the 
Y402H FH polymorphism, which is associated with increased risk for AMD, leads to 
reduced binding to MDA, thus potentially contributing to a chronic proinflammatory 
response.48
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8.6 WHAT DO THESE FINDINGS MEAN FOR THE PREDICTION AND 
TREATMENT OF AMD?
We are entering an exciting era of personalized medicine, where rapid technological 
advancements in all –omics fields will transform patient care. Currently vision loss in 
AMD is largely irreversible. The only available treatment for the wet form of AMD, 
which represents only a minority of AMD cases, is the intraocular injection of inhibitors 
of vascular endothelial growth factor (VEGF). 49 For the majority of AMD patients that 
suffer from early or intermediate AMD or geographic atrophy, currently, no treatment 
is yet available. As has been discussed in paragraph 8.1, all phase II and/or III clinical 
trials investigating complement inhibitors have failed in their effectiveness. 
The results obtained in Chapters 4 and 7 could help in the stratification of patient 
subgroups by facilitating the identification of individuals that are genetically primed 
towards higher complement activation levels. Such stratification has the potential of 
identifying patients in which complement-inhibition therapy could work. However, 
there are also other potential reasons why the trials have been unsuccessful to date. 
A major contributing factor may be that treatment was administrated rather late in 
the overall development of AMD. Patients with end-stage geographic atrophy were 
selected and monitored for disease progression, i.e. enlarging of the atrophic area. 
This means that potentially irreversible damage has already occurred, and inhibiting 
the complement at this stage would have little to no effect. Complement activation, 
in the context of a full immunological response, is an early responder. Its activation 
and degradation products play a role in attracting immune cells which, from that point 
onwards, begin to take over and coordinate the immunological response in either 
an M1 (pro inflammatory) or M2 (anti-inflammatory) manner. 50 Thus, after years of 
slowly progressing from early to intermediate stages, it may well be that the actual 
contribution and role of the complement system is rather different in end stages. 
If this would be the case, then the need for good prediction models is essential and 
genetic predisposition analysis will become even more relevant. The discussion would 
then rather be whether early intervention, at the intermediate stage or even earlier is 
justified.
So far, only a limited number of complement components have been targeted by 
complement-inhibiting therapies. Choosing different targets might yield better 
results.
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Another element that is worth considering is the fact that it is still not known whether 
higher levels of complement activation in AMD patients are a cause or a consequence of 
the disease. Mendelian randomization (MR) analysis, developed to unravel causes and 
consequences when multiple variables are tightly entwined, could help to shed light 
on this issue. MR was recently successfully implemented in AMD to show that long-
term elevated levels of plasma HDL-C increase AMD risk. 51 A similar approach could 
be done for the relationships between complement activation levels, complement 
activation-associated variables and AMD disease status. The SNPs that we identified 
in Chapter 7, central to systemic complement activation would be excellent candidates 
for this type of study.
Lastly, considering the complexity of AMD and the interplay of multiple pathways 
associated with the disease, it is not unlikely that a combined type of intervention, 
aimed at more than one contributing factor rather than monotherapy, is required. 
In order for this to become a reality, much more detailed work needs to be done on 
the exact role of the implicated pathways and their interactions, across the different 
disease stages of AMD. 
In summary, the results presented in this thesis have demonstrated that systemic 
complement activation is partly under genetic control and partly influenced by 
modifiable factors such as triglycerides and HDL. Also, this thesis demonstrates that 
systemic complement activation may not be the major driver of the disease as was 
previously thought. The results presented here embed the complement system in a 
tightly regulated and intertwined network of other biological systems, such as the 
lipoprotein metabolism. Combined, these results can be implemented to identify 
patients predisposed to a higher level of complement activation, and those patients 
could be excellent candidates for upcoming clinical trials, targeting the complement 
system. Moreover, the results presented here are a first step towards an even more 
detailed understanding of the role of complement in AMD and the interaction with 
other pathways. Developing these lines of research further has the potential to 
uncover novel therapeutic options for patients in early or intermediate stages of AMD.
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SUMMARY
Age related macular degeneration (AMD), the most common cause of blindness in the 
Western world, is a disease of the eye affecting the central part of the retina. AMD is 
a complex multifactorial disease where both genetic and environmental factors play 
a role in its development. In this thesis we investigated and combined genetic results 
with physiological measurements in AMD patients to gain a better understanding of 
the molecular drivers of AMD. 
Chapter 1 provides the reader with a general introduction to the major subjects of this 
thesis. 
Chapter 2 explored all available literature on potential biomarkers in AMD present 
in serum or in ocular fluid. The results of this exploration yielded a comprehensive 
overview where initially over 3600 articles, describing a plethora of compounds 
measured in serum, plasma, vitreous, aqueous humor and urine of AMD patients, were 
screened. After condensing that information, the review delivers for each compound 
a short description and a summary of its usefulness as a potential biomarker for AMD. 
We identified compounds belonging to the oxidative stress pathway, the complement 
system, and lipid metabolism to be the most promising biomarker candidates in AMD.
In Chapter 3 we examined genetic variants in the C3 gene, which encodes a central 
component of the complement system, in order to determine if rare mutations could 
give a high risk for developing AMD. We identified three rare variants (Lys65Gln, 
Arg735Trp and Ser1619Arg) at the C3 locus that were associated with AMD in the 
EUGENDA cohort. However, the Arg735Trp and Ser1619Arg variants could not be 
replicated in the Rotterdam Study. The Lys65Gln variant was only identified in patients 
from Nijmegen, the Netherlands, and thus may represent a region-specific AMD risk 
variant.
Chapters 4 and 5 investigated the relationship of known AMD-associated single 
nucleotide polymorphisms (SNPs) with complement activation levels. In Chapter 4 we 
analyzed the association of 32 SNPs in or near 23 AMD-associated genes with serum 
levels of C3d/C3 as a measure of complement activation. Only SNPs in C3, CFB and 
CFH were found to influence complement activation levels.
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In Chapter 5 we report on a novel complotype, which is a combination of SNPs that 
individually have small effects, but when they are combined, their effects amplify. This 
novel complotype was associated with both AMD status and complement activation 
levels. The complotype is composed of 2 SNPs in CFB and one in CFH. 
Chapter 6 bridges the gap between genetic associations and physiological lipid levels 
in AMD. Additionally, we observed, for the first time, strong correlations between 
complement activation and lipid/lipoprotein levels. The implication of these results is 
that two major systems that were previously thought to act independently in AMD, 
could in fact work in concert in the disease. 
In Chapter 7 we further advanced the work we had developed in Chapters 3, 4 and 
5 by undertaking an unbiased approach to identify genetic variants that influence 
complement activation levels. We identified 2 loci that are independently associated 
with AMD at a genome-wide significance level: One in CFH and the other one in 
CFHR4. These findings may help to identify AMD patients who would benefit most 
from complement-inhibiting therapies. In this study we uncovered that the haplotypes 
that are most associated with systemic complement activation levels are in fact not 
associated with AMD, which further finetunes our understanding about the role of the 
complement pathway and complement activation in AMD. 
Chapter 8 discusses the main findings of this thesis in a broader perspective. The 
entire discussion is structured as a series of questions and their potential answers. We 
cover topics ranging from genetic drivers of complement activation to why thus far 
complement inhibiting therapies have not been successful. Finally, we offer an outlook 
on how the results generated in this thesis could impact the research field of AMD as 
well as patient care.
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SAMENVATTING
Leeftijdsgebonden maculadegeneratie (LMD), de meest voorkomende oorzaak van 
blindheid in Westerse landen, is een oogaandoening waarbij het centrale deel van het 
netvlies aangetast is. LMD is een complexe ziekte, veroorzaakt door een combinatie 
van erfelijkheid en omgevingsfactoren. In dit proefschrift hebben we onderzoek 
verricht naar erfelijke factoren en stoffen in het bloed, en hun onderlinge relatie, om 
een beter begrip te krijgen van de moleculaire aanjagers van de ziekte LMD.
Hoofdstuk 1 informeert de lezer over de algemene begrippen en grote thema’s die in 
dit proefschrift worden besproken.
In Hoofdstuk 2 is alle literatuur op het gebied van mogelijke biomarkers in het bloed 
en in oogvocht verzameld, geanalyseerd en gerubriceerd. In eerste instantie zijn bijna 
3600 artikelen gescreend die een grote verzameling stoffen beschreven die gemeten 
zijn in serum, plasma, voorste oogkamerwater, glasvocht, en urine van patiënten. Deze 
informatie werd samengevoegd, waarna in het overzichtsartikel elke gevonden stof 
kort werd omschreven, gevolgd door een samenvatting over het nut van de stof als 
biomarker voor LMD. We vonden stoffen die betrokken zijn bij oxidatieve stress, bij het 
complement systeem en de vetzuurhuishouding de meest veelbelovende biomarkers 
voor de LMD.
In hoofdstuk 3 deden we onderzoek naar genetische varianten in het C3 gen en de 
relatie met LMD. We onderzochten met name of zeldzame varianten een verhoogd 
risico kunnen geven op LMD. We vonden drie zeldzame varianten (Lys65Gln, 
Arg735Trp en Ser1619Arg) in het C3 gen die geassocieerd waren met LMD in het 
EUGENDA cohort. De associaties met de Arg735Trp en Ser1619Arg varianten werden 
niet bevestigd in een cohort uit Rotterdam. De Lys65Gln variant vonden we alleen in 
LMD patiënten uit de omgeving van Nijmegen, wat suggereert dat dit mogelijk een 
regiogebonden variant zou kunnen zijn. 
In hoofdstukken 4 en 5 onderzochten we of bekende genetische varianten die 
betrokken zijn bij LMD ook geassocieerd zijn met complement activiteit. In hoofdstuk 
4 testten we 32 genetische varianten in 23 LMD genen en hun associatie met serum 
niveaus van C3d/C3 als maat voor complement activiteit. Alleen genetische varianten 
in C3, CFH en CFB bleken complement activiteit te beïnvloeden.
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Hoofdstuk 5 beschrijft een ‘complotype’, een combinatie van genetische varianten 
die elk afzonderlijk kleine effecten teweeg brengen, maar gezamenlijk een sterk 
effect hebben. We beschreven een nieuwe complotype dat zowel met LMD als met 
complement activiteit geassocieerd is. Het complotype bestaat uit twee varianten in 
CFB en een variant in CFH.
Hoofdstuk 6 beoogt een brug te slaan tussen genetische associaties en vetzuur niveaus 
in LMD. We vonden een sterke correlatie tussen bepaalde vetzuur-gerelateerde 
stoffen en het complement systeem. The implicatie van deze uitkomst is dat twee van 
de grote biologische systemen die eerder werden geassocieerd met LMD, maar als 
onafhankelijk van elkaar werden gezien, mogelijk samenwerken in het ziekteproces 
van LMD, iets wat eerder niet bekend was.
In hoofdstuk 7 onderzochten we of we, zonder vooraf bepaalde hypothese, genetisch 
factoren konden vinden die samenhangen met complement activiteit. We vonden 
twee gebieden op het genoom dicht bij elkaar die bepalend lijken te zijn voor 
systemische complement activiteit: Een in het CFH gen en een in het CFHR4 gen. Deze 
kennis kan mogelijk in de toekomst worden gebruikt om LMD patiënten te selecteren 
voor behandeling met  complement-remmende middelen in LMD. Verder vonden we 
dat bepaalde haplotypes, een opeenvolgende rij van genetische varianten, die sterk 
geassocieerd waren met complement activiteit, helemaal niet geassocieerd waren 
met LMD. Deze informatie scherpt onze gedachten over de rol van het complement 
systeem in LMD verder aan.
In hoofdstuk 8 worden de belangrijkste bevindingen van dit proefschrift samengevat 
en in een breder perspectief geplaatst. De discussie is gestructureerd in een aantal 
vragen en hun mogelijke antwoorden. We bespreken verschillende onderwerpen, 
zoals de genetische oorzaken van complement activiteit, en waarom behandeling met 
complement-remmende middelen tot nu hoe niet succesvol zijn geweest bij LMD. 
Tenslotte geven we een vooruitzicht in hoe de resultaten uit dit proefschrift gebruikt 
kunnen worden in toekomstig onderzoek naar de ziektemechanismen van LMD en 
hoe ze toegepast kunnen worden in de patiëntenzorg.  
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